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ABSTRACT

THOMAS WESLEY POWERS. Developing and Integrative Glycobiology Workflow for the
Identification of Disease Markers for Pancreatic Cancer (Under the Direction of Richard Drake)

A deeper understanding of dysregulated glycosylation in pancreatic cancer can provide
insights into disease mechanisms and the identification of novel disease markers. Recent
improvements in mass spectrometry techniques have been instrumental in profiling biologically
relevant tissue sections in order to identify disease marker candidates, but have either not yet been
adopted for studying glycosylation or applied directly to pancreatic cancer. In the dissertation
herein, new methods have been developed and adapted to the study of aberrant glycosylation in
pancreatic cancer, with the ultimate goal of identifying novel disease marker candidates. For the
first time, we describe a mass spectrometry imaging approach to study the localization of Nglycans. This technique demonstrated a histology-derived localization of N-glycans across tissue
sections, with identifications displaying remarkable consistency with documented studies.
Furthermore, the technique provides superior structural information compared to preexisting
methodologies. In the analysis of diseased specimen, changes in glycosylation can be linked to
aberrations in glycosyltransferase expression. When applied to pancreatic cancer in a highthroughput and high-dimensional analysis, panels of glycans displayed an improved ability to
differentiate tumor from non-tumor tissues compared to current disease markers. Furthermore, the
data suggest that glycosylation can identify premalignant lesions, as well as differentiate between
malignant and benign conditions. These observations overcome significant limitations that hinder
the efficacy of current disease markers. In an effort to link aberrant glycosylation to the modified
protein, a subset of glycosylated proteins were enriched and analyzed by mass spectrometry to
identify proteins that are integral to disease progression and can be probed for the early detection
iv

of pancreatic cancer. Known disease markers were among the glycoproteins identified, validating
the utility of the enrichment and detection strategy outlined. This approach also differentiated the
role of N- and O-glycosylation in antigen expression. Finally, we outline an integrated workflow
that takes advantage of the unique capabilities of high resolution mass spectrometers. This
workflow can capitalize on prior glycomic and proteomic experiments to provide a
comprehensive analysis of dysregulated protein glycosylation in pancreatic cancer.
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Chapter 1: Literature Review
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1.1 Introduction to Pancreatic Cancer
1.1.1 Symptoms, Mortality, and Standard of Care
As annual cancer death rates continue to decline for a majority of cancers due to a
reduction in disease-causing behaviors, improvements in early detection and screening
approaches, and improved treatments for the major cancer sites, pancreatic cancer has seen a rise
in death rates (1,2). Average 5-year survival rates for pancreatic cancer remain at a dismal level,
around 6%, and the disease accounts for the fourth most cancer related deaths in the United States
(2). For pancreatic cancer, poor clinical outcome is related to a poor understanding of the disease,
rapid progression, limited effective treatment options, and resistance to therapeutic interventions.
These factors are further enhanced by a pattern of delayed diagnosis, attributed to mild and
ambiguous clinical presentations. As the pancreas is located deep in the abdomen, tumor growth
may persist for extended periods of time before pressure or discomfort is detected. In addition to
pain and discomfort, other symptoms include jaundice, digestive difficulties, ascites, unexpected
weight loss and sudden onset diabetes (3,4). However, these symptoms are not specific to
pancreatic cancer, and are therefore often attributed to other diseases or conditions. For these
reasons, many patients remain asymptomatic until the disease has already progressed to late
stages. The difficulty in detecting pancreatic cancer translates to approximately 9% of patients
being diagnosed with localized cancer (5). For the remaining patients, the cancer has already
spread to regional lymph nodes or metastasized to distant sites by the time of detection.
Unfortunately, 5-year survival rates and median lengths of survival are dramatically
impacted by the stage of pancreatic cancer at the time of diagnosis. Stages of pancreatic cancer
range from stage 0 to stage IV, with certain stages being further divided (6). The stage is
determined at the time of diagnosis and is primarily based on the size of the tumor and the spread
of the cancer to other sites (Table 1). Stage 0, or carcinoma in situ, refers to abnormal cells found
2

in the pancreas that may become cancerous. Pancreatic cancer is classified as stage IA if the
tumor is less than 2 centimeters and is not found outside of the pancreas. Stage IV pancreatic
cancer refers to cancer that has metastasized to distant organs (6). For the largest subtype of
pancreatic cancer, 5-year survival decreases from 14% when the patient is diagnosed at with stage
IA pancreatic cancer, to 1% when the patient is diagnosed with stage IV cancer (7). The greatest
benefit of detecting pancreatic cancer early is the potential for complete surgical resection of the
tumor, which is the only chance of curative treatment. However, surgical resection is only
available for the 15-20% of pancreatic cancer patients that are deemed able to survive the surgery
and are determined not to have locally invasive or metastatic cancer (3,8). Even with surgical
resection, 5-year survival rates remain below 25% (2). A majority of tumors of the pancreas head
and proximal neck are resected using the Whipple procedure followed by adjuvant chemotherapy
(3,8). Patients with more advanced cancer are limited to chemotherapy. Gemcitabine, alone or in
combination with 5-fluorouracil (5-FU), has traditionally been considered the standard of care
chemotherapy for patients with locally advanced or metastatic cancer (8). However, gemcitabine
treatment results in only modest patient benefits due to limited drug uptake and acquired
resistance (9). Newer chemotherapy combinations, FOLFIRINOX and a combination of
gemcitabine plus nanoparticle albumin-bound paclitaxel (nab-paclitaxel), have been adopted as
the new standard of care based off of improved survival statistics (8). FOLFIRINOX, a
combination of leucovorin, 5-FU, irinotecan and oxaliplatin, showed an increase in survival to
11.1 months compared to 6.8 months for gemcitabine alone (10). Unfortunately, the toxicity of
FOLFIRINOX limits the therapeutic use. The combination of gemcitabine and nab-paclitaxel
outperformed gemcitabine alone in survival and progression-free survival (11). While therapeutic
intervention has been improved for more advanced stages of pancreatic cancer, these efforts have
only a modest effect on life expectancy.
3

Table 1. Stage, Resectability and Survival of Pancreatic Cancer
Clinical Stage
Stage 0 (Tis, N0, M0)

Resectable Median Survival Diagnosis

Stage IA (T1, N0, M0)
Local

Stage IB (T2, N0, M0)

13%
Yes

17-23 Mos

10%

Stage IIA (T3, N0, M0)

6%

Stage IIB (T1-3, N1, M0)
Locally Advanced
Metastatic

Stage III

5-Year
Survival

Borderline

<20 Mos

Stage III (T4, any N, M0)

No

8-14 Mos

Stage IV (any T, any N, M1)

No

4-6 Mos

T = Primary tumor
Tis: Carcinoma in situ
T1: Tumor restricted to pancreas, <2cm
T2: Tumor restricted to pancreas, >2 cm
T3: Tumor extends beyond pancreas
T4: Tumor affects coeliac axis or superior mesenteric artery

30%

3%

60%

1%

Resection:
18-24%

N = Regional lymph node
N0: No regional lymph-node metastasis
N1: Regional lymph-node metastasis
M = Distant metastasis
M0: No distant metastasis
M1: Distant metastasis

1.1.2 Pancreatic Cancer Subtypes
The pancreas is characterized as having both an exocrine and endocrine function.
Exocrine cells, which constitute a majority of the cells in the pancreas, are responsible for the
production and release of pancreatic juices involved in digestion. A majority of pancreatic
cancers are exocrine in nature; including ductal adenocarcinomas, cystic tumors and cancer of
acinar cells. Among the forms of exocrine pancreatic cancer, pancreatic ductal adenocarcinoma
(PDAC) is estimated to account for 90% of all pancreatic cancer instances. Ultimately, PDAC is
the exocrine tumor with the worst prognosis, as other exocrine tumors are slower growing and
have higher 5-year survival rates (12). The second most common subtype, cystic tumors, account
for less than 5% of all pancreatic cancers (13). While many of these cystic lesions are benign,
lesions with malignant potential include mucinous cystic neoplasms (MCN), serous
cystadenomas, and intraductal papillary mucinous tumors (IPMT). MCNs are characterized by
excessive mucin production while IPMNs resemble early stage PDAC lesions but form larger
cystic structures (14,15). Apart from morphological differences, the location of the lesion within
the pancreas can aid in diagnosis (12). For patients with exocrine cancer, both the cancer and
4

surgical intervention may result in exocrine insufficiency, a condition marked by a deficiency in
digestive enzymes produced in the exocrine pancreas (16,17). Treatment of these patients with
pancreatic enzyme replacement therapy can offset unintentional weight loss caused by
maldigestion and alleviate some symptoms of the disease (18).
Pancreatic cancer of the endocrine pancreas, whose biological function is to modulate
glucose regulation, occurs infrequently and constitutes less than 5% of the instances of pancreatic
cancer. Endocrine tumors, often referred to as neuroendocrine or islet cell tumors, are most often
indolent but have malignant potential if left untreated. Endocrine tumor metastasis to the liver is
the most common site of metastasis and the primary cause of death for these patients (19).
Endocrine tumors are classified as functional, where the tumor produces excessive amounts of
hormones; or nonfunctional, where the tumor does not secrete excess hormones. Individuals with
functional neuroendocrine tumors present with symptoms reflective of the hypersecreted
hormone. Functional tumors include insulinoma and glucagonomas, which secrete excessive
amounts of insulin and glucagon, respectively. Unlike functional tumors, which present with
symptoms specific to the hypersecreted hormone, nonfunctional tumors are less symptomatic and
are frequently discovered incidentally or at more advanced stages (20). The distinction between
functional and nonfunctional tumors is based on symptoms at the time of diagnosis as opposed to
concrete hormonal expression differences, meaning that nonfunctional tumors can eventually
trigger symptoms associated with functional endocrine tumors. Recently, treatment strategies for
endocrine tumors have transformed from a "wait-and-see" approach to a more aggressive
treatment approach (19). While still poor, 5-year survival is markedly higher for individuals with
endocrine tumors compared to exocrine pancreatic tumors. The 5-year survival rates for exocrine
tumors, largely biased by the high relative occurrence and poor outcome of PDAC, are 14%,
12%, 7%, 5%, 3%, and 1% for stage IA, stage IB, stage IIA, stage IIB, stage III, and stage IV,
respectively (7). In contrast, 5-year survival rates for patients with neuroendocrine tumors
5

following surgery are 61%, 52%, 41%, and 16% for stage I, stage II, stage III, and stage IV
tumors, respectively (7). The 5-year survival of individuals with exocrine tumors that are eligible
for surgical resection remains markedly lower than that of patients with endocrine tumors, except
those diagnosed with the worst stage of endocrine cancer.

1.1.3 Disease Etiology
1.1.3.1 Risk Factors
Both environmental cues and genetic predispositions are associated with the development
of pancreatic cancer. From a population standpoint, pancreatic cancer is most often diagnosed in
individuals between 60-80 years of age, and rarely before the age of 40 (12). Men are more likely
to develop pancreatic cancer, with rates for Caucasians being lower than other races (21). After
controlling for enviromentental factors, studies have established in increased risk of developing
pancreatic cancer associated with smoking, chronic pancreatitis, excessive alcohol consumption,
type-2 diabetes, and obesity (22–28). These factors can induce pancreatic cancer through different
mechanisms. Pancreatitis results in the release of growth factors, cytokines, and reactive oxygen
species, while smoking, diabetes and obesity result in chronic inflammatory states (14,26). These
environmental effects are often interconnected, such as heavy alcohol consumption promoting
chronic pancreatitis (27,28). Among the controllable risk factors, smoking has the most profound
effect on the population, and is estimated to result in a 2-fold increase in the rate of pancreatic
cancer development and accounts for approximately 25% of all instances of PDAC (21). Efforts
to identify the impact of dietary factors on PDAC incidence rates have been largely contested,
with the most likely impact being through obesity and diabetes (21). However, there is some
debate as to whether diabetes is in fact a cause of pancreatic cancer. Patients with new-onset type2 diabetes, as opposed to long time type-2 diabetic patients, have a higher risk of developing
PDAC, suggesting the onset of diabetes may instead be a manifestation of PDAC (29).
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Genetic predispositions are estimated to cause around 10% of the instances pancreatic
cancer (30,31). Individuals with 1, 2, and 3 first degree relatives with pancreatic cancer have a
greater than 3-, 4-, and 14-fold increased risk of developing pancreatic cancer compared to
individuals with no familial history of pancreatic cancer (26). Risk is further elevated when there
is a history of early onset pancreatic cancer (age < 50 years) (32). BRCA1, BRCA2, PALB2,
STK11, CDKN2A, PRSS1, and TP53 gene mutations are associated with elevated instances of
PDAC (33–36). Among these, individuals with STK11 and CDKN2A mutations have the highest
rate increase for developing PDAC compared to individuals without the gene mutations.
Germline BRCA2 gene mutations contribute to the most instances of hereditary pancreatic cancer
(32). Many of the genes mentioned above are frequently mutated in pancreatic cancer, and will be
discussed further in regards to their role in cell signaling. While chronic pancreatitis is often
induced by excessive alcohol consumption and thus characterized as an environmental risk factor,
hereditary pancreatitis is associated with a 40% an increased risk of acquiring pancreatic cancer
(21). It is likely that there are additional unknown genetic predispositions for pancreatic cancer.

1.1.3.2 Common Signaling Pathways Linked to Pancreatic Cancer
While the exact biological mechanisms that drive of pancreatic cancer initiation and
progression are not fully understood, recent studies have identified consistent molecular pathways
that are likely involved. These mutations appear to regulate different stages of malignant
progression, some appearing in early stage pancreatic intraepithelial neoplasia (PanIN) lesions
while others manifest only in later stage PanIN lesions and malignancy (Figure 1). While
malignant progression typically proceeds though PanIN lesions, other initiating lesions exist in
the form of IPMNs and MCNs (15). Activating KRAS mutations are observed in many cancers,
including pancreatic cancer (37). Gain-of-function KRAS mutations on chromosome p12 are
estimated to occur in over 90% of pancreatic cancers and 36%, 44% and 87% of PanIN1, PanIN2,
and PanIN3 lesions, respectively (15,38). While the substitution mutation of glycine for aspartate
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at codon 12 is the most common mutation, other single point mutations at residues G12, G13, and
Q61 have been observed (39,40). Mechanistically, substitutions at G12 and G13 produce steric
interference between KRAS and GTPase activating proteins (GAPs), prolonging KRAS
activation and enhancing downstream signaling (40,41). Under normal conditions, KRAS
localizes to the plasma membrane and mediates a variety of biological processes, including
proliferation, differentiation and survival (14,37). The prolonged KRAS activation in pancreatic
cancer results in increased proliferation, suppression of apoptosis, alterations in the metabolism of
the tumor microenvironment, and metastasis (40). While the exact KRAS-mediated pathways
utilized during pancreatic cancer tumorigenesis are unknown, the mitogen-activated protein
kinase (MAPK), phosphoinositide 3-kinase (PI3K) and ral guanine nucleotide exchange factor
(RalGEFs) pathways have all been implicated. KRAS-mediated MAPK/ERK activation results in
a proliferative, anti-apoptotic and invasive cellular phenotype in PDAC cell lines (14,42).
Furthermore, in a murine model, the selective activation of the Raf-MEK-ERK pathway by
oncogenic BrafV600E induced a more aggressive pancreatic cancer phenotype with more PanIN
lesions than the KRASG12D murine model (43). Similarly, KRAS-mediated PI3K/AKT signaling
regulates cell growth, motility and survival. PDAC is associated with increased signaling
attributed to KRAS activity, decreased expression of PTEN, or amplification of AKT2
(14,44,45). In murine models, expression of the oncogenic PIK3CAH1047R allele, which activates
expression of p110αH1047R and PI3K signaling in the pancreas, resulted in PDAC tumors with
nearly identical survival and metastasis rates as KRASG12D mutants (46). Additionally, blocking
downstream PI3K signaling by inactivating PDK1 stopped the formations of PanIN and PDAC in
KRASG12D mouse models(46). From a therapeutic standpoint, targeting downstream intermediates
of these pathways have been more fruitful than KRAS inhibitors. Inhibition of downstream
effectors of the MAPK or PI3K pathways, including MEKK, AKT2 and mTOR, results in growth
inhibition, increased sensitivity to chemotherapy and reduced invasiveness in PDAC cell lines
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and xenograft assays (26,45,47,48). While KRAS mutations appear early in tumorigenesis, they
are frequently absent in PanIN lesions that ultimately progress to pancreatic cancer, and present
in non-cancerous PanIN lesions, suggest that other signaling pathways are involved in the
induction of pancreatic cancer, likely working in conjunction with KRAS signaling.

Figure 1. PanIN to PDAC Transition is Associated with Genetic Mutations. The transition of
the cellular morphology that occurs from the progression early PanIN lesions to full blown
pancreatic cancer is accompanied with mutations of the KRAS oncogene and the P16, P53 and
SMAD4 tumor suppressors.

In addition to KRAS oncogene mutations, three tumor suppressors are frequently
inactivated in pancreatic cancer; these being CDKN2A, TP53 and SMAD4. Inactivation of the
p16/INK4/CDKN2A tumor suppressor in pancreatic cancer occurs through homozygous deletion,
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intragenic mutation, and hypermethylation of the promoter in 40%, 40% and 15% of instances,
respectively (49). The resulting loss of p16 function occurs in around 90% of pancreatic cancers
and is also observed in 30% of PanIN1 lesions, 55% of PanIN2 lesions, and 71% of PanIN3
lesions (15,38). While this mutation occurs sporadically in pancreatic cancer, germline mutations
of the p16/INK4/CDKN2A gene is associated with familial atypical mole-malignant melanoma
(FAMMM) syndrome, a condition that is linked to a 13-fold increased risk of pancreatic cancer
(14). Traditionally, the tumor suppressor gene p16/INK4/CDKN2A regulates cell cycle
progression during G1/S transition of the cell cycle. Cancer derived loss of p16 function increases
Rb phosphorylation via the interaction of CDK4/6 with Cyclin D1, resulting in the release of
E2F transcription factors and gene transcription required for S Phase (50). However, an additional
role of inactivation of the p16/INK4/CDKN2A gene has been hypothesized. It is now known that
p14ARF is located on the same gene locus, which functions to regulate p53-mediated cell cycle
arrest through the stabilization of p53 (14,15,50). As the p16/INK4/CDKN2A locus encodes for
two tumor suppressors, p16 and p14ARF, efforts to identify which gene plays a role in pancreatic
tumorigenesis are ongoing. Inactivating mutations that target p16 or p16 and p14ARF, emphasize
the importance of p16 as a tumor suppressor (33). Meanwhile, an analysis of pancreatic cancer
mouse models established a role for both p16 and p19ARF, the equivalent gene to p14ARF in
humans, in pancreatic cancer progression (38). Mutations in p16 may also be responsible for
avoiding senescence induced by KRAS oncogene signaling (14,15,46).
P53 is mutated in pancreatic cancer, diminishing the ability of the transcription factor to
regulate the G1/S and G2/M phases of cell-cycle progression and induce apoptosis. Uniquely,
pancreatic cancer commonly diminishes p53 function by two mechanisms; p14ARF deficiency as a
result of certain CDKN2A mutations or missense mutations in TP53 that encodes for the DNAbinding domain (15,51). In the first mechanism, mutations of the p14ARF gene elevates expression
of MDM2 and proteolysis of p53 (14). Alternatively, mutations in p53 are estimated to occur in
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over 70% of pancreatic cancers and in late stage PanIN lesions. The mutated protein forms
heterooligomers with wild-type p53, resulting in impaired association with DNA and
transcriptional activation (52–54). Unlike many cancers where these mechanisms are mutually
exclusive, TP53 mutations and p14ARF deficiencies are both present in around 40% of pancreatic
cancer patients (14). However, there are additional oncogenic, 'gain-of-function' properties that
are observed only in the presence of mutated p53, suggesting additional functions for mutated
p53 in pancreatic cancer progression. These properties result in chromosomal instability, the
inhibition of DNA repair pathways, and more aggressive and drug resistant cell phenotypes (55).
This aggressive phenotype is demonstrated by the observation that 65% of mice expressing
mutated p53 developed metastases, while none of the p53-null mice did (56).
DPC4/SMAD4/MADH4 is the third tumor suppressor that is commonly mutated in
pancreatic cancer. Like p53 mutations, loss of SMAD4 is seen late in pancreatic cancer
progression, appearing in 31-41% of PanIN3 lesions and 50% of cancers (14,15). The loss of
SMAD4 is thought to contribute to pancreatic cancer through TGFβ signaling. Under normal
conditions, TGFβ binds cell surface receptors and initiates an intracellular kinase cascade
resulting in the phosphorylation and translocation of SMAD4 to the nucleus, where SMAD4
transcriptionally regulates apoptosis, proliferation and migration. While TGFβ exerts growthinhibitory and growth-promoting effects, it is thought that the loss of SMAD4 results in decreased
growth inhibition in pancreatic cancer. Additionally, the loss of SMAD4 does not reduce the
TGFβ-mediated promotion of EMT, shifting TGFβ to a tumor promoter (52,57). This is in
accordance with the in vivo observation of reduced invasion upon TGFβ inhibition, elevated
invasion and EMT upon addition of exogenous TGFβ, and elevated levels of TGFβ in PDAC
cancer cells compared to normal cells and the effect (58–60).
Other signaling pathways and biological events have been also been implicated in
pancreatic cancer, albeit not as frequently as those described above. The tumor suppressors
11

LKB1/STK11 and BRCA2 can be mutated in both sporadic and familial pancreatic cancer (61,62).
Peutz-Jeghers syndrome, characterized by LKB1/STK11 gene mutation, is associated with a
>40%-fold increase in PDAC instances (14). Whereas LKB1 promotes tumorigenesis through the
regulation of mTOR, BRCA2 mutations impair DNA damage response pathways (63,64). BRCA2
gene mutations are observed in around 17% of pancreatic cancers, and present in later staged
lesions, suggesting a role in malignant transformation of precancerous lesions to full-blown
PDAC (14,62). Other studies have implicated constitutive NF-kB signaling in pancreatic cancer
based on the observation that inhibition of NF-kB inhibits tumorigenesis and increases sensitivity
to anticancer agents (65–67). Similarly, both notch and sonic hedgehog developmental signaling
pathways, which are absent in the normal adult pancreas, are activated in PanIN lesions and
PDAC (68,69). Finally, both growth factors (EGF, IGF, VEGF) and their corresponding receptors
have also been implicated in pancreatic cancer growth and proliferation (70–74). The disruption
of growth factor receptor signaling has been shown to suppress both in vivo and in vitro tumor
growth and enhance response to chemotherapy (74–78).

1.3.3.3 Origin of Pancreatic Cancer Initiation
The definitive origin of the cells responsible for pancreatic cancer initiation remains
unclear. Given the ductal-like morphology of the cancer, ductal cells were originally
hypothesized to be the cellular origin of PDAC (79). This theory is supported by evidence linking
the transformation of neoplastic ductal lesions (PanINs) to pancreatic cancer, including
similarities in genetic alterations. On the genetic level, approximately 30% of patients with
PanIN-1A lesions exhibit point mutations in the KRAS oncogene, a mutation that becomes more
prominent as the lesions ultimately progress to PDAC, where the mutation is present in about
90% of patients (80,81). Similarly, CDKN2A, TP53, and SMAD4 exhibit inactivating mutations in
PanIN lesions and, to a larger extent, pancreatic cancer (40). While evidence linking the early
genetic mutations in PanIN with those frequently observed in PDAC supports the theory of ductal
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cell origin, this concept is difficult to prove, especially as expression of oncogenic KRAS
specifically in ductal cells does not induce PanIN or PDAC in murine models (82). On the other
hand, more recent data suggests that acinar/centroacinar cells can acquire features of ductal cells
and progress to PDAC (83,84). Transgenic murine models with ectopic expression of TGFα or cmyc demonstrate acinar cell acquisition of ductal cell features culminating in PDAC (84,85).
Additionally, the insertion of activated KRAS into the open reading frame of Mist1, a
transcription factor that is implicated in acinar organization, results in the development of
aggressive pancreatic cancer in mice (86). Unlike ductal cells, the selective expression of
oncogenic KRAS in acinar/centroacinar cells does induce PanINs and PDAC (83). Alternatively,
subpopulations of cells that display characteristics analogous to stem cells have been
hypothesized to act as cancer stem cells in pancreatic cancer. The subpopulation of pancreatic
cancer cells that test positive for cell surface markers CD44+CD24+ESA+ represent <1% of
pancreatic cancer cells (87,88). These cells display highly tumorigenic properties and are
estimated to have greater than 100-fold higher tumorgenicity compared to cells that test negative
for the surface markers (88). In a xenograft mouse model, tumors that developed from the
CD44+CD24+ESA+ cells were indistinguishable from the parent tumor. Overall, the
CD44+CD24+ESA+ cells displayed properties of self-renewal, the potential to produce
differentiated cells, and resulted in the expression of sonic hedgehog signaling molecules, all
properties common in cancer stem cells (88). Alternatively, CD133+CXCR4+ cells influence the
metastatic phenotype of pancreatic cancer cells (89). These cells are predominantly localized at
the invasive front of the tumor and the different surface markers confer survival advantages to the
cells. CD133+ cells are more resistant to gemcitabine than CD133- cells, while the CXCR4+
marker identifies migratory cells. Liver metastases were unique in mice given CD133+CXCR4+
cells compared to CD133+CXCR4- cells (89).
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1.1.4 Detection and Diagnosis of Pancreatic Cancer
1.1.4.1 Clinical Approaches to Detect Pancreatic Cancer
Pancreatic cancer is difficult to detect due to ambiguous symptoms, as described
previously. When individuals present with symptoms, possess genetic mutations that increase
their probability of developing pancreatic cancer, or have a family history of pancreatic cancer, a
physician may perform a physical examination to check for jaundice, physical masses or fluid
buildup in the abdomen. Non-invasive and invasive imaging tests provide more information
regarding the status of pancreatic cancer. Abdominal ultrasounds are typically used for initial
examinations but are often followed up by other non-invasive strategies, such as computed
tomography scans (CAT),

magnetic resonance imaging (MRI),

magnetic resonance

cholangiopancreatography (MRCP) or positron emission tomography (PET) scans (90).
Depending on the approach, these imaging techniques can identify the presence of cancer, locate
metastatic sites, and differentiate between benign and metastatic masses. Invasive imaging tests,
termed endoscopic ultrasounds (EUS) or endoscopic retrograde cholangiopancreatography
(ERCP) tests allow for more detailed images, but can also be used to insert stents to compensate
for obstructed ducts or obtain fine needle aspirate (FNA) biopsy samples (12). EUS is capable of
detecting small pre-invasive lesions, making it well suited to identify lesions in high-risk
individuals (32). A combination of multiple screening strategies may be used to improve the
accuracy of cancer detection (91). The combination of EUS, multi-detector computed
tomography (MD-CT), MRI and MRCP offers the best sensitivity for the detection of pancreatic
cancer (90). Absolute certainty in identification is only achievable with a biopsy. In addition to
FNA biopsies, brush biopsies and tissue biopsies can be used for disease diagnosis. In a brush
biopsy, cells are collected during an ERCP test, whereas tissue biopsies are collected during
laparoscopy. In addition to imaging tests and biopsy collections, a blood test can be performed to
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assess the probability of pancreatic cancer. Blood work can assess levels of bilirubin, pancreatic
enzymes, CA19-9, and CEA. While altered levels of enzymes or markers in the blood work do
not conclusively determine if an individual has pancreatic cancer, they can determine the
necessity of further evaluations (92). After identification of pancreatic cancer, genetic testing may
be used to identify gene mutations. While screening is useful in prompting immediate family
members to undergo genetic testing, genetic testing is underutilized by physicians (32).

1.1.4.2 Gross and Microscopic Characteristics
Pancreatic cancer presents grossly as white-yellow firm masses, most often arising in the
pancreatic head, but also infiltrating and metastasizing into surrounding tissues, including lymph
nodes, spleen, peritoneal cavity, liver, and lungs (14,93). The tumor often has ill-defined edges
and is surrounded by a dense fibrotic stroma and ECM proteins (79,94,95). The mean diameter of
the tumor in the pancreatic head is between 2.5 and 3.5 cm, with larger tumors detected in the
body or tail of the pancreas (12). At the microscopic level, the progression from low-grade
(PanIN-1A or PanIN-1B) to high-grade (PanIN-3) lesions is accompanied by histological
changes. Low-grade lesions are often flat and retain nuclear polarity, while high-grade lesions
exhibit nuclear atypica, loss of nuclear polarity, and frequent mitoses (15). The transition from
PanIN-3 lesions to invasive carcinoma is marked by the invasion through the basement
membrane (93). The presence of cancer is frequently associated with infiltrating small glands
lined with mucin-containing cells, with the cancer surrounded by a desmoplastic reaction (93).
Malignant glands can be distinguished from benign glands based off on variations in the gland
architecture, location of the glands, variation in the size of nuclei, association with surrounding
pancreatic parenchyma, and the presence of necrotic debris (96). PDAC is typically moderately or
well differentiated, but there is often some variation in the degree of differentiation within the
tumor (12,97). As glands become less differentiated, the lumen boundary and overall shape of the
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duct becomes more irregular (96). These glands commonly appear directly adjacent to muscular
arteries or invade into perineural or vascular tissue.

1.2 Mass Spectrometry
1.2.1 Principles of Mass Spectrometry
1.2.1.1 General Introduction to Mass Spectrometry
Mass spectrometry (MS) is a powerful analytical approach to characterize analytes based
off of the molecules’ mass-to-charge ratio (m/z) and the fragmentation pattern. The functionality
of mass spectrometry relies on three primary components; the ion source, mass analyzer, and
detector. As the mass spectrometer measures m/z values, an ion source is required to generate
charged molecules during the ionization process. Charged ions are then separated by either an
electric or magnetic field, known as the mass analyzer, prior to reaching the detector. Initial
characterization of an analyte is commonly based on accurate mass from the MS, but further
validation can be achieved by tandem mass spectrometry (MS/MS), in which the configuration of
the mass spectrometer includes an initial ion selection step followed by fragmentation and
analysis of fragments, also known as daughter ions. While an in-depth description of the
underlying physics that drives the instrumentation is beyond the scope of this dissertation, a brief
introduction to the common techniques used in the biomedical sciences and for this dissertation is
provided.

1.2.1.2 Ion Sources
The two most influential ionization techniques for the analysis of biological molecules,
and thus the two ionization methods used in this dissertation, are electrospray ionization (ESI)
and matrix-assisted laser desorption/ionization (MALDI). Both of these ionization techniques are
regarded as soft ionization techniques, meaning they induce little molecular fragmentation, unlike
the ionization techniques that preceded them. The concept of electrospray ionization was
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introduced by Malcolm Dole in 1968 and developed and applied for the study of large biological
molecules by John Fenn in the 1980s (98,99). The basic principle of ESI is that the solvent
containing analytes is infused into a charged capillary resulting in a Taylor cone formation, which
emits an aerosolized spray, ultimately resulting in charged droplets that travel through an electric
field towards the mass analyzer. As the solvent evaporates, the charge density of the droplets
increases until the point where the charge exceeds the Rayleigh limit and the droplet undergoes
Rayleigh fission to create smaller charged ions (100). The presence of gas flow assists in the
process of nebulization, directs the spray towards the mass spectrometer, and aids in solvent
evaporation (101). The transition of analytes to the gas phase does not require exorbitant amount
energy and can proceed with minimal fragmentation. One advantage of ESI is that it ionizes
molecules in the liquid phase, allowing ESI to be in-line and coupled to conventional liquid
chromatography, including reverse phase chromatography (102). Additionally, the ability of the
ion source to generate multiply charged ions, and thereby smaller m/z values, results in ions that
are more compatible with mass spectrometers, which are often set to detect m/z values less than
2,000 Da. The presence of the same species with different charge states provides multiple
opportunities to identify and fragment a molecule, which is particularly useful if the
fragmentation produced by one charge state is not acceptable (103).
Franz Hillenkamp introduced MALDI as an ion source around the same time that John
Fenn introduced ESI (104). In MALDI, the sample is mixed and cocrystalizes with a matrix that
is present in large molar excess. Most matrices absorb UV light, which is fired in the form of a
pulsed laser at the matrix crystal, causing the matrix to absorb energy from the laser, resulting in
desorption of the matrix and the analyte (105). The matrix also acts as a proton donor or receptor,
resulting in ionization for negative or positive ion mode, respectively (105). As the matrix
absorbs the energy from the laser instead of the sample itself, MALDI is considered a soft
ionization strategy and results in minimal analyte fragmentation. MALDI primarily produces
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singly charged ions rendering mass spectra somewhat less complex than ESI spectra. However,
multiply charged ions can be detected by altering the matrix or protocol for matrix application
(106). MALDI is also more tolerant of contaminants, such as residual detergents, than ESI (107).
While most studies rely on either ESI or MALDI ionization, the techniques can be quite
complementary in nature. For proteomic analysis of complex samples, the use of MALDI in
addition to ESI ionization resulted in 45% more protein identifications, including many that were
identified based off of larger and more hydrophilic peptides, such as glycosylated peptides (108).

1.2.1.3 Mass Analyzer
Once ionized, the mass analyzer functions to separate ions based off of their m/z.
Importantly, the mass analyzer is responsible for the overall resolution, mass accuracy, mass
range, and fragmentation profile that can be achieved (109). The general classes of mass
analyzers are Quadrupole (Q), Time of Flight (TOF), Magnetic Sector, Electrostatic Sector,
Quadrupole Ion Trap (QIT), and Ion Cyclotron Resonance (ICR). Each mass analyzer relies on
specific physical properties to achieve ion resolution. Quadrupole mass analyzers consist of four
parallel metal rods that are used to separate ions based on their trajectory in an electric field. One
pair of rods is subjected to a direct voltage, whereas the other pair has an alternating
radiofrequency (RF) potential. Depending on the voltage conditions, only ions with a certain m/z
will be able to reach the detector (109). The quadrupole mass analyzer has been widely adopted
as it is mechanically simple and offers advantages in terms of cost, size and speed (110). The
TOF mass analyzer was popular in the 1960s but was surpassed due to limitations in sensitivity,
resolving power, and speed. However, instrumental improvements have overcome these
limitations resulting in a renewed interest in TOF (111). The principle behind TOF is that ions
with the same kinetic energy but different masses will have a velocity that is inversely
proportional to the square root of their m/z value (111). Thus, the time required to navigate the
flight tube will be shorter for smaller ions based off of their greater velocity. The m/z of an ion
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will be calculated based on the length of time it takes the ion to navigate the flight tube and reach
the detector. Similar to the quadrupole analyzer, quadrupole ion trap mass analyzers can trap and
accumulate ions using an electric field for the separation of ions based off of their m/z values.
Unlike the quadrupole analyzer, the quadrupole ion trap is composed of a ring electrode and two
end cap electrodes. Ions are trapped in the electric field and can be ejected by increasing the RF
voltage (112). The quadrupole ion trap mass analyzers provide superior sensitivity and data
acquisition speeds compared to other mass analyzers but are limited by reduced resolving power
and higher mass defects (107). Ion cyclotron resonance and Orbitrap mass analyzers are
becoming increasingly popular, due to their higher resolving power and mass accuracy. The FTICR mass spectrometer uses ion optics to transfer ions into the magnetic field and the ICR cell,
also known as a Penning trap. As the ions are orbiting, they are excited by an RF current to
induce a current image, which can be processed by a Fourier transform (113).
Each mass analyzer offers different advantages that can be exploited depending on the
nature and complexity of the experimental design. Additionally, certain analyzers seem to pair
nicely with specific ion sources. The most common mass analyzers paired with a MALDI
ionization source is the TOF mass analyzer (105). On the other hand, quadrupole mass analyzers
have historically been interfaced with ESI sources, as quadrupoles are tolerant of high pressures,
able to assess m/z values up to 3,000, and are considered low cost. More recently, quadrupole
mass analyzers have been largely replaced by ion traps. FT-ICR mass analyzers can be coupled to
both MALDI and ESI sources to improve resolution and mass defect errors.
As previously mentioned, tandem mass spectrometry is used to generate ion information
beyond the m/z value. Collision-induced dissociation (CID) is one fragmentation technique, in
which an ion is selected in the mass analyzer and fragmented through the collision of a gas in the
collision cell. The triple-quadrupole mass analyzer is a common instrumental setup used to
perform CID, in which a particular ion is isolated in the first quadrupole, fragmented in the
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second quadrupole, and the fragments are analyzed in the third quadruple. Similarly, Q-Q-TOF
instruments utilize the first quadrupole for precursor ion selection, the second quadrupole for
CID, and the ToF for resolution of the product ions (107). In contrast, ion-trapping instruments,
such as the QIT or FT-MS, operate in a tandem-in-time method, meaning that the fragmentation
is performed in the same mass analyzer (114). In these instruments, selected ions are trapped and
fragmented in the ion trap prior to the fragments being ejected onto the detector. The high
MS/MS efficiencies of the ion trap instruments have made them a prominent analyzer for
proteomic workflows. Other fragmentation techniques utilized in this dissertation include electron
transfer dissociation (ETD) and high energy collision dissociation (HCD). For ETD, negatively
charged reagent ions (fluoranthene radical anions) transfer electrons to the precursor cations
causing them to fragment. For peptides, ETD fragmentation produces c and z type fragment ions
of the peptide backbone (115,116). HCD fragmentation uses a beam-type CID mechanism, but
operates at a higher energy than traditional CID. This generates informative low molecular weight
ions that can be detected in the Orbitrap, which overcomes the one-third effect that is associated
with CID in linear ion trap instruments (117).

1.2.1.4 Mass Detector
In order for a signal to be generated from the ions, mass detectors rely on the process of
secondary ion amplification or the generation of a current. An electron multiplier is one of the
most common detectors and relies on a series of dynodes at increasing potential. As ions strike
the dynode surface, secondary electrons are emitted and attract to the next dynode, which occurs
in an iterative process to allow for signal amplification (105). Eventually, the emitted electrodes
are collected by a metal anode. Scintillation counters are similar to the electron multipliers in that
ions initially strike a dynode, initiating a cascade of electrons, but differ in that the electrons
strike a phosphorus screen that emits photons that are detected by a photomultiplier (105). The
quadrupole ion trap functions to trap ions and also to detect ions. As the potentials that are
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applied to the electrodes of the ion trap are altered, ions reach an unstable trajectory and are
scalned out of the ion trap and are monitored by an external detector (112). Charge detectors,
which detect a current induced by a passing ion, are common in FT-MS instruments. In the FTICR-MS, the m/z of an ion is determined by its ion cyclotron resonance frequency in the
magnetic field. The m/z in the Orbitrap mass spectrometer is determined by its oscillation
frequency in an electric field (118). This process generates an image current of an ion, which can
be Fourier transformed to ultimately yield the m/z.

1.2.2 Mass Spectrometry Applications in the Biomedical Sciences
Early applications for mass spectrometry were predominantly related to physics based
research, but the introduction of MALDI and ESI ionization sources in the 1980s ushered in a
new wave of biomedical research using mass spectrometry (119). These soft ionization sources
enabled the analysis of large molecules instead of focusing on molecules less than 1kDa. The era
of genomics enhanced the desire to assess broad “omic” studies of specimens in general, or for
the study of diseases. As the mass spectrometer is able to simultaneously detect and characterize
analytes in a single experiment as a function of their m/z and downstream fragmentation, the
technique is well suited for "omics" research, in which thousands of analytes may be present. To
this end, mass spectrometry has been instrumental in lipidomics, metabolomics, proteomics, and
the global analysis of post-translational modifications (PTMs) (120–124).
Applications relating to general proteomic experiments will be outlined in this section,
with a more in-depth review of glycoproteomics presented later in the dissertation. Proteomics is
the global study of proteins and their modifications in a sample. A distinction can be drawn
between classical proteomics, which aims to identify the entire proteome; and targeted
proteomics, which assesses a defined subset of the proteome (i.e. glycoproteins) (103). In
addition to protein identification, proteomic analysis can also be used to interrogate protein
abundance in a quantitative fashion. The standard workflow typically involves sample
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fractionation prior to analysis by mass spectrometry, which functions to allow the detection of
lower abundance ions. This is required, especially for complex biological fluids, due to the high
dynamic range of proteins in the sample. Proteomics is typically done at the peptide level
(bottom-up proteomics), further complicating the sample complexity by producing multiple
peptides for a single protein. The detection of peptides by the mass spectrometer is typically
accomplished in positive ion mode, where the peptides are analyzed at a low pH where arginine,
lysine and histidine amino acids are protonated (103). Fractionation and chromatography can be
done at the protein level, through techniques such as SDS-PAGE, or at the peptide level using
SPE cartridges. More commonly, chromatography can be applied in an on-line fashion by
connecting chromatography instruments (i.e. HPLC) directly to mass spectrometers.
The detection of product ions only provides a list of m/z values, so fragmentation of each
ion is required to determine the peptide sequence. Chromatographic separation prior to MS
analysis allows concentration and resolution of peptides prior to mass spectrometery, resulting in
more protein identifications. The selection of which ions to fragment can proceed through a
variety of different mechanisms which ultimately play a role in the outcome of the experiment.
The most common method is data-dependent acquisition (DDA) workflows, in which the most
abundant ions throughout the chromatographic separation are selected for fragmentation (125).
While commonly employed, DDA suffers in its ability to characterize low-abundance peptides in
complex biological mixtures (125). To compensate for these limitations, several alterations to
conventional DDA workflows can be applied (126). These include targeted LC-MS strategies,
such as selected reaction monitoring (SRM) and parallel reaction monitoring (PRM). These
targeted approaches function by acquiring MS/MS spectra for MS ions of interest, even when
they are not the most abundant ions present (125). Alternatively, data-independent acquisition
(DIA) strategies, fragment all m/z values, regardless of ion intensity, by fragmenting across m/z
ranges (127).
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While the ultimate goal of proteomics is to characterize the entire proteome of a sample,
this remains a significant challenge. Recent successes rely upon advances in instrumentation and
data processing strategies. During the last decade, mass spectrometers have made significant
improvements in resolution, mass accuracy, sensitivity and scan speed (128). For shotgun
proteomics, in which a peptide digest is processed by LC-MS/MS, peptide identification relies on
database searching algorithms for protein identification. The software works to compare tandem
mass spectra from the experimental data to that generated in an in silico protein digest, to
determine what peptides are present in the sample, to make inferences about the proteins present.
Many software packages are available to process complex shotgun proteomics data including
ProteoIQ, Proteome Discover, Scaffold, and MaxQuant. Improvements in instrumentation and
data processing software have resulted in a rapid growth of proteomics as a field, but
improvements can still be made. The human proteome (~100,000 proteins) vastly exceeds the
genome (~30,000 genes), even without considering the additional complexity provided by PTMs,
mutations and truncations. Considering the added diversity, it is not unreasonable to expect the
proteome to exceed 2,000,000 proteins (103,129).

1.2.3 Mass Spectrometry Imaging
Imaging Mass Spectrometry (IMS) is recent addition to the field of mass spectrometry.
This technique enables the simultaneous detection of analytes while retaining their spatial
localization within tissue sections. General "omics" techniques reflect trends in analyte
expression across the entire tissue, but may be biased by the presence of differing histology. To
compensate for tissue heterogeneity, laser capture microdissection (LCM) is one approach used to
selectively enrich specific cells of interest (130,131). However, the utility of LCM is limited in
that the approach is time consuming and requires a high number of cells. Another approach to
assess analyte distribution across a tissue section relies on voxelation followed by LC-MS, in
which an individual analysis is done for each defined region, or voxel, of the tissue (132). While a
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large number of analytes are detected, the spatial resolution of this approach is limited by the size
of the voxels and length of time required, as sample preparation and data analysis must be
performed on each voxel individually. To compensate for these limitations, IMS has been adapted
for use with secondary ion mass spectrometry (SIMS), MALDI, and desorption electrospray
ionization (DESI). Although SIMS-IMS is capable of achieving a higher overall spatial resolution
(as small as 50 nm), the approach is not commonly used because of undesired fragmentation
attributed to the high-energy ions used to promote ionization (133). Recent sample preparation
strategies have improved the efficiency of SIMS ionization, which has a niche utility in imaging
at the single cell level (134). DESI-IMS, in which ions are desorbed by targeting charged droplets
and ions at the surface of the tissue, suffers from low spatial resolution and low sensitivity (133).
MALDI-IMS is capable of achieving a relatively high spatial resolution, while inducing less
fragmentation compared to SIMS, and thus represents the most popular ionization source for IMS
analysis. Efforts to optimize the sample preparation are essential to MALDI-IMS experiments, as
uneven distribution of matrix or the formation of large matrix crystals will negatively impact the
experiment. Importantly, all IMS platforms generate parent ions that can be fragmented for
further structural confirmation. As a platform, MALDI-IMS has been instrumental in the analysis
of lipids, proteins, peptides, therapeutics, and metabolites (135–143).
All MALDI-IMS experiments require the same basic sample preparation steps prior to
imaging, although variations to the general workflow can significantly impact the overall results
or class of biological molecule that is detected. In the workflow schematic provided (Figure 2),
solid connecting arrows represent conserved steps across all imaging experiments, while steps
connected by dashed arrows can be utilized for selected experiments. Initially, tissues are
sectioned and placed on a platform compatible with a MALDI adaptor, most commonly glass
slides. A homogenous layer of matrix is then applied to the slide containing the sectioned tissue
and allowed to crystallize. During the imaging process, a MALDI spectra is generated at specified
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increments across the tissue section (termed spatial resolution). Software for data processing
merges all of the individual spectra while maintaining their original location in the tissue section.
Individual m/z values can be selected and visualized by the relative intensity for the ion across the
entire tissue section. This approach is specifically useful in discovery phase research, where
undefined ions are only observed in a specific compartment of a tissue, but are not commonly
observed in global omics research due to ion suppression from more abundant species. While the
general approach applies to all MALDI-IMS experiments, efforts to optimize sample preparation
have been performed to enhance sensitivity performance for certain molecular targets. Initial
MALDI-IMS workflows utilized fresh/frozen tissue sections, but the adaptation of
immunohistochemical workflows has enabled MALDI-IMS analysis of formalin-fixed paraffinembedded (FFPE) tissue blocks and tissue microarrays (144). Depending on the target of the
imaging experiments, different washing procedures can be employed. While MALDI-IMS of
lipids does not require washing of the slide, washing with ammonium formate or ammonium
acetate can improve the overall ionization efficiency and number of ions observed (145). To
analyze proteins or peptides by MALDI-IMS, lipids should be removed by washing the slide in
organic solvents to mitigate ion suppression (144,146). Following the wash, in situ enzymatic
digestion can be performed by the application of an enzyme (i.e. trypsin) followed by MALDIIMS. Both the method of matrix application and type of matrix used can significantly affect the
type of molecules detected and the overall quality of the experiment. Automated spray stations
and microdroplet inkjet printers are among the most common instruments used for matrix
application, but suffer from solvent-induced analyte delocalization and the formation of large
matrix crystals (138,147). On the other hand, matrix application by sublimation produces a
homogeneous layer matrix with reduced sizes of matrix crystals (136). Different matrix
compositions can improve analysis of specific classes of molecules in MALDI-IMS, largely
reflective of traditional MALDI-MS. Both 2,5-dihydroxybenzoic acid (DHB) and α-cyano-425

hydroxycinnamic acid (CHCA) are commonly applied matrices for MALDI-IMS of lipids, but
are primarily used for the detection of PCs and SMs in positive ion mode. 1,5Diaminonaphthalene (DAN) matrix was demonstrated to be efficient in positive and negative ion
mode, enabling the detection of lipids that are primarily detected in negative ion mode, such as
sulfatides, ceramides and gangliosides (136).

Figure 2. MALDI-IMS Workflow Schematic. Universal (Solid Arrows) or optional (dashed
arrows) steps can be optimized to achive better MALDI-IMS results. Optimal conditions are often
dependent on the tissue and experiment performed.
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1.2.4 Mass Spectrometers in the Dissertations
1.2.4.1 Bruker SolariX FTICR
A majority of the MALDI MS and MALDI-IMS experiments in this dissertation were
carried out on Bruker SolariX 7 Tesla FTICR mass spectrometer. The instrument possesses both
an ESI and MALDI ion source. After ionization in the MALDI source by a smartbeam-II laser,
ions are focused into an ion beam using DC and RF voltages. At this stage, ions pass through a
vacuum stage and are decelerated. Ions then traverse to the quadrupole, in which a specific m/z
window can be defined to only allow ions within that range to pass through to the hexapole. If
desired, specific ions can be fragmented in the collision cell. Ions are then focused by optical
lenses prior to entering the magnetic field of the ICR cell, which is under ultrahigh vacuum
conditions. The infinity cell, which exists at the center of the 7T magnet, consists of three sets of
electrodes that are used for ion trapping, excitation and detection. The magnetic field traps ions
and induces cyclotron motion, but a small electrical field is required to prevent ions from
escaping the ICR cell. The trapped ions are then excited by a RF frequency sweep, which
increases the radius of selected ions and enables detection by the detection plate (148).

1.2.4.2 Thermo Orbitrap Elite
The Thermo Scientific Orbitrap Elite mass spectrometer is considered a hybrid mass
spectrometer that couples a linear ion trap with an Orbitrap mass analyzer. The linear ion trap on
the front-end is the Thermo Scientific Velos Pro mass spectrometer. This functionality provides
excellent sensitivity and data acquisition speed associated with ion trap mass analyzers, and is
capable of trapping, isolating and fragmenting ions (149). The linear ion trap possesses an
independent MS detector, so that the ions can be detected in the ion trap or proceed to the
Orbitrap for further analysis. The transition to the Orbitrap requires ions to move from the RF27

only octopole into the curved linear trap (C-trap). As the ions go from a gas-free environment to
the gas-filled C-trap, ions lose their kinetic energy by colliding with the nitrogen collision gas.
Ions are transferred to the Orbitrap by ramping off RF voltages applied to the C-trap and applying
extracting voltages onto the Orbitrap electrodes. As described in Thermo literature, the Orbitrap
analyzer consists of a central spindle-shaped electrode surrounded by bell-shaped outer
electrodes. Injected ions begin axial oscillations around the central electrode of the Orbitrap, and
applied voltages prevent collision with the electrode. An image current is detected by two split
halves of the outer electrode of the Orbitrap, which can ultimately determine the frequency of
axial oscillation and m/z ratio of ions. The Orbitrap mass analyzer enables the detection of
analytes with high mass accuracy, resolution and expands the dynamic range that can be detected
(149). The combination of two divergent mass analyzers enables peptides to be measured at subppm mass accuracy which significantly improves bottom-up protein identification. The Orbitrap
Elite is setup to allow CID, HCD, and ETD fragmentation of selected precursor ions (116). For
HCD fragmentation, ions enter the HCD cell from the C-trap and the fragment spectra are
detected in the Orbitrap analyzer. The ETD source is located on the back of the Orbitrap Elite
mass spectrometer and can fragment peptide ions in the linear ion trap by the transfer of electrons
from negatively charged reagent ions.

1.3 Glycosylation
1.3.1 Broad Overview of Glycosylation
1.3.1.1 The Complexity of Protein Glycosylation
Glycosylation refers to the addition of monosaccharide or oligosaccharide chains,
commonly referred to as glycans, onto biomolecules such as proteins, lipids, proteoglycans and
glycophosphatidylinositol (GPI) anchored proteins. Recently, free, unbound glycans have been
discovered and implicated as important signaling molecules (150). It is estimated that over 50%
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of human proteins are glycosylated, making it the most common and complex post-translational
modifications. There are nine monosaccharide units from which glycans are constructed, but
additional diversity can be achieved by further modification of those monosaccharides (150). A
general classification system groups monosaccharides based on their molecular weight. Hexose
(Hex) monosaccharides consist of glucose (Glu), galactose (Gal) and mannose (Man) residues. Nacetylhexosamine (HexNAc) monosaccharides, which differ from Hex monosaccharides by the
addition of an acetyl functional group, consist of both N-acetylglucosamine (GlcNAc) and Nacetylgalactosamine (GalNAc). The remaining monosaccharides include fucose (dHex, fuc), Nacetylneuraminic acid (NeuAc), glucuronic acid (GlcA) and xylose (Xyl). Figure 3 provides a
schematic of monosaccharides compositions as they will appear throughout the rest of this
dissertation. While most of these monosaccharides are present throughout all species and across
all glycoconjugates, some monosaccharides display a specificity to certain biological species or
types of glycoconjugates. In contrast to plants, in which complex N-glycans contain xylose
residues, these residues are only observed in humans on proteoglycans (150,151). In addition to
variation in the type of monosaccharides found, species wide differences in glycosylation also
appear as differences in glycosidic bond linkages. For example, plant N-glycans express nonhuman glycan linkages, such as α1,3-linked core fucose residues (151). While limited in the
number of monosaccharides, glycosylation is quite complex. Unlike transcription and translation,
the process of glycosylation is not template encoded but depends on a variety of cellular factors.
Substrate availability, developmental stage, nutrient availability, pH and enzyme localization all
alter the observed cellular glycoforms, and allow for the glycome to respond to subtle biological
changes (152). Glycosyltransferases and glycosidases, which add and remove monosaccharides
from glycans, are responsible for the structure of the glycoform. It is estimated that around 5% of
the genome encodes enzymes that are involved in cellular glycosylation in some fashion (150).
Multiple enzymes can reside in the same region of the cell and compete over the same substrate,
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resulting in a complex array of glycoforms (152). However, glycan synthesis is not completely
random, as glycosyltransferases exhibit some degree of specificity for the protein, glycopeptide
and growing glycan structure (152). Glycosidases promote trimming of the glycan, both during or
after synthesis, but are equally responsible in yielding glycan structures. As these enzymes
function sequentially, the absence of a single glycosyltransferase that acts early in glycan
synthesis can result in pronounced differences in all observed glycoforms (153,154).

Figure 3. Molecular Weight of Monosaccharides.

Glycosylation, like all post-translational modifications, renders the proteome more
complex than the transcriptome would suggest. Given the seemingly stochastic nature of glycan
synthesis, it is not surprising that glycosylation is associated with an enormous degree of
heterogeneity.
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microheterogeneity and macroheterogeneity. In the field of glycobiology, microheterogeneity
refers to the observation that multiple glycoform compositions are present at an individual
glycosylation sites. Furthermore, glycan branching results in divergent glycans with the same
monosaccharide composition (155). It is estimated that the human serum N-glycome consists of
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around 300 to 500 glycan compositions, representing close to 5000 structures (156).
Macroheterogeneity of glycosylation refers to the rate of glycan occupancy on an individual site
of glycosylation. Even with the complex nature of cellular glycan processing, many proteins
display consistent glycosylation patterns across independent samples, suggesting an important
role of glycosylation in cellular function.

1.3.1.2 Physiological and Pathological Roles of Glycosylation
Glycosylation is integral to cell survival, demonstrated by role of glycoconjugates in cell
viability and embryonic development. While specific changes in glycosylation are well
documented, the global elimination of a single class of glycan results in cell death (157). More
subtle modifications of the glycan biosynthetic pathway have variable impacts on cell viability,
depending on what stage of glycosylation is impacted. For N-glycan synthesis specifically,
termination of N-glycan synthesis prior to the formation of hybrid and complex glycans is
embryonic lethal, while modification of terminal glycan structures elicits more limited
abnormalities (153). The role glycosylation plays in embryonic development is emphasized by
the detection of glycans which are expressed embryonically but are absent in adult tissues (152).
Even the process of fertilization is mediated by glycan epitopes on the sperm interacting with
selectins on the ECM of the oocyte (158).
The biological role of glycosylation is not limited to the developmental stages of cells.
Glycosylation regulates normal biological activity through direct and indirect effects. Direct
effects refer to the interaction of the glycan with various glycan binding proteins (GBPs),
including lectins, GAG-binding proteins and antibodies (152). Biologically, direct interactions are
important in the cells interaction with cells, the ECM and other molecules. While all GBPs use
direct effects to modulate biological function, the mechanisms for binding vary between the types
of GBPs. For instance, lectins recognize terminal glycan epitopes and fit them into shallow
binding pockets, while GAG-binding proteins use electrostatic interactions between the anionic
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GAG chains and cationic amino acids (150). While direct effects typically lack specificity
between similar glycoforms, the interaction can sometimes be highly specific. For example, Pselectin exclusively recognizes and binds to P-selectin glycoprotein ligand-1 (PSGL1) when
SLeX is expressed on a core 2 O-glycan, but not on a core 1 O-glycan (159). While direct effects
depend on the glycan itself, indirect effects of protein glycosylation refer to effects that are
caused by the physiochemical properties of the glycan or alterations in the properties of the
protein resulting from the addition of bulky hydrophilic sugar group. These indirect effects impart
broad regulatory functions on both secreted and membrane proteins. Glycosylation of secreted
proteins reduces nonspecific interactions, protects the protein from proteases and antibodies, and
improves the solubility of the secreted proteins (160). These indirect effects may or may not
depend on the composition of the glycan. Terminal sialic acid residues are important for reducing
nonspecific interactions due to their negative charge, while the general presence of bulky,
hydrophilic groups can shield sites from protease digestion (160). In addition to these effects,
indirect effects of membrane protein glycosylation ensure proper folding of the protein, enable
ECM localization and maintain the tissue structure and integrity (150). The fact that all cells are
coated with an external layer of glycoconjugates, highlights the importance of glycosylation in
molecular recognition and signaling. In fact, glycosylation can mediate downstream signaling by
directly modulating functionality or cell surface receptor expression. For example, both
glycosylated and deglycosylated beta-human chorionic gonadotropin exhibit similar receptor
binding affinity, but only the glycosylated hormone can stimulate adenylate cyclase (150).
Glycosylation of epidermal growth factor receptors (EGRFs) has been directly linked to elevated
signaling due to reduced receptor turnover and prolonged exposure on the membrane (161).
Glycosylation plays important roles in regulating the immune system and inflammatory
responses. In the immune system, the presence of protein glycoforms can be used to define self
glycans but also impacts the efficacy of immunoglobulins. Human ABO blood groups are
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determined by the status of specific glycosyltransferases possessed by an individual, resulting in
specific oligosaccharide moieties on proteins and lipids (162). For this reason, when blood is not
appropriately matched during transfusions, antibodies recognize foreign glycan antigens and elicit
an immune response. Autoimmune diseases, such as lupus or rheumatoid arthritis, arise due to the
aberrant immune response triggered by self-glycans (157). In mice, the absence alphamannosidase-II (αM-II) mimics the systemic lupus erythematosus phenotype. Functionally, the
absence of αM-II results in incomplete N-glycan branching and an increase in hybrid-type Nglycans with a terminal mannose, which results in an immune response and inflammation (163).
The glycosylation patterns of immunoglobulins also plays a role in regulating the efficacy of the
mounted immune response. The absence of fucose or sialic acid residues on IgG enhances the
antibody dependent cell mediated cytotoxicity (ADCC) as a function of higher-affinity binding to
FCγRs (164). IgG glycosylation can elicit pro- or anti-inflammatory effects. Patients with
rheumatoid arthritis frequently present with reduced galactosylation levels of serum IgG, even
prior to the onset of RA, suggesting that the pro-inflammatory effect of aberrant glycosylation
ultimately drives rheumatoid arthritis (164). Given the role glycosylation plays in regulating basic
immune response functions, it is unsurprising that defective immune cell function is the most
common phenotype in mice that survive deletion of specific glycosyltransferases (157). The
regulator role of immunoglobulin glycosylation on inflammation is not the only mechanism by
which inflammation is linked to glycosylation. Cytokines generated in response to pathogenassociated molecular patterns (PAMPs) or damage-associated molecular pattern molecules
(DAMPs), interact with glycoprotein receptors and lectins during leukocyte homing to inflamed
tissues. Glycan fragments released during the process of leukocyte degradation of ECM
glycoconjugates signal for more leukocyte chemotaxis and activation, resulting in further
inflammation (157).
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In addition to normal biological functions, abnormal glycosylation has been observed in
nearly every disease. Diseases may be caused by the presence of unique glycans, elevated
expression of glycans, or the absence of glycans in a biological system. In cardiovascular disease,
evidence suggests that glycosaminoglycans (GAGs) on proteoglycans are responsible for
initiating early stages of atherogenesis (165). After initiation, monocyte entry into the
subendothelial regions of blood vessels relies upon the interaction of SLeX on PSGL-1 with
endothelium selectins. This observation was verified in vivo by the reduction of fatty streaks in
mouse models that are deficient in P- or E-selectins compared to control mice (166,167). In
contrast, the absence of specific glycans can result in disease. One such example is inclusion cell
disease, a lysosomal storage disease that is characterized by the buildup of substances in the
lysosome. This buildup is caused by the absence of enzymes in the lysosome due to the absence
of mannose-6-phosphate, which targets enzymes to the lysosome (153).
Host-pathogen interactions are often mediated by the interaction of pathogens with
specific glycan patterns on the host cell. The functionality of the influenza virus depends on two
glycoproteins, hemagglutinin and neuraminidase. Hemagglutinin binds to sialic acids on the hostcell glycoproteins and glycolipids to initiate viral infection. Following viral replication,
neuraminidase cleaves the sialic acid to allow the virus to release from the host-cell and continue
to infect more cells (168). Similarly, cholera toxin binds sialylated glycolipids, primarily GM1,
present on the intestinal epithelia (169). Occasionally, the absence of specific glycoforms can
result in pathogen invasion. The absence of terminal α-GlcNAc residues on mucin core 2 Oglycans results in Helicobactor pylori colonization (170). Apart from the direct host-pathogen
interaction, glycans on the viral glycoprotein coats can aid in pathogenesis. In human
immunodeficiency virus (HIV), N-glycosylation on the envelope glycoprotein (Env) provides
resistance to antibody neutralization and enhances infectivity (171). Alternatively, pathogens can
adapt to mimic host glycan structures in an effort to evade the hosts immune system (172).
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Given the broad nature of glycosylation in diseases, it is understandable that
glycosylation is frequently exploited for therapeutic purposes. Rational vaccine design has
benefited from an increased knowledge of aberrant glycosylation in diseases and improved
synthetic approaches for glycopeptide synthesis. Traditionally, carbohydrate antigens initiate lowaffinity, short-lived IgM responses, but fail to induce a T-cell response (173). However, by
combining carbohydrate antigens to a specific carrier protein, T-cell responses can be initiated.
This approach has been applied in the generation of anticancer vaccines, which aim to eliminate
preexisting cancer cells (172). Using this rationale, Muc1 glycopeptides were determined to
initiate immune responses and antibody-dependent cellular cytotoxicity (ADCC) more efficiently
than non-glycosylated Muc1 peptides (174,175). Neu5Gc-bearing gangliosides have been
successful targets in immunotherapy based on the antigenicity of the non-self Neu5Gc
monosaccharide (172). Host-pathogen interactions are another area where knowledge of
glycosylation can be used to improve therapeutic outcomes. As the initial stage of pathogen
infection often involves the pathogen interaction with specific glycan sequences on the target
cells, the disruption of this interaction is associated with improved therapeutic effects. The use of
free glycans that mimic the pathogen interaction sequence has been reported to inhibit infection
by various pathogens (172). Free glycans, along with the presence of immunoglobulins, are the
suggested reasons that breastfed are on average healthier than formula fed infants (176,177). In
addition to disrupting the initial interaction between the host and pathogen, the glycosylation
related mechanisms can also be exploited to inhibit the release of the pathogen from cells. An
example of this is the influenza virus, which requires neuraminidase activity to release from the
cell surface of infected cells. Two current treatments for the influenza virus, zanamivir and
oseltamivir, function by inhibiting neuraminidase activity and thereby preventing the release and
further propagation of the virus (178,179). Unique glycosylation patterns on viral coats are also
being exploited for rational vaccine design. The HIV coat protein is heavily glycosylated, but
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with oligomannose-type glycans that are rare in cell surface and secreted glycoproteins (180).
Antibodies that recognize various glycan-peptide epitopes on the HIV coat protein are projected
to be useful in developing HIV vaccinations. A therapeutic approach for treating patients with
glycosylation-based genetic disorders is to provide exogenous monosaccharides. Patients
diagnosed with leukocyte adhesion deficiency II (LAD II), a disease associated with a loss of
SLeX-mediated leukocyte rolling, display improved immune function following treatment with
exogenous L-fucose (181). Conversely, lysosomal storage diseases, characterized by defective
enzyme activity of lysosomal enzymes, can be treated by enzyme replacement therapy. For
instance, both Fabry disease and Mucopolysacchridosis I, can be treated by the administration of
recombinant enzymes α-galactosidase A and α-L-iduronidase, respectively (182,183).
Biotherapeutic glycoproteins represent a robust market for pharmaceutical companies.
The presence of specific glycoforms on glycoprotein therapeutics can modulate immune
response, impact therapeutic pharmacokinetics, and therapeutic functionality (184). Therapeutic
glycoproteins are often expressed in nonhuman cell lines and are therefore subject to non-human
epitopes and linkages. Efforts to humanize glycans are being investigated through the use of cell
glycosylation mutants and transgenically altered cell lines. By using cell lines with specific
glycosylation machinery, scientists can exert some control over the ultimate glycoforms on
therapeutic glycoproteins, which play important roles in therapeutic efficacy. Erythropoietin is a
prime example of this, where deglycosylated erythropoietin exhibits similar in vitro activity
compared to glycosylated erythropoietin, but the in vivo activity is reduced by about 90%. The
reduced in vivo activity was found to be a function of rapid renal clearance of the deglycosylated
erythropoietin (150). Similarly, proper glycosylation of antibodies also increases the circulatory
lifetime (185).The ability to regulate the sites and structures of glycoforms is a focal point in
glycoprotein therapeutic research.
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1.3.1.3 Mechanisms Involved in Protein Glycosylation
The addition of N-glycans to proteins occurs co-translationally in the endoplasmic
reticulum and is followed by further glycan processing in the Golgi. During protein synthesis, an
amino acid sequence targets proteins to the secretory pathway resulting in their co-translational
transportation to the ER, where a signal-recognition particle (SRP) binds the receptor in the ER
membrane, promoting the protein complex to enter the ER through the translocon (186). The en
bloc addition of N-glycans is essential for secretory and membrane protein folding. Two lectinlike chaperones in the ER, calnexin (CNX) and calreticulin (CRT), bind glucose residues on the
nascent glycan to ensure proper folding and prevent aggregation of the protein (187). Ultimately,
glycosidase trimming releases properly folded proteins from the CNX/CRT complex. Misfolded
proteins are reglucosylated by UDP-Glc:glycoprotein glucosyltransferase (UGGT), which can
then interact with CNX/CRT or be transported to the cytosol and degraded by ER-associated
degradation (150). Properly folded proteins are packaged in COPII-coated vesicles and then
transported to the Golgi where further glycan processing occurs.
N-glycan synthesis begins with the transfer GlcNAc-P from UDP-GlcNAc to the lipidlike precursor, dolichol phosphate, to form dolichol pyrophosphate N-acetylglucosamine (Dol-PP-GlcNAc). Dol-P-P-GlcNAc is further extended on the cytoplasmic face of the ER membrane by
the sequential addition of one more GlcNAc and five mannose residues. A "flippase" is then used
to flip the N-glycan precursor to the lumen of the ER, although the mechanism is not completely
understood. In the ER lumen, the glycan is further extended by the addition of four mannose
residues and three glucose residues, completing the synthesis of the mature N-glycan precursor,
Glc3Man9GlcNAc2-P-P-Dol. The transfer of activated sugars to the growing N-glycan is
mediated by the ALG genes, which encode unique glycosyltransferases that carry out specific
transfers of sugar residues at defined stages of glycan synthesis (188,189). The completed
precursor (Glc3Man9GlcNAc2-P-P-Dol) is then transferred to an asparagine residue in the N37

glycan consensus sequence by an oligosaccharyltransferase (OST) complex. The N-glycan
consensus sequence is N-X-S/T, where X is anything other than proline. After protein
glycosylation, the glycan is further trimmed in the ER by α-glucosidases I and II and αmannosidase I (Figure 4a). Trimming resumes in the cis-Golgi, where glycans can be processed
to Man5GlcNAc2, which serves as the precursor to complex and hybrid glycan structures.
Glycans that are not processed or incompletely processed by α1-2 mannosidases in the cis-Golgi
cannot be further modified and are detected as high-mannose glycans (Man5-9GlcNAc2) (Figure
4b). In the medial-Golgi, Man5GlcNAc2 is acted upon by N-acetylglucosaminyltransferase I
(GlcNAcT-I) and α-mannosidase II to form GlcNAcMan3GlcNAc2. Decoration of the GlcNAc
residue at this stage results in the formation of hybrid N-glycans (Figure 4c). Alternatively, the
transfer of an additional GlcNAc by GlcNAcT-II generates the base of complex N-linked glycans.
Triantennary and tetraantennary complex glycans utilize GlcNAcT-IV and GlcNAcT-V to add
additional branches, while GlcNAcT-III transfers a bisecting GlcNAc residue onto the complex
glycan (Figure 4d). Finally, in the trans-Golgi, further maturation may take place to provide
additional glycan diversity. Among the most common additions are the transfer of β-linked
galactose residues to the non-reducing end, the addition of α1,6-linked fucose residues to the
GlcNAc directly bound to the asparagine (termed core fucosylation), and the addition of sialic
acids and fucose residues on branched LacNAc chains.
Secreted and membrane proteins are frequently O-glycosylated with mucin-type Oglycans, which can appear as linear or branched arrangements of glycans with an O-GalNAc at
the reducing end. While this type of glycosylation is termed mucin-type, it is also present on
proteins that are not part of the mucin family. In fact, it is estimated that over 80% of proteins that
are processed through the secretory pathway are O-glycosylated (190). Unlike with Nglycosylation, O-glycosylation does not appear to occur on conserved consensus sequences, but
does target serine or threonine amino acids. The synthesis of mucin-type O-glycans is initiated in
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the golgi by the transfer of GalNAc from UDP-GalNAc to a Ser/Thr in an α-linked manner by the
polypeptide GalNAc-transferase (ppGalNAcTs) family of enzymes, forming the Tn antigen
(152). The Tn antigen is further modified to form core 1-4 structures, and less frequently core 5-8
structures. The core 1 structure (T antigen) is synthesized by the transfer of Gal from UDP-Gal to
Tn by the enzyme Core 1 β3-galactosyltransferase (C1GalT1, T-synthase) in the cis and medial
Golgi. Interestingly, this enzyme is associated with a molecular chaperone Cosmc, the only
known glycosyltransferase chaperone. Cosmc functions to insure proper folding of T-synthase in
the rough ER (191). Alternatively, Core 3 N-acetylglucosaminylfransferase (C3GnT) transfers a
GlcNAc from UDP-GlcNAc in a β1,3 fashion to form Core 3 structures. The family of Core 2
GlcNAc Transferases (C2GnT) or a subset of the family, the C2/4GnT enzyme, add a branched
β1,6-linked GlcNAc to Core 1 and Core 3 glycans respectively, generating Core 2 and Core 4 Oglycans. The core can be further extended to generate biologically relevant glycan moieties, such
as blood group antigens (ABO), Lewis antigens, and large extended structures.

Figure 4. N-Glycan Processing. The glycan precursor is transferred onto proteins in the ER and
upon trimming of glucose residues, ensures proper folding (a). The glycoprotein is then
transferred to the Golgi, where high mannose glycans are formed in the cis-Golgi (b), hybrid and
complex glycans are formed in the medial-Golgi (c,d), and terminal modifications are added in
the trans-Golgi.
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Nuclear and cytoplasmic proteins may also be glycosylated to include O-GlcNAc, O-Glc
or O-Fuc modifications. O-GlcNAc is an especially dynamic modification that can crosstalk with
phosphorylation to regulate signal transduction (152). O-GlcNAc cycling by O-GlcNAc
transferase (OGT) and O-GlcNAcase (OGA) can rapidly add or remove the modification from
protein substrates to respond quickly to biological signals (192). Ultimately, the process of OGlcNAc glycosylation allows for the timely regulation of cell cycle progression, response to
stressors, and cell survival (192).

1.3.1.4 Glycosylation in Cancer
The first example of aberrant glycosylation in cancer was discovered in the 1950s by the
observation that peptides were larger in transformed cells compared to untransformed cells. It is
now known that this increase in peptide molecular weight is linked to elevated levels of β1,6
branched N-glycans. Around the same time, plant lectins demonstrated enhanced binding to
tumor cells compared to non-tumor cells (193,194). In the 1970s and 1980s, following the
discovery of monoclonal antibodies, researchers began to immunize mice against tumor cell
extracts to generate antibodies. A majority of the antibodies generated act directly against a
glycan antigen or glycopeptide epitopes, including B72.3, CA19-9, CA15-3, and CA-125 (195–
199). Since these original experiments, alterations in glycosylation are now recognized to be a
hallmark of cancer.
Cell surface changes in glycosylation can be categorized as oncofetal antigens, neoantigens, and normal antigens. Oncofetal antigens are glycan epitopes that are expressed during
embryonic development, are absent in normal adult tissue, but reappear in the presence of tumor
tissue. In contrast, neo-antigens are novel glycan structures that are not present in embryonic or
adult tissues. Oncofetal antigens and neo-antigens primarily exist in the form of truncated Oglycans (152). Both structures make ideal disease markers as they are tumor specific and rarely
detected in patients with benign disease. Tn, sialyl-Tn and T antigens have been classified as pan40

carcinoma antigens based off of their presence in most cancers. In fact, T and Tn antigens have
been observed in around 90% of carcinomas, while the two antigens are rarely co-expressed in
benign diseases (200). As these truncated antigens are often co-expressed in tumors, comparing
the ratio of Tn to T antigen can provide prognostic information regarding cancer progression
(201). Normal antigens are glycans that are present in normal physiological situations but have
altered levels of expression that correlate with a disease. Normal antigens most often vary in their
terminal and extended structures. Unlike oncofetal and neo-antigens, alterations in normal
antigens exist on N-linked glycans in addition to O-linked glycans. While the form of aberrant
glycosylation varies across different forms of cancer, the general trends of elevated β1,6 GlcNAc
branching, decreased β1,4 bisecting GlcNAc, increased cell surface sialylation, elevated core
fucosylation, elevated expression of Lewis antigens, and alterations in ABO structures are
commonly detected (158,198,202–206). An example of system dependent variation in glycan
expression is the deregulation of ABO structures in cancer. ABO structures are not observed in
healthy colon tissues but are present in tumor colon tissue. In contrast, lung cancer tissues exhibit
mismatched ABO structures compared to the normal tissue (206–208). Another example of the
differential effect of glycosylation is the role of bisecting GlcNAc in reducing tumor volume and
metastasis in most cancers, but promoting liver metastasis in melanoma and leukemia cell lines
(209). The identification of aberrantly expressed glycans can often be linked to the
glycosyltransferases that are responsible for their synthesis (210,211).
The mechanisms employed by glycosylation to regulate tumor initiation to metastatic
progression are still under investigation. Truncated O-glycans are detected early during malignant
progression and are thus hypothesized to be important to the early stages of tumor development
(198,212–214). Other modifications, such N-glycan branching, present later during the
tumorigenic process and are mainly linked to the later stages of tumor growth and metastasis.
While it has long been suggested that interactions of branched glycans with GBPs promotes
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metastasis, a recent manuscript has hypothesized N-glycan branching may also alter the half-life
and conformation of cell surface receptors (215). Changes in terminal monosaccharide residues
can impact the functional role of the glycan. Many tumors, including those of the pancreas,
express elevated levels of sialyl Lewis antigens, which have terminal sialic acid residues. These
antigens play important roles in metastasis through their interaction with selectins. E-selectins
enable tumor cells in the vasculature system to adhere and infiltrate distant sites, while P-selectins
interact with the cancer cell and protect it from the immune system (152). It is through this
process that cimetidine and heparin, which have been reported to block the interaction of sialyl
Lewis antigens with selectins, are thought to improve cancer-related disease survival (152,198).
Elevations of α2,6 sialylation, specifically on integrins, have also been implicated in metastasis
(216,217).

1.3.2 Glycomics
1.3.2.1 General Introduction into Glycomic Analysis
As glycosylation plays a pivotal in many diseases, numerous studies have attempted to
characterize broad disease-associated alterations in the glycome. A complete survey of the entire
glycome should determine the molecular composition of the glycan, the structure and branching
pattern, and the anomeric linkages of each monosaccharide (218). These studies attempt to
identify broad changes in glycosylation, which are ultimately representative of the partial or
global proteome (219). While different approaches are commonly used to study the glycome, the
general

procedure

typically

involves

[1]

glycan

release,

[2]

labeling,

[3]

enrichment/chromatography, and [4] detection and characterization.

1.3.2.2 Release of Glycans
Prior to analysis of the glycome, glycans must be released from the protein by enzymatic
or chemical methods. Enzymatic release of glycans is primarily reserved for N-linked glycans due
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to the availability of enzymes. Endoglycosidases are used for glycan release, while
exoglycosidases can be used for structural analysis of released glycans. Endoglycosidases release
the entire glycan, or a defined subset of the glycan, from the protein at the reducing end. For
example, PNGaseF severs the bond between the asparagine amino acid and the glycan (220).
PNGaseF is capable of releasing high-mannose, complex and hybrid glycans, with the only
limitation being those with an α1,3-linked core fucose. However, the core α1,3 fucose linkage is
not present in mammals, so the limitation is not a factor in the digestion of human samples.
Endoglycosidase H (Endo H), an enzyme that cleaves between the two core GlcNAc residues on
an N-glycan, can be used to digest high-mannose and hybrid glycans (220,221). Non-fucosylated
glycans released by PNGaseF and EndoH will vary by the mass of a GlcNAc residue. Other
endoglycosidases (i.e. EndoM, EndoF1, EndoF2, EndoF3) release classes of N-glycans
depending on fucosylation and amount of branching (221). There are few commercially available
enzymes that can release O-linked glycans, and none can universally release all classes of Olinked glycans (220). For instance, endo-α-N-acetylgalactosaminiadase, is only capable of
releasing core 1 O-glycans (222). Thus, studies that profile the O-glycome rely on chemical
methods for glycan release, primarily β-elimination and hydrazinolysis (223). The original
protocol for reductive β-elimination utilizes basic sodium hydroxide conditions to cleave Oglycans under moderate temperatures, followed by the reduction of the terminal monosaccharide
to an alditol (224). A faster release of O-glycans can be achieved by using dimethylamine instead
of sodium hydroxide (225). Reductive β-elimination is not amenable to certain glycan detection
strategies, as glycans cannot be labeled with a fluorophore or chromophore, as will be discussed
in the glycan derivatization section. Approaches to release O-glycans by nonreductive βelimination have been explored, but are subject to glycan degradation at the reducing end,
referred to as "peeling" (226–228). Hydrazinolysis represents another nonreducing glycan release
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strategy that can be applied to both N-and O-glycans (223). However, selectivity for O-glycan
release can be achieved under lower temperatures (229).

1.3.2.3 Glycan Derivatization
Derivatization of native glycans is almost universally performed prior to glycan analysis.
While native glycans can be profiled by modern instrumental methods, derivatization functions to
[1] allow glycans be detected by alternative approaches, [2] stabilize monosaccharide residues
that are labile under native conditions, [3] improve detection sensitivity, and/or [4] provide more
informative structural information following tandem mass spectrometry (230). The most common
N-glycans derivatization strategies can be classified into the broad categories of reductive
amination, Michael addition, hydrazide labeling, permethylation, and the selective modification
of terminal monosaccharides. In reductive amination, the reducing end of the glycan is labeled by
a condensation reaction with a primary amine, resulting in a Schiff base that is then reduced to
yield a secondary amine (230). Reductive amination is commonly used in glycomic analysis is to
incorporate fluorescent tags on the reducing end of glycans, thereby allowing detection by a
fluorescence detector after chromatographic separation. This strategy is compatible with a wide
variety of labels, including 2-aminobenzamide (2-AB), 2-aminobenzoic acid (2-AA) and 2aminopyridine (2-PA). Efforts to monitor the process of 2-AB and 2-AA labeling demonstrate a
high labeling efficiency and negligible loss of sialic acid (231). However, glycans released by
reductive β-elimination are incompatible with derivatization by reductive amination as the glycan
is already reduced during glycan release. Michael addition labels the reducing end of the glycan,
but under alkaline conditions reducing the loss of sialic acids. 1-Phenyl-3-methyl-5-pyrazolone
(PMP) is the most common labeling reagent added through Michael addition, but no fluorescent
labels are known (230). In an effort to improve throughput, a one-pot method to release and label
O-glycans by β-elimination has been developed (232). Hydrazide labeling at the reducing end of
the glycan results in a permanent positive charge on the glycan. Other labeling strategies are
44

directed at the non-reducing end or terminal monosaccharides. Permethylation replaces hydroxyl,
amine and carboxyl groups with methyl groups, generating a more hydrophobic glycan, which
can dramatically improve downstream chromatography and analysis (233). During the first step
of this procedure, alcohol groups on the glycan are converted into alcoholate ions by sodium
hydroxide in DMSO. A methyl group from methyl iodide is then substituted onto the alcoholate
ions (220). In one adaptation of the method, the processes of O-glycan release and permethylation
are combined (234). Other derivatization approaches selective modify the monosaccharides that
complicate downstream analysis, specifically sialic acids. P-toluidine can incorporate onto the
sialic acid residues on glycoprotein and the derivatized glycans can then be released with
PNGaseF (235). Other approaches offer the ability to differentially modify sialic acids based off
of their linkages. Methyl esterification results in the lactonization of α2,3-linked sialic acids and
the formation of methyl esters on α2,6-linked sialic acids (219,236). A more recent study
examined methanol, ethanol, 2-propanol, and 1-butanol as alkyl donors. Both methanol and
ethanol performed well in initial testing, but ethanol [ethyl esterification] was concluded to
exhibit more selectivity between α2,3- and α2,6-linked sialic acids (237). The modification of
sialic acids enhances the stability of sialic acid residues, while enabling detection in positive ion
mode.

1.3.2.4 Glycan Enrichment/Chromatography
The glycan enrichment/chromatography step serves two primary roles in the analysis of
the glycome. The first function is the removal of salts and labeling reagents, which are often
present in significant excess over the glycans. Solid phase extraction (SPE) approaches reduce the
amount of labeling reagents present after glycan derivatization, especially for reductive amination
or hydrazide labeling approaches (230). Liquid-liquid extraction is used to remove additives from
permethylated glycans (238). The second function of chromatographic separation of native or
derivatized glycans is to separate the glycans prior to detection, thereby reducing suppression of
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lower abundance glycans or enabling structural isomers to be distinguished (239,240). Efficient
chromatographic separation often relies upon on-line chromatography interfaced with the method
of detection. Native glycans are hydrophilic and are not efficiently retained on reverse phase (RP)
columns, but derivatization often increases the hydrophobicity of glycans and enables the use of
RP chromatography for separation (239,241,242). In addition to RPLC, the hydrophilic properties
of native glycans and some derivatized glycans encourages the use of hydrophilic interaction
chromatography (HILIC), where there is a direct correlation between retention time and the size
and polarity of the glycan (241,243). Ultimately, chromatography steps that employ RPLC are
advantageous as labs that are currently equipped for bottom-up proteomics can process glycans
with minimal alterations to the existing workflows already in place. Porous graphitized carbon
(PGC) resin can enrich glycans in both on-line and SPE workflows, with enrichment following
the same principles as HILIC enrichment (239,240,244). Thin layer chromatography (TLC) and
gel electrophoresis (GE) can be used in place of LC to chromatographically resolve glycans
(245). The emphasis placed on chromatographic separation of glycans has resulted in novel
modalities developed specifically to study glycosylation, such as the GlycanPac AXH-1
analytical column, which can separate glycans based on charge, size and polarity (243). While the
interaction is similar to HILIC chromatography, the charge state of the glycan does not play a role
in HILIC enrichment.

1.3.2.5 Glycan Detection and Characterization
Traditional glycomic approaches rely upon chromatographic retention in comparison to
reference glycan libraries from standard samples (239). For this approach, glycans are labeled
with a fluorophore or chromophore, which not only stabilizes the glycan but also serves to enable
detection by fluorescent or UV detectors following chromatography (223). In addition to
retention time, glycan structures can be validated by sequential glycosidase digestions (219,246).
After exoglycosidase digestion, a change in the retention time denotes the presence of the enzyme
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substrate that is targeted by the exoglycosidase. While useful, this approach is limited by the
number of commercially available enzymes. Complete structural assignment may be unobtainable
as enzymes, such as those to specifically digest bisecting GlcNAc residues, are unavailable (246).
More recently, glycomic analysis has benefitted from advances in the field of mass
spectrometry, as mass spectrometry is more sensitive and consumes less sample. Importantly,
studies have shown that the signal derived from neutral and permethylated glycans increases with
glycan abundance (233,247). MALDI-MS is a fast and convenient way to profile the glycome.
Both neutral and acidic native glycans can be profiled by MALDI but the presence of both types
in a single sample complicates analysis (231). In positive ion mode, neutral glycans are
predominantly detected as [M + Na]+ ions, but [M + H]+ and [M + K]+ are also observed (220).
However, MALDI-MS in positive ion mode is the not ideal for detecting sialylated glycans, as
sialic acid residues are often labile and released by in-source decay due to the energy of the laser
and vacuum conditions in the ion source (248,249). The use of ion sources with higher-pressure
conditions reduces the dissociation of sialic acids. Negative ion mode is primarily used for the
detection of sialylated glycans, which are detected as [M - H]- ions, as opposed to [M + Na]+ and
[M - nH + (n + 1Na)]+ ions in positive ion mode (247). Sialylated glycans profiled in negative ion
mode do not suffer from sialic acid loss to the extent observed in positive ion mode. The choice
of MALDI matrix has a pronounced effect on the signal observed for the detection of native
glycans. Both DHB and CHCA can be used to survey glycans in positive ion mode, with CHCA
promoting more sialic acid dissociation (250). Furthermore, the combination of matrices has been
demonstrated to improve glycan analysis over individual matrices. DHB/CHCA and DHB/SA
combinations were shown to effectively increase ionization efficiency of glycans and improve
shot-to-shot reproducibility (251). Additionally, DHB/SA enables detection of both glycans and
deglycosylated proteins in a single experiment. In addition to MALDI, ESI, typically preceded by
chromatographic separation, is also widely used for glycomic analysis. However, ESI generates a
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weaker signal compared to peptides and proteins, in part due to limited surface activity in ESI
droplets caused by the hydrophilicity of the glycans (230,233). Using ESI, quantitation of Nglycans can be achieved using multiple-reaction monitoring (MRM) in the mass spectrometer
(252).
It is often beneficial to derivatize glycans prior to analysis by mass spectrometry. The
increased hydrophobicity of glycans as a result of permethylation increases the ionization
efficiency and results in higher signal and increased stability. As permethylation functions by
substituting methyl groups for hydrogen groups on hydroxyl, amine, and carboxyl groups,
permethylated glycans do not differ by a consistent mass difference compared to the native
glycans. Instead, a larger glycan will have a relatively larger shift in molecular weight, due to
increased substitutions sites on the glycan. When derivatization only occurs at the reducing end of
the glycan, the resulting mass shift will not vary with the size of the glycan. An example of this is
the 2-AB label, which is commonly used for fluorescence detection, but is also compatible with
MALDI and ESI (231). The labeling of labile and acidic residues can also consolidate the polarity
used for glycan detection. Labeling by permethylation or p-toluidine enables sialylated glycans to
be detected in positive ion mode (230,235).
The initial assignment of the glycans present in a sample is often done by mass accuracy
or retention time, but an additional structural validation is sometimes required (253). As
previously mentioned, sequential exoglycosidase digestion represents a traditional approach to
study monosaccharide linkages. This technique is often employed prior to chromatography, but
can be implemented prior to mass spectrometry as well (219,246). Given the limitations in
throughput and enzyme availability, mechanisms to structurally differentiate glycan isomers by
mass spectrometer have been investigated. Fragmentation in a mass spectrometer represents a less
time consuming and easier technical approach to characterizing the composition and linkages of a
glycan. Initial fragmentation techniques relied on spontaneous post-source decay, taking
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advantage of the poor stability of glycans, albeit usually at a poor resolution (218,247). While
useful for verifying the glycan composition, this approach was unable to produce information
relevant for defining the structure. More recently, CID is more commonly utilized. It is important
to understand information produced by specific ions when evaluating the efficiency of
fragmentation for structural elucidation of glycans. The original nomenclature for glycan product
ions, established by Domon & Costello, defined two series of fragment ions; a, b and c, and x, y,
and z (254). The first series of ions (a, b, and c) contain the non-reducing terminus, while the
second series (x, y, and z) contain the reducing terminus (Figure 5). The b, c, y and z ions are
generated from fragmentation across the glycosidic bonds, while a and x ions are generated from
cross-ring cleavages (254). Defining anomeric linkages by fragmentation requires the generation
of a and x ions. Unfortunately, when selected for fragmentation by low energy CID in positive
ion mode, [M + H]+ and [M + Na]+ ions primarily fragment across the glycosidic bonds, with the
sodium adduct providing more linkage-informative cross-ring cleavages. Ramping up the
fragmentation energies promotes more cross-ring cleavages (255). While not ideal, fragmentation
across glycosidic bonds can sometimes provide structural information based off of characteristic
diagnostic ions, such as those generated from the presence of a bisecting GlcNAc residue or core
fucose (247,255). Efforts to improve the fragmentation efficiency and formation of cross-ring
cleavages have focused on the using sample additives, different MALDI matrices, and glycan
derivatization. The addition of alkali metal additives into the glycan sample enhance
fragmentation efficiencies (Li>Na>K>Rb>Cs) and activation energies (256). For MALDI-MS
analysis, the choice of matrix significantly impacts the glycan fragmentation pattern. CHCA is
characterized as a “hot” matrix and primarily promotes cleavages at the glycosidic bonds,
predominantly forming b and y type ions (218). In contrast, DHB provides a more informative
fragmentation pattern, promoting glycosidic and cross-ring cleavages. The glycan structural
information can be further enhanced by glycan derivatization. CID in negative ion mode is quite
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productive in structurally defining glycans. Fragmentation of glycans in negative ion mode
promotes more cross-ring cleavage and diagnostic ions that denote branching patterns, the
presence of bisecting GlcNAc residues, and the location of fucose residues. As with positive ion
mode, fragmentation can be enhanced by the addition of anions, such as chloride, nitrate, and
phosphate salts (246).

Figure 5. Glycan Fragmentation Series. Fragmentation of glycans results in different series that
either contain the reducing end (x, y, and z ions) or do not contain the reducing end (a, b, and c
ions). The types of ions generated often depend on the fragmentation strategy used.

1.3.3 Glycoproteomics
1.3.3.1 General Introduction into Glycoprotein Analysis
Given the dynamic role of glycosylation in biological and pathological functions,
glycoproteomics has become extremely relevant in the initial phase of biomarker discovery
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research. Protein glycosylation is highly specific, both in regards to the site of glycosylation and
the oligosaccharide structures. However, disease related changes in glycoproteins can manifest as
one or multiple of the following characteristics; [1] alterations in the site or frequency of
glycosylation, [2] overall changes in protein abundance, or [3] changes in structure of the
oligosaccharides at a specific site. Thus, an uncoupled analysis of the glycome and proteome
results in a significant void of information by not linking the proteins to their attached glycans.
General glycomic analysis results in a loss of information about the modified protein and specific
sites of glycosylation, while proteomic analysis ignores the site and structure of oligosaccharide
modifications. Glycoproteomics aims to rectify these limitations by characterizing and
quantifying the protein and glycan attachments for each glycoprotein in the sample.
Glycoproteomic research is typically directed at secreted proteins detected in bodily fluids (i.e.
saliva, cysts, serum, secretions from cells) or membrane proteins (i.e. tissue sections or cell
membrane fractions). Generally, secreted glycoproteins represent ideal biomarkers for the noninvasive detection of diseases, while membrane glycoproteins provide information on the cellular
mechanisms that drive the disease (257).

1.3.3.2 Glycoprotein Enrichment
1.3.3.2.1 General Enrichment Overview
While recent analytical advances have improved the analysis of the glycoproteome,
significant limitations in mass spectrometry-based glycoproteomics persist due to the inherent
complexity of glycosylation. This complexity is attributed to poor digestion efficiency, the
presence of non-glycosylated peptides, glycan heterogeneity, and the physiochemical properties
of the glycan modification. A majority of glycoproteomic research relies upon bottom-up
proteomic analysis of glycopeptides or previously glycosylated peptides, due to the limitations of
top-down mass spectrometry (129,258). Trypsin is the most common enzyme used for
glycoprotein digestion, but often produces prohibitively large glycopeptides due to limited
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digestion sites and missed cleavages when the glycan is in close proximity to the cleavage site
(259,260). Thus, the use of other enzymes with complementary cleavage sites can improve the
number of glycoproteins detected (261). While it is estimated that >50% of human proteins are
glycosylated, only 2-5% of peptides are glycopeptides, thus there is a significant need to enrich
glycopeptides from the total peptide mixture (262). Another complication for glycoproteomics is
the issue of protein dynamic range. Serum proteomics for low abundance biomarkers often
necessitates multi-dimensional separation strategies to overcome the large dynamic range of
serum proteins, which is approximately 10^12 (263). It is estimated that 22 of the most abundant
plasma proteins constitute 99% of the total protein mass, including some (i.e. albumin) which are
non-glycosylated (150,221,264). As these proteins provide little clinically relevant information,
depletion often improves the total number of identified proteins (63). Even though the dynamic
range is not as robust in tissue sections, enrichment strategies are still required (258).
Macroheterogeneity and microheterogeneity further enhance the complexity of glycoprotein
analysis (221,265). In conjunction with dynamic range issues, micro- and macroheterogeneity
result in a low abundance of identical glycopeptides, especially compared to peptides with no
posttranslational modifications. Finally, the hydrophilicity of glycans reduces the ionization
efficiency of the peptides when analyzed by mass spectrometry. Taken together, the low
abundance, complexity and low ionization efficiency of glycopeptides necessitate glycopeptide
enrichment prior to mass spectrometry. While enrichment can be performed at the protein level,
enrichment at the peptide level is beneficial as some glycans are masked by the protein tertiary
structure (257). Enrichment of glycoproteins can be performed at the protein and peptide level
and can be classified into three broad categories; affinity enrichment, covalent interactions, and
physiochemical enrichment methods (266).
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1.3.3.2.2 Affinity Enrichment
Affinity enrichment approaches rely on lectins or antibodies that recognize specific
glycan epitopes or monosaccharide linkages. Under both strategies, glycoproteins that interact
with the lectin or antibody are retained, while other molecules are removed by washing. Lectins
are carbohydrate-binding proteins that recognize specific oligosaccharide epitopes with various
degrees of specificity. Lectin enrichment offers the capability to do both broad, or targeted
glycoprotein enrichment, depending on which lectins are used. Broad specificity lectins, such as
concanavalin A (ConA) or wheat germ agglutinin (WGA) display a broad specificity for common
glycoforms. Other lectins interact with specific monosaccharides at defined linkages, such as
sambucus nigra lectin (SNA), which interacts preferentially with α2,6-linked sialic acids (267).
Even though not all anomeric linkages can be differentiated using lectins, the combination of
lectins and sequential exoglycosidase digestion can provide relevant structural information based
off of changes in glycoconjugate binding (268). A general redundancy exists in glycoprotein/
glycopeptide identification when comparing enrichment with different lectins, as glycoforms
interact with multiple lectins (269). After enrichment, bound glycoconjugates are eluted by
adding sugars with high affinity for the lectin to outcompete glycoconjugate binding. This
reversible binding mechanism enables downstream analysis of intact glycoconjugates (270). The
scope of glycoprotein analysis can be broadened by using multiple lectins simultaneously
(MLAC) or sequentially (SLAC) to enrich glycoconjugates with broad glycosylation motifs
(271). These approaches are used to provide a more global glycoconjugate enrichment or to
enrich structures the do not interact with a single lectin. Total enrichment efficiency can be
improved by incorporating nonionic detergents (221). While some glycoprotein enrichment
approaches require the removal of abundant, non-glycosylated proteins (i.e. albumin), a
comparison of lectin enrichment before and after depletion demonstrated little utility (269).
Several limitations of lectin enrichment include variation due to poor standardization of lectins
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from different commercial sources, poor reproducibility across large cohorts of samples, and low
binding efficiency (269). When applied to global glycoproteomics, lectin enrichment may result
in experimental bias due to variation in lectin-glycan binding affinity across glycoforms. In
addition to glycoconjugate enrichment, the use of lectins in a microarray format can identify
which lectins will be useful in an experimental study. Using this technique, proteins are
fluorescently labeled and allowed to interact with immobilized lectin spots. Lectins that display
altered binding between two conditions, such as tumor and non-tumor, represent promising
targets to enrich aberrantly glycosylated proteins (221). This is especially useful as over 160
lectins have been identified and at least 60 are sold commercially (267). Commercially available
lectins are available in pure, resin-bound, biotinylated and fluorescently-labeled forms (269).
Alternatively, antibodies targeted against glycan antigens can be used for glycoprotein
enrichment. However, this approach is limited as glycans are poor antigens, resulting in few
antiglycan antibodies with high affinity and specificity (272). Antiglycan antibodies have been
utilized to enrich glycoproteins with O-GlcNAc, O-GalNAc, SLeX, CA19-9, and polysialic acid
epitopes (221,273). However, the ability to generate antibodies requires the presence of multiple
monosaccharides or the combination of a monosaccharide with a peptide. This has limited the
success of generating antibodies specific to truncated glycoforms (274,275). Most antiglycan
antibodies recognize terminal residues, but the underlying glycoform and class of glycan can play
a role in binding affinity (150).
1.3.3.2.3 Covalent Interactions
Glycoconjugate enrichment strategies that rely on covalent bond formation improve the
specificity of glycoconjugate enrichment by increasing the efficiency of non-glycoconjugate
removal (276). These approaches enrich glycoconjugates by forming covalent bonds between the
glycan moiety and a functionalized solid support. In the most established method, hydrazide
chemistry, protein-bound carbohydrate cis-diol groups are oxidized to aldehydes, which then
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react with the hydrazide resin to form hydrazone linkages. In the initial protocol, nonglycosylated proteins were removed by stringent washing, and bound glycoproteins were digested
with trypsin to release non-glycosylated peptides from the glycoproteins. The bound
glycopeptides were then removed by incubation with PNGaseF and analyzed by LC-MS/MS
(277). More recently, this approach has been adapted for enrichment at the peptide level, which
reduces sample complexity and exposes concealed N-glycopeptides to the hydrazide resin
(262,278). Interestingly, there is poor overlap between protein identification when hydrazide is
performed at the peptide level compared to the protein level (279). At the peptide level, the
overall specificity of hydrazide-mediated enrichment of glycopeptides is improved (221,262). On
the other hand, enrichment at the glycoprotein level is associated with a larger number of
glycoprotein identifications (63,279). To date, hydrazide enrichment has been broadly adapted for
glycoconjugate enrichment of cell lysates, fluids, and tissues (63,258,261,262,279–283).
PNGaseF is used to release glycopeptides from the resin, resulting in asparagine deamidation,
which can be used to identify the site of glycosylation. Misidentification caused by chemical
deamidation, or deamidation not attributed to PNGaseF, can be reduced by performing the
digestion in 18O water, which results in a mass shift of 3Da (129,284,285). Furthermore, the use
of higher resolution mass spectrometers and optimized search parameters can increase
glycopeptide identification and reduce misidentification to around 1%. Unlike lectin enrichment,
traditional hydrazide enrichment does not exhibit preference towards specific glycoforms, making
it an ideal approach for global glycoprotein analysis. In one adaptation of the standard protocol,
the use of mild oxidizing conditions can specifically enrich glycopeptides that contain a sialic
acid (286). In this approach, acid hydrolysis is used to release the glycopeptide by cleaving the
glycosidic bond between the sialic acid and the rest of the glycoform, enabling intact
glycopeptide analysis (276). Given the importance of hydrazide enrichment in glycoprotein
research, efforts to improve enrichment by altering wash conditions, enzymatic digestion, pre55

enrichment depletion, and membrane protein solubility have been investigated (63,261). Of note,
the depletion of common proteins, and the use of detergents to solubilize membrane proteins,
improved glycoprotein identifications. Incorporation of isotopically labeled compounds enables
quantitative glycoprotein analysis (277). The primary limitation of hydrazide enrichment is that
glycopeptides are released by PNGaseF, resulting in a complete loss of information about the
structure of glycans on specific peptides. However, the deglycosylated peptides exhibit more
efficient retention to RP columns and improved sensitivity in mass spectrometers, making
glycoprotein identification easier than intact glycopeptides.
Boronic acid chemistry is another glycoprotein enrichment strategy that utilizes covalent
binding (270). This enrichment strategy has been used for the enrichment of carbohydrates,
nucleosides, glycolipids, RNA and glycoproteins. In boronic acid chemistry, basic conditions
result in covalent ester bonds formation between the boronic acid and cis-diols on the glycans.
These bonds are reversibly hydrolyzed under neutral or acidic conditions, rendering intact
glycopeptide analysis possible (221,287). Like general hydrazide enrichment strategies, boronic
acid enrichment is unbiased in terms of enriching specific glycoforms.
Glycoproteins can be enriched using the concept of "bioorthagonal click chemistry", a
term coined by Carolyn Bertozzi, which refers to the incorporation of non-native molecules into
biological systems without the impairment of biological processes (288). Importantly, the
reaction involves the incorporation of a monosaccharide analog with an azide functional group,
and a subsequent interaction with an exogenous probe that reacts with the analog through click
chemistry, allowing for detection and enrichment of the target (289). The utility of the azide
functional group lies in its small size, biological stability, and absence in native biological
systems. These traits allow the azide-labeled monosaccharide analogs to incorporate into
glycoconjugates using the cell’s natural biosynthetic machinery, without modifying the
underlying protein structure or function (289,290). Acetylation of the sugar analog increases the
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lipophilicity and allows the monosaccharide to passively diffuse through the plasma membrane,
which can then be deacetylated by nonspecific esterases (291). Once incorporated, the sugar
analogue can be assessed by reactions that involve azide-alkyne cycloaddition or Staudinger
ligation. Global changes in glycosylation can be accessed by a variety of analytical approaches,
including flow cytometry, confocal microscopy, and gel electrophoresis (292,293). For mass
spectrometry-based proteomic applications, glycoproteins can be enriched using alkyne resin,
which reacts with the azide functional group forming a 1,4 disubstituted 1,2,3-triazole linkage
(294). The use of alkyne-agarose resin, as opposed to biotin-alkyne reduces the number of
enrichment steps and results in higher glycoprotein specificity (294,295). Metabolic labeling of
glycans was initially optimized for in vitro labeling glycans, but has more recently been applied
to in vivo models (296–300). Multiple sugar analogs have been used to enrich glycoproteins with
various

monosaccharides

compositions.

For

instance,

tetraacetylated

N-azidoacetyl-D-

mannosamine (ManNAz) incorporates into glycoproteins in place of sialic acids. The
incorporation of ManNAz onto sialic acid containing glycoproteins was validated by Western blot
analysis before and after sialidase treatment (301). Tetraacetylated N-azidoacetylglucosamine
(GlcNAz) can be utilized to survey O-GlcNAc-modified proteins (192,298). While the efficiency
of incorporation is low, treatment with O-GlcNAcase inhibitors has been reported to improve OGlcNAz incorporation. Tetraacetylated N-azidoactylgalactosamine (GalNAz) was originally
reported to incorporate in place of GalNAc monosaccharides, but can also incorporate in place of
O-GlcNAc modifications following the conversion of UDP-GalNAz to UDP-GlcNAz by UDPgalactose 4'epimerase (GALE) (192,297). Interestingly, GalNAz is more efficient at labeling sites
of O-GlcNAc modifications than GlcNAz, which is attributed to the rate-limiting UDP-GlcNAc
pyrophosphorylase step in the GlcNAc salvage pathway (192). Peracetylated 6-azidofucose
(6AzFuc) is converted intracellularly to GDP-FucAz prior to incorporating in place of fucose
(302). Conversely, treatment directly with GDP-FucAz improves the incorporation efficiency by
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bypassing the fucose salvage pathway (289). For all analogs, the incorporation efficiency varies
amongst different cell lines (290). During the click chemistry enrichment process, covalently
bound glycoproteins are separated from non-glycosylated proteins following extensive washing
steps. After the removal of non-glycosylated proteins, glycoproteins are digested with trypsin
enabling protein identification by LC-MS/MS. Glycopeptides remain bound to the click resin, but
can be assessed following PNGaseF digestion. Unfortunately, given the nature of peptide release,
all information regarding the exact structure of the glycoform is lost.
1.3.3.2.4 Physiochemical Enrichment
Glycans substantially alter the physiochemical properties of the underlying peptide.
Unlike non-glycosylated peptides, glycopeptides are poorly retained on the C18 stationary phase,
due to their increased hydrophilicity (221). This causes most glycopeptides to elute early during
chromatography, with little resolution of unique glycopeptides. Even glycopeptides with different
glycoforms are not adequately resolved on RP columns, with the exception being those that differ
in their levels of sialylation (303). However, RP-HPLC-MS remains integral to glycoproteomic
workflows involving the analysis of deglycosylated peptides. Alternatively, RP-LC can be used in
conjunction with other chromatographic approaches that are able to resolve glycopeptides (303–
305). These other chromatographic approaches are better suited to enrich and resolve
glycopeptides.
Hydrophilic interaction chromatography (HILIC) is used to enrich all glycopeptides,
irrespective of the glycan structure. HILIC enrichment is based off of the increased peptide
hydrophilicity due to the bound glycan. Glycopeptides are retained on the hydrophilic stationary
phase, and are eluted with an increasingly aqueous buffer (267). While mechanistically similar to
normal phase (NP) chromatography, analyte retention on HILIC columns is based on the
association of the analyte with a water layer surrounding the polar stationary phase, instead of the
stationary phase itself (306). Multiple materials are amenable to HILIC enrichment of
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glycopeptides, including zwitterionic (ZIC), amide-based (TSKgel Amide-80), and carbohydratebased materials (cotton wool, sepharose) (307). ZIC-HILIC enrichment involves polar and ionic
interactions, while cotton HILIC materials utilize hydrogen bonding (308). In a comparison
between HILIC materials, ZIC-HILIC provides higher selectivity and efficiency in glycopeptide
enrichment. The use of both materials in tandem further improves glycopeptide selectivity
(303,308). Unlike RP-LC, HILIC-LC is able to resolve glycopeptides that vary only in the
composition of neutral monosaccharide residues (303). When applied in a SPE format, HILIC
material is able to enrich glycopeptides and remove detergents, prior to downstream LC-MS
applications (309). A drawback of HILIC enrichment is the relatively poor enrichment specificity
compared to other enrichment strategies. Hydrophilic non-glycosylated peptides are often
retained during HILIC enrichment, while more hydrophobic glycosylated peptides are lost (310).
To improve the specificity of glycopeptide enrichment, TFA can be added as an ion-pairing
reagent, which acts to decrease the hydrophilicity of non-glycosylated peptides, while not
affecting the hydroxyl groups of the glycan on glycopeptides. The net effect of using ion-pairing
agents is to further separate the hydrophilicity of glycopeptides from non-glycosylated peptides
(306,308).
Physiochemical enrichment strategies can be applied to enrich selected glycopeptides.
Glycopeptides with sialic acids can be enriched with TiO2 through the interaction of negatively
charged carboxylic acid and hydroxyl groups of sialic acids with Ti4+ (311). TiO2 also enriches
phosphopeptides, so the specificity of glycopeptide enrichment is improved by pretreating with
phosphatases (267,311). Larsen et al. compared glycopeptide enrichment pre- and postneuraminidase treatment to demonstrate the importance of sialic acid in TiO2 enrichment (311).
New approaches to enrich glycopeptides are continually being evaluated. Takakura et al.
demonstrated the ability to selectively precipitate glycopeptides over non-glycosylated peptides in
acetone (312). Preliminary unpublished evidence demonstrates the utility of strong anion
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exchange (SAX) for glycopeptide enrichment, with initial results showing improved enrichment
compared to HILIC. Finally, Alvarez-Manilla et al. used an in-silico analysis of all human
peptides to propose size exclusion chromatography as an enrichment strategy for glycopeptides,
based on the added molecular weight imparted on the peptide by the glycan. In their analysis of
digested peptides, 90% of peptides are smaller than 2000 Da, while nearly all glycopeptides are
larger than that threshold (313).
1.3.3.2.5 Selection of Enrichment Strategies and Combinatorial Approaches
The determination of an ideal enrichment strategy depends on the ultimate goal of the
study. Most published studies of the glycoproteome focus primarily on the N-glycoproteome as
opposed to the O-glycoproteome due to [1] reduced protease shielding from fewer sites of
glycosylation, [2] predictable N-glycan consensus sequences, [3] a common core structure of Nglycans, [4] and a larger size of N-glycans resulting in more pronounced physiochemical changes
(257). For cancer studies, the appropriate enrichment strategy is determined by preceding data
implicating differential glycosylation; including differential lectin staining, altered glycosylationrelated gene expressions, or changes observed at the glycan level. This preexisting data may
dictate whether it is beneficial to enrich specific glycoforms as opposed to all glycoproteins.
Efforts directed at identifying both the glycoform and underlying peptide backbone typically
gravitate towards the use of lectins or physiochemical enrichment strategies, due to the reversible
mechanism of glycoconjugate release. However, these approaches do not provide the specificity
of covalent-mediated glycopeptides enrichment. In a comparison of enrichment methods in the
cell secretome, Li et al. reported a higher selectivity of glycopeptides with hydrazide enrichment
(80% specificity) compared to ZIC-HILIC enrichment (30% specificity) (314).
Combinations of enrichment strategies can enhance the specificity of glycoconjugate
enrichment and the total number of identified glycoproteins. Combinations can use similar
enrichment approaches, such as the combination of multiple lectins, or different enrichment
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strategies. There is often little overlap in the glycopeptides and glycoproteins identified using
different enrichment strategies, resulting in more glycoprotein identifications (282,314). For
instance, a comparison of hydrazide and lectin enrichment approaches for blood serum revealed
only a 42% overlap in common glycoproteins (282). The differential enrichment can be explained
in part by the specificity of lectins and antibodies for a subset of glycan structures compared to
the non-selective hydrazide approach.

1.3.3.3 Mass Spectrometry Strategies for Glycoprotein Identification
1.3.3.3.1 Ionization Strategies
Following glycoconjugate enrichment, the selection of the proper ionization source and
fragmentation parameters can dramatically improve glycoprotein identification and reduce
analytical complexity (271). As previously referenced, glycosylated peptides are not ionized as
efficiently as their deglycosylated counterparts. Multiple studies have compared the utility of ESI
and MALDI for intact glycopeptides. MALDI-TOF instruments operating in linear mode result in
broad peaks that contain information on the average carbohydrate content at the glycosylation site
(249,315). The removal of glycans or further digestion of the underlying peptide is required to
obtain more informative information (315). When performed in reflectron mode, MALDI-TOF is
able to profile glycopeptides with isotopic resolution (249). Studies have shown that the overall
signal strength of glycopeptides when assessed by MALDI-TOF correlates with the relative
abundance, regardless of the peptide backbone (316). Unfortunately, in-source decay of the
oligosaccharide frequently occurs during MALDI ionization, specifically at sialic acid and fucose
residues, rendering the use of derivation approaches essential. The use of MALDI-FTICR instead
of MALDI-TOF improves the glycopeptides resolution and aids in the retention of sialic acids
(249). ESI is the more common ionization approach for intact glycopeptides analysis. As ESI is a
more gentile ionization strategy than MALDI, fragmentation is less common (315). Additional
advantages are that ESI ionization is more efficient than MALDI, can process glycopeptide
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mixtures quickly following chromatographic separation, and can be used to trigger MSn scans
(317). One disadvantage for ESI is that the ionization results in multiply charged analytes,
rendering the spectra more difficult to process manually. Irungu et al. found that the two
ionization sources are quite complementary, with ESI-MS/MS generating the most complete
information on the glycan moieties and MALDI-MS/MS providing high confidence peptide
assignments (317).
1.3.3.3.2 Fragmentation for Glycopeptide Identification
The need to characterize both the glycan and underlying peptide backbone complicates
mass spectrometry approaches for glycopeptides. CID fragmentation is insufficient to fragment
both the glycan and peptide. Complete fragmentation of the glycan moiety is achieved at lower
collision energies that leave the underlying peptide backbone largely intact (267,318,319). The
peptide-glycan bond is also cleaved at lower collision energies diminishing information about the
site of glycosylation (320). At higher collision energies, only peptide backbone b and y
fragmentation series are observed. Thus, other fragmentation approaches have been investigated
for intact glycopeptide analysis. Electron-activated dissociation methods, such as ETD and ECD,
fragment the peptide backbone into c and z fragments, while retaining the glycan on the original
site of glycosylation. Therefore, peptide sequencing can be performed using the c and z type
fragmentation series, while the glycan is still bound to the glycosylation site (320). Conversely,
HCD primarily fragments the glycan, generating oxonium ions specific to monosaccharides.
Importantly, HCD in the C-trap and detection in the Orbitrap is not limited by the low mass cutoff
associated with ion trap mass spectrometers, and is thus able to overcome the 1/3 cut-off rule to
enable the detection of low molecular weight oxonium ions. While fragmentation of the
underlying peptide is generally inefficient, HCD does generate a characteristic y1 ion that is
representative of the peptide + GlcNAc (221,267). HCD fragmentation and subsequent detection
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in the orbitrap, is also compatible with tandem mass tag (TMT) labeling for quantitative mass
spectrometry analysis (319).
Due to the inadequacies of single ionization approaches in determining the site of
glycosylation and the structure of both the glycan and peptide, multiple ionization approaches
have been used in succession for the analysis of glycopeptides. One such strategy utilizes the
Thermo Orbitrap Elite mass spectrometer to combine HCD and ETD in a product dependent
manner (HCD-pd-ETD) (Figure 6). Using this approach, abundant precursor ions are selected for
HCD fragmentation. HCD fragmentation of glycopeptides results in the generation of diagnostic
oxonium ions, which are then detected by the mass spectrometer and trigger ETD fragmentation
of the original precursor ion (320). Information gathered by the HCD and ETD fragmentation can
be combined to provide relevant information on both the glycan and underlying peptide. This
approach improves the duty cycle of the mass spectrometer in comparison to alternating HCD and
ETD (HCD-alt-ETD), by initiating ETD fragmentation only on glycopeptides. In a comparison of
HCD-pd-ETD to HCD-alt-ETD, Yin et al. demonstrated that HCD-pd-ETD was more useful in
identifying low abundance glycopeptides, while HCD-alt-ETD predominantly identified high
intensity glycopeptides (321). However, both approaches identified fewer total proteins than
analysis of deglycosylated peptides. Additionally, only 16 out of 151 glycoproteins were
identified by all three strategies (321). Improvements in analytical instrumentation continue to
improve glycopeptides analysis. The Orbitrap Fusion outperforms the Orbitrap Elite by enabling
data acquisition on the highest charged precursors, which have the most robust fragmentation by
ETD, as opposed to the most intense ions. In contrast to HCD-pd-ETD, HCD-pd-CID can better
elucidate the glycan structure (322). The new trihybrid Orbitrap configuration allows CID to also
be incorporated into the HCD-pd-ETD workflow. This HCD-pd-CID/ETD fragmentation
workflow reduces glycan assignment errors, provides an additional validation step, and can
provide structural assignments based off of the CID fragmentation pattern (322).
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Figure 6. HCD-pd-ETD Workflow. Abundant precursor ions are selected for fragmentation by HCD,
which generates diagnostic oxonium ions. The presence of oxonium ions triggers ETD on the original
precursor ion, which is used for glycan, peptide, and protein characterization.
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1.3.4 Glycoproteins and Glycans Antigens as Biomarkers
1.3.4.1 Glycoprotein Cancer Biomarkers
The detection of cancer at early stages of tumor progression is advantageous from a
therapeutic treatment standpoint, resulting in improved treatment efforts and survival statistics
(161). Disease markers, often referred to as biomarkers, can be utilized to indicate normal
biological functions, disease processes, or response to therapy (323). The detection of one subset
of biomarkers, tumor markers, which arise from either the tumor or the host, indicate the presence
of a tumor (324). Ideal tumor markers should have very high performance in terms of sensitivity,
specificity and predictive value, originate from specific organs instead of being ubiquitously
expressed, and correlate with disease prognosis; including the tumor stage, volume, and
likelihood of recurrence (325,326). For early stage cancer diagnosis, markers should ideally
present prior to malignancy. Disease markers have been classified as proteins, glycoproteins,
glycan antigens, hormones, hormone receptors, enzymes, genetic mutations or aberrations, and
RNA (324,326). However, when looking at protein-based biomarkers, nearly all FDA approved
biomarkers for cancer are glycoproteins or individual glycan antigens (160). Biomarkers
experiments directed at identifying glycoconjugates are popular due to [1] the success for these
molecules as biomarkers, [2] the prevalence of these molecules in biological fluids, and [3] the
role that glycosylation plays in tumor progression. Clinically, these markers can be detected in a
variety of complex biological matrices, including serum, plasma, urine and tissue. While research
has been directed at identifying new tumor markers, very few prospective markers progress to
clinical application. The poor transition from biomarker discovery to clinical assay can be
explained by a variety of factors, including technical limitations, sample complexity, and
experimental design. Techniques utilized to identify disease markers, including mass
spectrometry based "omics" strategies, are not easily implemented in clinical labs (324).
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Additionally, biomarker assays directed at individual proteins suffer from the broad dynamic
range of protein expression, with biomarkers often expressed at very low levels compared to
abundant serum proteins (325). Changes in glycosylation resulting from malignancy are also
difficult to detect and obscured by more abundant glycoforms (160,327). Among other reasons,
prospective biomarkers rarely transition to clinical biomarkers because research scientists do not
have the knowledge or experience needed to navigate the regulatory requirements necessary to
advance the biomarker to a clinical assay. To adjust for these limitations, the National Research
Council Early Detection Research Network (EDRN) has laid out a series of phases for biomarker
development (324). Narimatsu demonstrates the workflow by taking a small number of potential
disease markers identified in tissue, assessing their presence and serum, and then developing a
simplified assay to assess the most promising biomarker on a large number of serum samples in a
high-throughput fashion (327). While it is ideal for biomarkers to work with non-invasive
biological fluids, tissues are frequently used to identify initial disease marker candidates. In
comparison to serum, tissues have a reduced protein dynamic range and a direct relationship with
the origin of the biomarker. As described above, these initial targets can be validated in fluids
(328). Clinical diagnosis may require the use of tissue/biopsy cores, but biofluid analysis is
preferable, as the process of obtaining the biopsy is invasive and risky.
While biomarkers can be difficult to identify in initial biomarker discovery approaches,
targeting specific molecules with known identities is a more effective strategy. Mass
spectrometry represents a powerful approach for initial serum/tissue biomarker investigations, but
is often too complicated, expensive, and time-consuming to be utilized in clinical labs. The most
common assays used in the clinic to measure biomarkers are immunohistochemistry (IHC) for
tissue sections, or immunoassays for biological fluid samples. Assays to measure glycoprotein
biomarkers in fluids can be compartmentalized into 3 categories; [1] the use of monoclonal
antibodies directed against the protein, [2] the use of antibodies or lectins to measure the level of
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an antigen/glycan motif, and [3] a combination of the previous approaches to quantify both the
protein and associated glycoforms (325). An example of each category of biomarker is described
in the text below by prostate-specific antigen (PSA), CA19-9, and alpha fetoprotein (AFP),
respectively. The use of monoclonal antibodies to determine protein expression primarily relies
on enzyme-linked immunosorbant assays (ELISA) (326). Similarly, enzyme-linked lectin assays
(ELLA) or monoclonal antibodies directed against glycan antigens are used to measure total
glycan antigen levels. The combination of protein and glycoform quantification can be achieved
by either capturing all glycoproteins with immobilized lectins and then assessing the abundance
of a specific protein with antibodies, or using an antibody to capture a specific protein and then
detecting the abundance of the glycoform with lectins (325,327).

1.3.4.2 Selected Glycoprotein Biomarkers
1.3.4.2.1 Prostate-Specific Antigen (PSA)
PSA is a protein secreted from the prostate that is detected in the blood at small amounts
in healthy males. However, PSA is often elevated in males with benign prostate hyperplasia
(BPH), prostatitis and prostate cancer (161). While PSA measurements can distinguish healthy
patients from diseased patients, elevations in PSA do not distinguish between benign and
malignant conditions (160). Overall, the utility of PSA screening for prostate cancer is highly
controversial, due to limited conceived benefits, the risks of therapeutic intervention upon
detection of prostate cancer, and uncertainties regarding the screening strategy (329). These
factors have lead to the argument that PSA screening has resulted in overdiagnosis and
overtreatment of prostate cancer (330). Recent evidence suggests that factoring in site-specific
glycoform composition may improve the PSA screen in distinguishing malignant prostate cancer
from benign conditions. PSA glycans from patients with BPH consist predominantly of complex
biantennary glycans with various degrees of core fucosylation and sialylation. In contrast, PSA
glycoforms from patients with prostate cancer exhibit elevated multiantennary complex
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glycoforms with altered sialylation, fucosylation, and LacdiNAc groups (160,161,331). Thus,
utilizing absolute PSA levels can identify diseased patients and subsequent analysis of the
glycosylation patterns can distinguish malignant from benign conditions.
1.3.4.2.3 Carbohydrate Antigen 19-9 (CA19-9)
CA19-9 (sialyl Lewis A, SLeA), a glycan motif initially identified by Koprowski et al. in
a colorectal cancer cell line, is currently the only FDA approved blood test for the management of
pancreatic cancer (332,333). It is now recognized that the CA19-9 antigen is present on
glycoproteins and glycolipids (334,335). CA19-9 is composed of four monosaccharides,
consisting of a Gal and GlcNAc residue with a terminal α2,3-linked sialic acid on the galactose
and an α1,4-linked fucose on the GlcNAc. In contrast, SLeX differs in regards to the fucose
linkage. The synthesis of both structures are mediated by α2,3 sialyltransferases and α1,3/4
fucosyltransferases, with various degrees of specificity between SLeA and SLeX synthesis (336).
CA19-9 is thought to play an important role in disease metastasis through the interaction of the
antigen with endothelium E-selectin (337). This claim is evidenced by the abolished interaction of
cancer cells with E-selectin following [1] treatment with antibodies against SLeA, [2] the
exogenous addition of mucins containing CA19-9 to compete for E-selectin binding, and [3]
inhibition of CA19-9 expression (338–340).
While CA19-9 is used as a blood test for pancreatic cancer, the antigen is not used
clinically to diagnose pancreatic cancer. Low sensitivity and specificity of CA19-9 in the
prediction of pancreatic cancer are exacerbated by the low prevalence of pancreatic cancer,
rendering CA19-9 ineffective as an early stage diagnostic biomarker (333). The specificity of
CA19-9 is hindered by diseases other than pancreatic cancer, many of which are benign, that
express elevated CA19-9 levels; including biliary obstruction, thyroiditis, diabetes, and chronic
pancreatitis (341–343). The sensitivity of CA19-9 as a pancreatic cancer biomarker is limited by
the fact that between 5-15% of the population do not express fucosyltransferase 3 and are
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therefore incapable of expressing CA19-9 (333,343). Efforts to investigate CA19-9 as a screening
marker in asymptomatic individuals yield a dismal predicative value positive of .5-.9%, due to a
large percent of false positive identifications (344,345). The clinical utility of CA19-9 for the
diagnosis of symptomatic patients is also low (346).
While not an ideal diagnostic marker, pre-operative and post-operative serum CA19-9
levels can be useful in assessing cancer stage, resectability, prognosis, response to chemotherapy
and postoperative recurrence. A study by Kim et al. demonstrated a rise in mean pre-operative
serum CA19-9 levels at each cancer stage, starting at 40.05 U/mL for stage IA patients, and rising
to 3239 U/mL for stage IV patients (344). Pre-operative CA19-9 serum levels were found to be
lower in patients with localized tumors compared to patients with advanced or metastasized
tumors (347). Therefore, it is unsurprising that patients with normal pre-operative CA19-9 levels
have a higher 5-year disease specific survival (DSS) than patients with elevated CA19-9 levels,
even when comparing patients with similarly staged tumors (348). Furthermore a decline in
CA19-9 serum levels following treatment is associated with longer overall survival (346).
1.3.4.2.3 Alpha Fetoprotein (AFP)
AFP is a glycoprotein with a mass of around 70 kDa with one N-glycosylation site,
typically occupied by a complex biantennary N-glycan (160). AFP expression is abundant in the
human fetus, but levels decrease rapidly during fetal development and after birth (326).
Therefore, the detection of AFP in adults is used as a marker for hepatocellular carcinoma (HCC).
However, elevated levels of AFP are also observed in benign liver diseases, limiting the use of
AFP in distinguishing malignant from benign conditions. An additional limitation of AFP as a
biomarker of HCC is the low sensitivity for early stage cancer (349). Efforts to improve the utility
of AFP have focused on differential glycosylation of AFP, where α1,6 core fucosylated AFP
outperforms AFP alone as a biomarker for HCC (350–352). AFP can be fractionated into three
groups using lens culinaris agglutinin (LCA) lectin to provide information of the underlying
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cause of AFP elevation; these being AFP-L1, AFP-L2, and AFP-L3. AFP-L3 elevation is linked
to malignancy, while AFP-L1 and AFP-L2 are linked to non-malignant liver disease and yolk sac
tumors, respectively (160). Other studies have suggested that AFP sialylation can distinguish
malignant from benign liver diseases, providing another avenue to enhance biomarker specificity
(161). The use of AFP as a biomarker is the best example of how proteomic and glycomic data
can be combined to diagnose a cancer.

1.4 Aberrant Glycosylation in Pancreatic Cancer
1.4.1 Biological Factors that Promote Aberrant Glycosylation in Pancreatic Cancer
Pancreatic cancer, like many other cancers, has been characterized as a glycolytic tumor
based off a reliance on glycolysis for energy production, as opposed to oxidative phosphorylation,
which enables rapid energy production in the hypoxic tumor microenvironment (353,354).
Anaerobic glucose metabolism in pancreatic cancer relies on an upregulation of glucose
transporters

(GLUTs)

and

glycolytic

enzymes

including

hexokinase

II

(HK2),

phosphofructokinase I and II (PFK1, PFK2), and pyruvate kinase (PKM2) (354). Even
surrounding, well oxygenated PDAC cells can utilize lactate produced during glycolysis to
promote cell proliferation, as the surrounding cells express elevated levels of the lactate uptake
enzyme, monocarboxylate transporter I (MCT1) (353). Pancreatic cancer cells also exhibit a
glutamine addiction, in which glutamine can be metabolized to glutamate by glutaminases (GLS1
and GLS2) as a major source of energy. In fact, cells cultured in the glutamine-deficient media
exhibit decreased cell viability and proliferation (353). The metabolism of glucose and glutamine
both converge upon the hexosamine biosynthetic pathway (HBP) and increase the presence of
monosaccharides that can ultimately be incorporated into glycans. The need for glycolytic energy
production in pancreatic cancer is perpetuated by the dense stroma and ECM accumulation
resulting in a desmoplastic region that surrounds the cancer promotes hypoxia (355). For cancer
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in general, more pronounced hypoxic conditions have been linked to metastatic spread, resistance
to therapy, and poor prognosis. These trends that hold true in pancreatic cancer, as there is a
correlation between hypoxia and reduced survival (355). In addition to promoting glycolysis,
hypoxia transcriptionally upregulates glycosyltransferase and sugar transporter expression in
cancer cells through the hypoxia-inducible factors (HIFs) (356). Hypoxia has been directly linked
to increased glutamine-fructose-6 phosphate aminotransferase I and II (GFPT1 and GFPT2)
expression in cell lines (353). Additionally, hypoxia plays a role in cancer invasion and metastasis
by promoting the expression of the selectin analogs, SLeA and SLeX, in malignant cells by
upregulating fucosyltransferase (FUT7) and sialyltransferase (ST3Gal1) expression (357). Sialin
expression, a transporter for NeuGc and NeuAc, is also induced by hypoxia, providing one
potential mechanism of the incorporation of non-human NeuGc in malignant cells (211,358).
GBPs, such as Galectin-1, are also observed to be elevated in hypoxic tissues.
In addition to altering the glycan biosynthetic machinery, the hypoxic environment in the
tumor provides a selective pressure that favors the growth of the most aggressive cells that are
capable of surviving in conditions with limited oxygen and nutrients (355). These conditions
promote the expansion of cells with mutations in oncogenes and tumor suppressors, such as
KRAS and TP53 mutations, respectively (359,360). These mutations are also interconnected with
the HBP. Mutated KRAS increases GLUT1, HK1, HK2, PFK1, and lactate dehydrogenase A
(LDHA) expression, all of which impact glycosylation by directing glycolytic intermediates to
the HBP (40). Extinction of mutated KRAS in cell or xenograft models results in downregulation
of a variety of metabolic processes and inhibited tumor grown. The inhibitory effect was directly
attributed to diminished glycosylation, as the knockdown of GFPT1 exhibited the same effects on
tumor growth (361). In addition to O-glycosylation, activating mutations of RAS oncogenes have
also been associated with N-glycan branching.
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Given the broad scope of aberrant glycosylation in PDAC, efforts have been directed at
identifying the source of aberrant glycosyltransferases that play a role in tumor progression.
Specific alterations of glycans structures can, but do not always, coincide with alterations in the
expression of glycosyltransferases (210,217). CA19-9 expression is the most well defined marker
for pancreatic cancer, so efforts have been directed at identifying the enzymes culpable for the
elevated expression of the antigen. Sialyltransferases and fucosyltransferases responsible for
sialyl Lewis structure synthesis have been reported to be elevated in pancreatic cancer, including
α2,3-sialyltransferases, ST3Gal III, ST3Gal IV, and ST3Gal VI (336). Ectopic expression of
ST3Gal III and ST3Gal IV has been linked to an increase in expression of sialyl Lewis antigens
and a reduction of α2,6-linked sialic acids, resulting in increased cell motility, reduced adhesion,
and increased metastasis in mouse models (336,362,363).

1.4.2 Protein and Glycoprotein Alterations in Pancreatic Cancer
Early efforts to identify proteins that are aberrantly expressed in pancreatic cancer
performed comparative studies on whole tissue sections with cancerous and non-diseased regions.
Pancreatic cancer cells are often surrounded by stromal cells, which are capable of occupying up
to 90% of the total tumor volume, so the overall conclusions did not definitively identify
differences between tumor and non-tumor tissue. However, these experiments did provide some
mechanisms for cancer progression. There is a disease-related variation in proteins responsible
for tumor growth, migration, invasiveness, metastasis and ECM interactions, highlighting the
importance of the cancer cell interactions with the stroma and ECM during tumor progression
(364,365). Proteins involved in cytoskeletal or ECM regulation, such as annexin A2, cathepsin B,
cathepsin D, fascin, gelsolin, and plectin-1, were upregulated in the tumor tissue, providing
mechanisms for tumor cells to degrade of the ECM and enter the bloodstream (365–367). Overall,
these studies identified a larger number of proteins elevated in the tumor compared to the
matched non-tumor tissues, but elevated expression could not be directly linked to the stromal or
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epithelial cells (365,366,368). Digestive enzymes, including amylases, peptidases, lipases and
elastases, were the main category of proteins that were downregulated in the tumor tissue
(366,369). From these initial experiments, proteins of interest were selected for further analysis.
Pan et al. evaluated gelsolin concentration as a potential biomarker for pancreatic cancer by SRM
analysis, and determined that serum levels of gelsolin to have an AUC = .89 for distinguishing
PDAC from pancreatitis and control serum (370). In another study, Bausch et al. found that IHC
staining of plectin-1 was able to identify late-stage PanIN lesions and metastatic sites (367). In
addition to proteins that regulate cytoskeletal or ECM regulation, proteins that play a role in cellcell and cell-matrix interaction were also elevated in PDAC and late stage PanIN lesions;
including

galectin-1,

galectin-3,

integrin

β1,

actinin-4,

laminin

β1,

and

vimentin

(365,366,368,371). The identification of altered proteins in PanIN lesions and full-blown PDAC
implicates these proteins in early stages of tumor progression, through their role in cell motility
and cell interaction (368,371). Similar studies tabbed versican and lumican as PDAC-elevated
proteins that promote metastasis, with plasma levels of lumican achieving an AUC = .94 for
differentiating PDAC from control serum by SRM analysis (370). In order to mitigate the role of
stromal proteins in the analysis, laser capture microdissection (LCM) was used to isolate
pancreatic cancer cells. Downstream proteomics identified S100A6 and annexin III to be elevated
in tumor cells, while trypsin and LDH were elevated in non-tumor cells (372). The analysis of
serum and biofluids has identified protein families that are consistently observed in pancreatic
cancer. Mucin and CEACAM proteins are predominantly expressed in cancer specimen.
Additionally, both proteins have been recognized to act as CA19-9 carriers. Research has
identified MUC1, MUC2, MUC4, MUC5 and MUC16 as proteins that can be used for the
diagnosis or prognosis of diseased pancreas tissue (15,373–375). These proteins have been linked
to tumor progression, altered adhesion, and the promotion of perineural invasion. MUC4
stabilizes HER2 expression on the cell surface, which promotes downstream signaling through
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FAK and p42/44 (375). MUC1 interacts with Siglec-4a to promote perineural invasion (374).
Numerous integrins are upregulated in PDAC including α1, α2, α4, α6, and β1 subunits
(363,376).
While initial proteomic experiments were important from a disease marker perspective,
the data were also useful in elucidating potential driving mechanisms for pancreatic cancer. These
studies largely conclude that among all proteins, glycoproteins are overexpressed (364). Gene
ontology annotation of the human pancreas N-glycoproteome demonstrates that a majority of
pancreas glycoproteins are involved in cell organization, immune response, adhesion and
mobility. The deregulation of these processes may be directly related to the tumorigenic process
(377). In addition to alterations in glycoprotein expression, the overall level or structure of
glycosylation is altered in pancreatic cancer. Numerous potential disease markers have been
identified that differ only in glycosylation and not protein abundance. The ratio of glycosylated
RNase1 to total RNAase1 has been tested clinically as a serum biomarker for pancreatic cancer
(378). The comparison of non-diseased and diseased ductal fluids revealed kininogen-1 and
biglycan to exhibit elevated levels of glycosylation while maintaining a similar protein level
(283). Alternatively, fibrillin exhibited elevations in protein expression but a reduction in glycan
occupancy. The same study found that occupancy rates of different glycopeptides from the same
protein varied significantly and independently, allowing unique sites to be concurrently elevated
and diminished in diseased samples compared to non-diseased samples. For example,
apolipoprotein B-100 had two glycosylation sites that exhibited elevated occupancy and three
sites that had reduced occupancy in diseased samples (283).
Unfortunately, there is a large degree of similarity between the pancreatic cancer and
pancreatitis proteome, especially when comparing PDAC to severe chronic pancreatitis, which
exhibited more dysregulation of the proteome than mild pancreatitis. Among highlighted proteins
identified in the earlier global proteome analysis, cathepsin D, integrin β1, plasminogen, versican
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and lumican are all over-expressed in both PDAC and pancreatitis compared to control samples
(379,380). Factoring information about the protein expression level and associated glycoforms
can distinguish malignant from benign conditions. At the protein level, the trend of elevated
glycoproteins in PDAC was also observed in pancreatitis. However, efforts to identify
glycoproteins that can distinguish PDAC from both benign and non-diseased samples following
glycoprotein enrichment have been fruitful. Ingenuity pathway analysis (IPA) of elevated
glycoproteins unique to PDAC in patient ductal fluids emphasized the role of the proteins in
endothelial and tumor cell movement and interaction. Mucin and CEACAM proteins were
represented among the proteins that were only elevated in tumor (283). A similar study identified
members of the REG protein family, phospholipase A2 and elastase 2B to be present in only
ductal fluid from patients with cancer or premalignant lesions (381). Other proteins were elevated
in tumor compared to pancreatitis specimen, including versican, biglycan, haptoglobin, annexin
A2, IGFBP-2 and apolipoprotein E (283,364,382). In addition to assessing glycoprotein
expression levels, studies have also assessed glycoform structure and occupancy on those
proteins. Nie et al. used AAL lectin to enrich fucosylated glycoproteins in an effort to identify
individual serum glycoprotein discriminators to distinguish serum from patients with PDAC, no
disease, diabetes, pancreatitis, obstructive jaundice, and benign cysts (343). Using LC-MS/MS for
initial glycoprotein identification followed by ELISAs and lectin ELISAs for validation,
numerous glycoproteins were determined to perform better than CA19-9 in disease
discrimination. Importantly haptoglobin, lumican, α-1-antichymotrypsin and α-1-antitrypsin were
able to distinguish pancreatic cancer from benign diseases more effectively than CA19-9 (343).
Finally, a biomarker panel of proteins consisting of α-1-antichymotrypsin, thrombospondin-1, and
haptoglobin showed improved utility and an increased AUC for distinguishing PDAC from
cancer (AUC = .95), diabetes (AUC = .89), cyst (AUC = .82), and pancreatitis (AUC = .90)
(343). As the expression of these proteins was not highly correlative with CA19-9, adding CA1975

9 into the biomarker panel improved the AUC values. Other assays also showed improved
biomarker performance by combining protein and CA19-9 expression (383). Lectin enrichment of
α2,6-linked sialic acids from serum samples revealed elevated levels of disialylated biantennary
glycans (Hex5HexNAc4NeuAc2) on α-1-antitrypsin in PDAC, but decreased levels of the
glycoform in pancreatitis (318). Overall, both conditions had elevated levels of α-1-antitrypsin, so
only the glycoform difference can be used to distinguish benign from malignant conditions. The
same glycoform was found to be elevated on transferrin in pancreatitis over PDAC (318). Protein
expression and glycoform occupancy do not always correlate. While haptoglobin was elevated in
pancreatic cancer serum, glycoform differences were only observed in pancreatitis (318,382).
Given the divergence between the proteome and the glycome, the combination can be used to
enhance the utility of biomarkers. Li et al. evaluated a multiplexed bead assay directed at
quantifying specific proteins and the corresponding levels of α2,6-linked sialic acid in order to
distinguish PDAC from pancreatitis and control serum. This study concluded that serum levels of
amyloid P were significantly lower in PDAC than non-diseased serum, while the glycoforms on
α-1-β glycoprotein vary significantly between PDAC and pancreatitis (384). The functional role
of dysregulated protein glycosylation has also been investigated. Integrins have also been
implicated in PDAC progression through their modulatory effects on adhesion and invasion.
Integrins frequently exhibit higher levels of sialylation, which alters their binding to the ECM and
regulates tumor cell migration (336,363).

1.4.3 Pancreatic Cancer Glycomics
Most experiments assessing glycosylation changes in pancreatic cancer have utilized
serum samples. While noninvasive to obtain, serum glycoproteins often originate in areas other
than the malignant site, reducing the probability of cancer identification based off of global
glycosylation changes (327). Broad changes in PDAC serum glycosylation have been assessed by
interaction with specific lectins and have identified a notable increase in terminal α-fucosylation
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in serum from PDAC patients compared to non-diseased and benign controls (343). Additional
lectin array data has identified a variety of other glycan patterns that are elevated in PDAC,
including the CA19-9 antigen, complex/branched glycans, O-GlcNAc modifications, β-GalNAc
residues, and α2,6-linked sialic acids (373). However, limited studies have assessed individual
glycoform variations in pancreatic cancer. A broad glycomic analysis of N-glycans from serum
and ductal fluids found that only serum glycans could distinguish diseased from non-diseased
patients, and that the glycans could also provide information on metastatic progression (381,385).
Serum from PDAC patients exhibited an overall higher amount of glycosylation, specifically in
regards to elevated branching, fucosylation, and sialylation. On the other hand, the level of highmannose and hybrid glycans did not differ in PDAC serum compared to control serum (385).
Elevated levels of LacdiNAc groups have also been observed in pancreatic cancer (331).
Glycomic analysis of ductal fluid was marred by glycoform heterogeneity but did identify driver
glycans that could cluster glycans into specific groups, which could then be used for diagnostic
classification. However, this study was done on an extremely limited sample set, so it remains to
be seen how this clustering method performs over larger sample sizes (381).

1.5 Broad Overview
To summarize, the dismal outcomes of pancreatic cancer necessitate in-depth research to
identify early stage disease markers and evaluate mechanisms involved in disease progression.
Aberrant glycosylation, a hallmark of cancer, has been linked to pancreatic cancer through the
regulation of glycosylation synthetic machinery and elevated expression of CA19-9. Apart from
potential roles of CA19-9 and sialylated glycoconjugates in adhesion and metastasis, the role that
aberrant glycosylation plays in the tumorigenic process is undefined. Cancer-related trends in
glycosylation have been observed, but knowledge of individual glycoforms that are encompassed
within these trends is absent. Efforts to study pancreatic cancer glycosylation are further hindered
by the low prevalence of pancreatic cancer, which limits the number of samples available to study
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While alterations of glycoforms can be used to identify the presence of a disease, it is perhaps of
more use to identify aberrantly expressed glycoproteins that are indicative of pancreatic cancer,
both in terms of protein abundance and glycoform occupancy on the protein. Linking aberrantly
expressed glycoforms, including the CA19-9 antigen, to the underlying protein in pancreatic
cancer offers the potential to identify pancreatic cancer biomarkers. Both glycomic and
glycoproteomic experiments initiated in tissue specimen can be further assessed in biological
fluids as non-invasive disease markers. While glycomic and glycoproteomic research related to
pancreatic cancer is lacking, the advent of novel methodologies to improve throughput, reduce
sample handling, and overcome limitations in detection, can advance our understanding of the
pancreatic cancer glycoproteome and identify putative disease markers for further validation. The
relevance of technologies such as MALDI-IMS, glycan derivatization, click chemistry, and intact
glycopeptide analysis will be outlined in this dissertation in relation to pancreatic cancer
glycomics and glycoproteomics.
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Chapter 2: Hypothesis
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The overarching goal of this research project is directed at developing and applying novel
mass spectrometry-based technologies for the identification of glycan and glycoprotein disease
markers for pancreatic cancer. The methods developed and adapted towards this goal include: [1]
the development of a MALDI-IMS approach to identify N-glycoforms with retention of their
spatial distribution across tissue sections, [2] adaptation of a novel N-glycan derivatization
strategy that stabilizes sialic acid residues and differentiates their linkages based on an induced
mass difference, [3] azido-sugar metabolic labeling of sialic acids followed by protein enrichment
and identification by LC-MS/MS, and [4] intact analysis of glycopeptides using a productdependent fragmentation strategy. The importance of applying these novel technologies for
pancreatic cancer is based on the fact that pancreatic cancer consistently ranks among the most
deadly cancers, due to delayed diagnosis, rapid disease progression, and limited therapeutic
efficacy. The only curative treatment for pancreatic cancer is disease resection, and this option is
available to only a small subset of patients whose disease is not locally invasive or metastasized
at the time of diagnosis. Identification of early stage disease markers for pancreatic cancer offers
the potential to improve clinical outcome by increasing the number of patients who can undergo
disease resection.
Glycoproteins and the glycoforms present on those proteins represent a promising avenue
for early detection biomarker discovery research, given the established evidence linking aberrant
glycosylation to pancreatic cancer. In addition to elevated levels of CA19-9 in pancreatic cancer,
evidence has also shown that pancreatic cancer is associated with alterations in glycosylation
biosynthetic machinery, broad structural changes in N-linked glycans, and robust changes in
glycoprotein expression levels. However, the low prevalence of disease and even lower number
of clinical specimen available, have hindered the ability to identify disease markers. Furthermore,
techniques directed at studying glycobiology are both labor and time intensive, and require large
amounts of sample material. While glycobiology research has lagged behind proteomics and
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genomics in recent years, new analytical technologies offer the potential to produce profound
improvements in the sector. Therefore, I hypothesize that the application of analytical techniques
that characterize the glycome of the tumor and adjacent regions, and a subsequent analysis of the
dysregulated glycoproteome, will identify molecular events associated with the development and
progression of pancreatic cancer. A premise of this hypothesis is that these alterations in
pancreatic cancer glycosylation are conserved across multiple patients. This hypothesis is tested
by the following specific aims:

Aim 1: Develop a method to simultaneously indentify and localize N-glycans on tissue sections,
while maintaining information related to relative abundance

Approach
A novel method to spatially profile N-linked glycans on biologically relevant tissue
sections will be developed for MALDI-IMS to enable the identification, abundance and
localization of N-linked glycans in tissue sections. While most MALDI-IMS approaches utilize
fresh/frozen tissue sections, the method will be optimized to include formalin-fixed paraffinembedded (FFPE) tissue blocks. Initial characterization will rely on mass accuracy of released
glycans, but secondary characterization strategies, including glycan fragmentation and
derivatization, will confirm glycan compositions. Once optimized, this method will be used to
identify diagnostic and prognostic glycan alterations directly in the clinical tissue blocks.
Towards this end, the use of tissue microarrays (TMAs) will improve assay throughput and
reduce experimental acquisition times.
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Rationale
The intent of Aim 1 is to improve glycobiology methodologies relating to the study of Nglycan localization. In 2012, the U.S. National Research Council laid out a series of goals to
advance the field of glycobiology research; one being to develop imaging methods to assess
glycan localization (386). The current method for localizing N-glycans in tissue sections relies on
staining with broad affinity lectins or antibodies specific to one glycan antigen. Therefore, a
global profiling of N-glycans using traditional approaches requires serial staining of multiple
slides, requiring the use of excessive materials (i.e. tissue slices, lectins, and antibodies), and still
does not definitively identify the glycan composition. MALDI-IMS is a developing technique that
has been used to study the biological localization of drugs, lipids, metabolites and proteins in
tissue slices. MALDI-IMS following enzymatic digestion has already demonstrated promise in
the field of bottom-up protein imaging. By adapting a similar workflow, we aim improve
throughput and dimensionality of N-glycan imaging by globally profiling all N-glycans in a
single experiment. PNGaseF will be applied to tissue sections prior to imaging to release glycans
at the N-glycan consensus sequence. Following analysis, each slide will be stained with
hematoxylin and eosin and processed by a pathologist to enable a comparison of glycan
localization with histology. Tissue embedding in FFPE blocks is considered the gold standard for
sample preservation, so adapting the imaging method to enable FFPE tissue analysis will expand
the scope of studies (387). An additional benefit of optimizing the method for FFPE tissues is the
ability to use FFPE cores housed in a TMA blocks to look at a large number of samples in a
single imaging run.

Aim 2: Use higher-throughput MALDI imaging approaches to identify N-glycan biomarker
panels for the identification of pancreatic cancer
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Approach
The developed MALDI-IMS platform will be applied to the study of pancreatic cancer by
profiling N-glycans from pancreas tissues and TMA blocks containing patient matched tumor and
non-tumor tissue cores. Initial disease markers for pancreatic cancer will be discovered by higherthroughput N-glycan profiling of 6 TMAs with tissue cores from 76 patients. Data will be
processed by supervised machine learning algorithms to identify panels of N-linked glycans that
are capable of distinguishing tumor from non-tumor cores. The utility of individual glycan and
glycan panels can be validated in high resolution imaging experiments of entire pancreatic cancer
tissue blocks. Given the heterogeneous nature of tumors and the presence of a significant
percentage of the population that is unable to express CA19-9 antigen, we expect biomarker
panels to improve the overall disease marker utility.

Rationale
The goal of our work in Aim 2 is to assess the ability of N-glycans to serve as disease
markers for pancreatic cancer, a facet ignored by most glycosylation-centered pancreatic cancer
studies. The observation of specific glycoproteins has been used to detect early stage pancreatic
lesions, suggesting that aberrant glycans may have a similar role. Additionally, the development
of a glycan disease-marker panel can improve the sensitivity and specificity of disease markers
compared to CA19-9. To identify individual glycans and glycan panels that can be used as
biomarkers for pancreatic cancer, we aim to utilize the method developed in Aim 1 to perform
discovery phase experiments in TMAs and tissue sections. Tissues are ideal for discovery phase
disease marker studies due to reduced sample complexity compared to serum, as molecules are
obtained directly from the organ of interest and are present in higher levels. An added benefit of
MALDI-IMS is the ability of the technique to link glycan structures with histology. Pancreatic
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cancer is a very complex disease that requires input from cancer cells and surrounding stromal
cells, an interaction that would be missed by traditional biochemical approaches (95).

Aim 3: Link aberrant glycosylation to modified proteins and develop an integrative
glycoproteomics method that incorporates glycoform and glycoprotein expression in a single
experiment

Approach
Additional disease markers will be identified by leveraging information relevant to
individual protein expression and glycoform occupancy/heterogeneity. Due to the inherent
complications of glycoprotein analysis, novel methods will be adapted to the study of the
pancreatic cancer glycoproteome. In one approach, putative carriers of the CA19-9 antigen will
be assessed using a targeted glycoprotein enrichment procedure specific for sialic acids. In this
approach, cells with known CA19-9 expression levels will be treated with an azide-labeled sialic
acid analog. Alterations at the protein level may identify common trends associated with CA19-9
expression, and selected proteins can be further evaluated as CA19-9 carriers. Additionally, this
approach will catalogue sialylated glycoproteins in pancreatic cancer. In another approach, an
intact glycopeptide enrichment step followed by a product-dependent fragmentation of selected
glycopeptides will be used to simultaneously characterize both glycan compositions and peptide
sequences. This experimental workflow will be developed with protein standards and then
attempted on complex biological mixtures (i.e. tissue, serum, cell lysates). Glycoconjugate
enrichment will be performed at the peptide level though unbiased enrichment strategies that rely
on the physiochemical properties of the glycan.
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Rationale
The ultimate goal of Aim 3 is to identify aberrations in both glycans and their
corresponding glycoproteins that can be used as disease markers for pancreatic cancer in a
clinical setting. While it is doubtful that MALDI-IMS will be used clinically for biomarker
classification, derivative experiments based off of identified glycan or glycoproteins can be
assessed by immunohistochemistry, ELISA, lectin-ELISA, or MRM analysis. Clinically, secreted
glycoproteins are successful non-invasive biomarkers for a variety of diseases, including
hepatocellular carcinoma, prostate cancer, colon cancer and breast cancer (271). However, these
glycoproteins are often elevated in benign diseases, resulting in false diagnosis and additional
screens. Recent evidence has suggested that monitoring site-specific protein glycosylation can
improve the biomarker, an example being elevated core fucosylated glycoforms of AFP in
hepatocellular carcinoma compared to benign liver diseases (352). In pancreatic cancer, certain
glycoproteins have displayed improved sensitivity and specificity over CA19-9 in distinguishing
between pancreatic cancer, normal pancreas tissue, and other diseases (i.e. pancreatitis or
pancreatic cysts). However, these trends are observed in small subsets of data, but require further
validation in larger trials (343). Targeted approaches, focusing on glycosylation motifs will be
used to assess specific aberrations at the glycoprotein level. However, the click chemistry
approach utilized in this aim does not retain glycans on the protein. Mapping specific changes in
glycosylation unique to pancreatic cancer may require glycoproteins to be isolated in order to
reduce sample complexity, prior to glycoproteomic analysis. The workflow for intact
glycopeptide analysis will be optimized using glycoprotein standards.
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Chapter 3: N-Glycan Imaging by
MALDI-IMS
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3.1 Introduction
MALDI-IMS can simultaneously map the molecular distribution and relative abundance
of hundreds of analytes on a single tissue section. Furthermore, the distribution can be directly
linked to cellular histology on serial tissue sections. While MALDI-IMS has not been applied to
the study of glycosylation, the technique has been used to profile the distribution of lipids,
metabolites, drugs, proteins and peptides within tissue sections. Given that MALDI-MS is a
powerful technique to study N-glycosylation, albeit usually following glycan derivatization and
enrichment, the application of PNGaseF to tissue sections should release glycans and enable
analysis by MALDI-IMS. Glycosylation is a dynamic PTM that is dysregulated in response to
malignant transformation and promotes cancer progression and metastasis. Mapping
glycosylation in correlation with disease histology could identify cancer related glycans and
implicate glycosylation-related processes in disease progression. In comparison to other classes of
molecules, defining the underlying monosaccharide composition of N-linked glycans is relatively
straightforward, as N-glycans possess a common core structure and elongation proceeds through
a limited number of well characterized processes. Current approaches to define glycan
localization are limited to broad affinity lectins and a small number of antibodies directed against
glycan antigens, both of which enable the localization of structural classes of glycans but not
identification of individual structures. Furthermore, glycans bound to proteins should be
accessible in FFPE tissue blocks. As FFPE fixation represents the gold standard of tissue
preservation, adaptation of an imaging approach to profile N-glycans on these sections is
extremely relevant. From a biomarker discovery standpoint, individual tissue cores from different
patients can be profiled simultaneously in a higher-throughput TMA based format. A targeted
MALDI-IMS approach to localize N-linked glycans in relation to histopathology can serve as a
platform for identifying novel disease related targets for biomarker and therapeutic applications.
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3.2 MALDI-IMS Workflow For N-Glycan Imaging
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3.2.1 Abstract
A new Matrix Assisted Laser Desorption Ionization Imaging Mass Spectrometry
(MALDI-IMS) method to spatially profile the location and distribution of multiple N-linked
glycan species in tissues is described. Application of an endoglycosidase, peptide N-glycosidase
F (PNGaseF), directly on tissues followed by incubation releases N-linked glycan species
amenable to detection by MALDI-IMS. The method has been designed to simultaneously profile
the multiple glycan species released from intracellular organelle and cell surface glycoproteins,
while maintaining histopathology compatible preparation workflows. A recombinant PNGaseF
enzyme was sprayed uniformly across mouse brain tissue slides, incubated for two hours, then
sprayed with 2,5- dihydroxybenzoic acid matrix for MALDI-IMS analysis. Using this basic
approach, global snapshots of major cellular N-linked glycoforms were detected, including their
tissue localization and distribution, structure and relative abundance. Off-tissue extraction and
modification of glycans from similarly processed tissues and further mass spectrometry or HPLC
analysis was done to assign structural designations. MALDI-IMS has primarily been utilized to
spatially profile proteins, lipids, drug and small molecule metabolites in tissues, but it has not
been previously applied to N-linked glycan analysis. The translatable MALDI-IMS glycan
profiling workflow described herein can readily be applied to any tissue type of interest. From a
clinical diagnostics perspective, the ability to differentially profile N-glycans and correlate their
molecular expression to histopathological changes can offer new approaches to identifying novel
disease related targets for biomarker and therapeutic applications.

3.2.2 Introduction
The majority of proteomic and metabolomic analytical techniques require the macro- or
microdissection and subsequent extraction of analytes from the target tissue. This process leads to
loss of the spatial distribution and associated histopathology of the tissue. A novel but maturing
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technology, MALDI imaging mass spectrometry (MALDI-IMS), has been used to generate twoand three-dimensional molecular maps of hundreds of analytes directly from the surface of a
tissue section, allowing the display of the relative abundance and spatial distribution of individual
analytes (388–392). The distribution of the analytes are also readily linkable to molecular
histology and pathology data from the same tissues (393,394). To date, most applications of
MALDI-IMS have focused on profiling of proteins, lipids and drug metabolites in tissues, but the
technique has not yet been defined for analysis of complex carbohydrates, typified by N-linked
glycans (138,143,395–399). Glycosylation is a major post-translational modification to proteins
critical in regulating protein folding and vesicular transport, cell-cell communication and
adhesion, immune recognition and other extracellular functions (150,400,401). N-linked glycans
are specifically attached to asparagine residues in proteins via a conserved amino acid motif of NX-S/T, where X represents any amino acid except proline, and represent a diverse but
biosynthetically definable group of carbohydrate structures ranging generally from m/z = 1000 5000 in size (150). Because MALDI-TOF analysis is one of the most robust and well established
methods for profiling multiple species of N-linked glycans, imaging of glycans directly on tissue
by MALDI-IMS should be feasible (402,403).
Using a recombinant source of peptide N-glycosidase F, which allowed an abundant
supply of enzyme for optimization, and adaptation of a molecular spraying method developed for
on-tissue protease digestions, a method workflow for MALDI-IMS of released N- glycans has
been developed that maintains their spatial distribution in frozen tissue specimens (395,404).
Combinations of permethylation derivatization, 2-aminobenzoate-modified normal phase HPLC
separations, glycan standards, and existing structural database resources were used to confirm
glycan release and initial structural determinations (238,405,406). Examples of the method
development and verification workflows for robust on-tissue N-linked glycan profiling by
MALDI-IMS are presented for mouse brain and human kidney tissues.
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3.2.3 Materials and Methods
3.2.3.1 Materials
The glycan standard A2 and sialidase S were obtained from ProZyme (Hayward, CA).
Asialofetuin glycoprotein, 2,5-dihydroxybenzioc acid (DHB), trifluoroacetic acid, sodium
hydroxide, dimethyl sulfoxide (DMSO), and iodomethane were obtained from Sigma-Aldrich (St.
Louis, MO). HPLC grade methanol, ethanol and water were obtained from Fisher Scientific. ITO
slides were purchased from Bruker Daltonics (Billerica, MA) for MALDI-IMS experiments.

3.2.3.2 Tissue Specimen
Mouse brains were excised from four euthanized C57BL/6 mice and snap frozen. Mice
were housed in an Institutional Animal Care and Use Committee-approved small animal facility
at MUSC, and brains were harvested as part of approved projects. Whole excised brains were
placed in plastic weigh boats and rapidly frozen at the vapor phase interface of a liquid nitrogen
containing dewar. A human kidney tissue was obtained from an Institutional Review Board
approved study from the Mayo Clinic (Jacksonville, FL) evaluating the molecular changes
associated with matched patient non-tumor and clear cell renal cell carcinoma tissues. A slice of
kidney from a non-tumor region was selected for use in this current study. No personal identifier
information was provided to the laboratory investigators. This particular tissue section represents
a distal section of kidney where there was no evidence of tumor. Coronal sections of mouse
brains (10 microns) and the human kidney (10 microns) were prepared using a Thermo Microm
HM550 cryostat and stored at −80°C. For each section analyzed, a serial section was collected for
histological analysis and staining with hematoxylin and eosin (H&E).

3.2.3.3 Recombinant Peptide N-Glycosidase F Expression
The entire Peptide N-Glycosidase F (PNGase F) gene (P21163.2) from the genome of
Flavobacterium meningosepticum was cloned, expressed and purified into the T7 expression
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vectors pET 29-b (Novagen) and pQE-T7 (Qiagen). This insertion results in the addition of the
sequence for an in frame histidine tag at the C-terminal end of the PNGase F gene sequence. The
recombinant PNGase F HIS-tagged construct (rPNGase F) was transformed into bacterial strain
BL21 Star (DE3) that carries the gene for the T7 RNA polymerase under control of the lacUV5
promoter and allows for high level isopropyl-beta-D-thiogalactopyranoside (IPTG) inducible
expression of gene products from T7 expression vectors such as pET and pQE. Bacterial
transformation and cell culture growth conditions were done following manufacturers protocol
(Invitrogen). Cells were harvested by centrifugation and cell pellets were washed with 1X
phosphate buffered saline (PBS) containing protease inhibitors (SigmaFast EDTA-free). Total
cellular protein lysates were made using an Avestin C5 high pressure homogenizer. FPLC
purification methods for the rPNGase F histidine tagged protein used Ni-NTA (Qiagen) and
IMAC HisTrap HP (GE Healthcare) columns. Bacterial cell lysate from IPTG induced cultures
was loaded onto to the column in binding buffer; 50 mM NaHPO4, 1M NaCl (pH 7.0) and bound
histidine tagged rPNGasE F was washed and eluted using an imidazole step gradient (250mM to
800mM imidazole) in binding buffer. Purified enzyme was dialyzed and stored in PBS buffer at a
concentration of 1mg/mL, analogous to concentrations found in commercial sources of this
enzyme.

3.2.3.4 MALDI Imaging Mass Spectrometry
Sectioned mouse brain tissue samples were mounted on ITO coated slides, and desiccated
at room temperature for 20 minutes. A sequential ethanol wash was done in 70% ethanol for two
minutes, two times, and one wash in 100% ethanol for two minutes, then a final desiccation at
room temperature for 10 minutes. An ImagePrep spray station (Bruker Daltonics) was used to
coat the slide with a 0.2mL solution containing 20μL of 1mg/mL PNGaseF stock in water. This
solution was sprayed by the ImagePrep using settings originally optimized for spraying of trypsin
that result in minimal volumes and retention of spatial distribution (395,403). If sialidase was
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used, 0.1 units of enzyme were diluted in 200μL water and sprayed following PNGaseF
application using the same ImagePrep settings. Control tissue slices were blocked with a glass
slide during the spraying process. Following application of glycosidase, slides were then
incubated at 37°C for 2hrs in a humidified chamber, then dried in a desiccator prior to matrix
application. 2,5-Dihydroxybenzoic acid (DHB) matrix at a concentration of 0.2M in 50% MeOH
1% TFA was sprayed on to the slide using the ImagePrep for positive ion mode analysis. Spectra
were acquired across the entire tissue section on a SolariX 70 dual source 7T FTICR mass
spectrometer (Bruker Daltonics) to detect the N-glycans (m/z = 690–5000) with a SmartBeam II
laser operating at 1000 Hz, a laser spot size of 25µm and a raster width of 125µm unless
otherwise indicated. For each laser spot, 1000 spectra were averaged. Images of differentially
expressed glycans were generated to view the expression pattern of each analyte of interest using
FlexImaging 3.0 software (Bruker Daltonics). Following MS analysis, data were loaded into
FlexImaging Software focusing on the range m/z = 1200–4500 and reduced to 0.98 ICR
Reduction Noise Threshold. Glycans were identified by selecting peaks that appeared in an
average mass spectrum from the tissue that received PNGaseF application but did not appear in
the control tissue. Observed glycans were searched against the glycan database provided by the
Consortium for Functional Glycomics and known glycans that exist in mouse brain (407).

3.2.3.5 Permethylation and Normal Phase HPLC of Tissue Extracted N-Glycans
PNGaseF sprayed mouse brain tissue slides were incubated for 2hr at 37°C; 50μL water
was applied on top of the tissue and incubated for 20 minutes to extract the released native Nglycans. The water was removed from the tissue, then concentrated under vacuum by
centrifugation. Permethylation was performed as described, and glycans analyzed by MALDI
(238). Masses detected in the permethylation experiments were searched against the
permethylated glycan database provided by the Consortium for Functional Glycomics (407).
Alternatively, concentrated glycans were labeled with 2-aminobenzamide (2-AB) for subsequent
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normal phase HPLC analysis (405,406). Glycan identification was made through sequential
exoglycosidase digestions as previously described (406).
PNGaseF (0.02mg) sprayed mouse brain tissue slides were incubated for 2hrs at 37°C;
50uL water was applied on top of the tissue and incubated for 20 minutes to remove the released
glycans. The water was removed and concentrated under vacuum by centrifugation.
Permethylation was performed by dissolving the dried glycans in 0.2μL H2O, 22μL iodomethane
and 50μL dimethylsulfoxide and applied over a sodium hydroxide microspin column as described
(238). The permethylated glycans were dissolved in 5μL 50% MeOH/water and spotted with
DHB (10mg in 1mL 50% MeOH). N-glycans were detected by averaging 10 MALDI scans at 25
μm laser width, averaging 1000 shots in each acquired scan between m/z = 690-5000. Masses
detected in the permethylation experiments were loaded into DataAnalysis 4.0 and searched
against the permethylated glycan database provided by the Consortium for Functional Glycomics
(407).
Tissue extracted PNGaseF released N-glycans (as above) were prepared for rapid glycan
sequencing using previously optimized procedures (405,406).

Briefly, the concentrated N-

glycans were labeled with 2-aminobenzamide (2-AB) for subsequent normal phase HPLC
analysis (406). Glycan identification was made through sequential exoglycosidase digestion as
previously described by Guile et al., as well as bovine kidney fucosidase (406). The resulting
peaks, separated by time of appearance, correspond to specific glycan structures on the basis of
glucose unit values (data not shown). All HPLC analyses were performed using a Waters
Alliance HPLC System and quantified using the Millennium Chromatography Manager (Waters
Corporation, Milford, MA). Glycan structures were identified by the calculation of the glucose
unit value, as previously described, as well as through the comparison to known standards and
sequential exoglycosidase digestion22,23 (405,406).
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3.2.3.6 Analysis of Asialofetuin and Glycan Standards in Mouse Brain Tissues
A frozen mouse brain was cored with a disposable 1.5mm tissue coring tool. A quartile of
a different brain from a littermate, which contained the same region of tissue cored in the other
sample, was homogenized in a glass Dounce homogenizer in 0.5mL water. The goal was to
maintain a highly viscous preparation, which was then supplemented with 0.02mL of water
containing 1mg purified asialofetuin glycoprotein standard. This solution was added back to the
cored brain, and refrozen at -80°C. This brain was subsequently prepped for MALDI imaging as
described for other brain samples.

3.2.4 Results
A workflow for on-tissue analysis of PNGaseF released N-glycans was developed, as
summarized in Figure 7. Initial experiments were done to verify that PNGaseF is active on mouse
brain tissues following application by an ImagePrep sprayer, and that the products of the reaction
are N-glycans. Two frozen mouse brain tissue slices (10 micron) were mounted on ITO-coated
glass slides and dehydrated in sequential ethanol washes. One brain slice was covered by a glass
slide to serve as an experimental control, and the other section was sprayed with 20μg PNGaseF.
The tissues were incubated for 2hr at 37°C in a humidified chamber. After drying, DHB matrix
was applied to the entire slide and MALDI-IMS imaging done for each brain slice. The spectra
from the PNGaseF sprayed brain slice revealed multiple novel ions peaks that are consistent with
release of N-glycans (Figure 8a). Additionally, these ions displayed regional localization
following PNGaseF spray (Figure 8b, 2d, 2f, 2h) but were not detected in the absence of
PNGaseF spray (Figure 8c, 2e, 2g). These obvious patterns of differential glycan expression
distributions associated with brain substructure is a novel finding, and a representative overlay
image of PNGaseF released glycans is shown in Figure 8h.
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Figure 7. MALDI-IMS of N-Linked Glycans Workflow. A summary schematic of the ontissue PNGaseF digestion for MALDI-IMS
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Figure 8. Application of PNGaseF Results in Enzyme-Mediated Generation of Ions. The
PNGase F workflow was applied to one mouse brain while the other mouse brain was prepared
with an identical workflow without PNGase F. (a). The upper spectrum is from the brain slice
incubated with PNGase F and the lower spectrum is from the non-PNGase F control brain slice.
Example masses that were detected following PNGase F treatment are shown for three ion peaks
that also displayed regional expression distributions in the mouse brain. The m/z = 2421.5
(b and c), m/z = 2745.5 (d and e) and m/z = 2786.5 (f and g) were only detected after PNGase F
digestion (panels b,d,f,h). An overlay of these three peaks in the PNGase F digested brain slice is
shown in panel h. A raster distance of 75 microns was used per MALDI laser acquisition across
the tissues.
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Figure 9. Addition of a Glycoprotein Standard Following PNGaseF Digestion and MALDIIMS. Asialofetuin was incubated with PNGase F and the native glycans were analyzed by FTMS. Hex5HexNAc4 + Na (m/z = 1663.5) and Hex6HexNAc5 + Na (m/z = 2028.7) were detected.
Asialofetuin was incorporated into a mouse brain and the PNGase F imaging method was
performed. The two inset images show the same N-glycans at m/z = 1663.5 and m/z = 2028.7 m/z
detected on-tissue following PNGase F digestion.
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Purified glycoprotein and glycan standards were added to mouse brain tissues prior to
PNGaseF digestion and matrix application, to further verify the on-tissue PNGaseF activity and
the ability to detect native N-glycans on tissue. A common purified glycoprotein standard,
asialofetuin, was mixed with brain tissue homogenate and added back to the brain for refreezing
and MALDI-MS imaging analysis of the tissue. Focusing on two known N- linked glycans of
asialofetuin, Hex5HexNAc4 + Na (m/z = 1663.5) and Hex6HexNAc5 + Na (m/z = 2028.7), these
glycans were detected following in-solution digest of asialofetuin alone (Figure 9). Following ontissue PNGaseF digestion, these same glycans were readily detected in the supplemented brain
tissue following PNGaseF digestion (inset of Figure 9), but not in the tissue without the enzyme
sprayed (data not shown). Furthermore, addition of a glycan A2 standard (m/z = 2223.8,
Hex5HexNAc4NeuAc2) directly on mouse brain tissues revealed multiple glycan ion peaks that
differed in loss of sialic acids (−1 NeuAc, m/ z = 1954.7; −2 NeuAc, m/z = 1663.5) (Figure 10), a
common occurrence in MALDI analysis of sialylated glycan structures, and multiple sodium ion
adducts (247). The corresponding MALDI imaging distribution of the standard glycan peaks are
shown for each ion in Figure 10. Analysis of these standards further verified detection of Nlinked glycans by MALDI-IMS.
Two off-tissue approaches were used to further verify the release of N-glycans and begin
to identify specific glycan structures associated with on-tissue native glycan peaks. Brain tissues
were digested with PNGaseF on-slide as already described. Released glycans were extracted from
the on-slide digestion in water. On-slide extracted glycans were treated with 2-aminobenzoate
(2AB) for subsequent normal-phase HPLC analysis, or permethylated for further MALDI
analysis and comparison to structure and reference spectra databases (405–407). Reference
spectra for these extracted glycans following permethylation and MALDI profiling and normal
phase HPLC separation of 2AB glycans are presented in Figure 11 and Figure 12. Structural
identification of the permethylated N-glycans were assigned by searching for the same ion in the
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MALDI structural databases and reference spectra of mouse brain glycans provided by the
Consortium for Functional Glycomics (407). A majority of the permethylated glycans extracted
from the tissues were the same masses as the glycans listed in the Consortium for Functional
Glycomics mouse brain tissue spectral libraries.

Figure 10. Analysis of A2 Standard on Tissue Sections. An A2 Standard
(Hex5HexNAc4NeuAc2; 0.1 µg) was spotted directly on a ground steel plate (a.), or 0.1 µg/µL
standard was spotted onto a mouse brain tissue slice prior to matrix application (b‐g). The
MALDI mass spectrum demonstrates the spectral complexity of non‐derivatized native sialic acid
N‐glycans due to loss of sialic acid residues and different numbers of sodium adducts.
Representative images correspond to the ions detected in the mass spectrum localized to the tissue
area where they were spotted (b‐g). The glycan composition and number of sodium adducts per
analyte are indicated above each image panel. The colored stars in the spectra correspond to the
colors in the image panel.
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Figure 11. Linkage of Permethylated Glycan Masses with Native Tissue Glycan Ion
Distribution. The N-glycan imaging method was applied to a mouse brain for tissue imaging and
an off tissue permethylation was performed for glycan verification. (a.) Permethylated glycans
Hex5dHex3HexNAc5 + Na (m/z = 2837.6), Hex4dHex2HexNAc5 + Na (m/z = 2459.3), and
Hex3dHex1HexNAc5 +2Na (m/z = 2081.1) were identified and the corresponding glycans
displayed specific localization in the tissue image (b). M/z = 2306.1 corresponds to
Hex5dHex3HexNAc5 + 2Na (red), m/z = 1996.1 corresponds to Hex4dHex2HexNAc5 + Na
(green), and m/z = 1710.9 corresponds to Hex3dHex1HexNAc5 + 2Na (blue). A raster distance
of 125 microns was used per MALDI laser acquisition across the tissues.
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Figure 12. HPLC Analysis of 2-AB Labeled N-Glycans. Mouse brain tissues (10 um slices)
were digested on‐slide with PNGaseF, extracted with water then concentrated for derivation with
2‐aminobenzoate (2AB) and separated by normal phase HPLC. Sialidase digestion was done in
solution with the 2AB modified glycans, prior to HPLC separation. The structure key for
indicated normal phase peaks in panel below the chromatogram.
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Figure 13. Mouse Brain N-Glycan Imaging Panel. 28 N-glycans were observed in both the
MALDI-IMS dataset and the permethylation spectra. These ions vary with respect to brain
histology.
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Figure 14. N-Glycan Permethylation Spectra. Permethylation analysis of the same glycan
extract as done with the HPLC analysis, with MALDI spectra split into two overlapping mass
ranges: (top panel) m/z = 1550‐2900; (bottom panel) m/z = 2700‐4550.

104

These permethylated masses and structures were used to correlate back to the expected
native mass/structure of the glycan. As an example, an overlay of Hex5dHex3HexNAc5 + Na,
Hex4dHex2HexNAc5 + Na, and Hex3dHex1HexNAc5 + Na demonstrates the spatial pattern of
expression for these specific glycans by MALDI-IMS linked to the corresponding extracted
permethylated peaks (Figure 11). A reference panel of 28 glycan structures was generated that
lists structural composition (Figure 13), expected and observed masses of the permethylated
glycans (Figure 14), and the masses of their corresponding native glycan masses for crossreferencing permethylated glycan spectra and native tissue glycan masses. Additionally, the
majority of the identities of the off-tissue native glycan species reacted with 2AB and separated
by normal phase HPLC are also common to those listed in Figure 13. The majority of the detected
masses were within 0.5 mass units of the predicted masses. The few discrepancies of more than
0.5 mass units generally occurred with native glycans of larger mass (>2500) and were associated
with complex overlapping ion signals in those specific tissue regions.
Many larger glycans are branch-chained with terminal sialic acid residues, thus a
comparison was done for detection of on-tissue glycans released by PNGaseF digestion alone
versus a combination of PNGaseF and sialidase. If larger sialylated structures were present, then
sialidase digestion would result in new glycan peaks detected in the spectra relative to PNGaseF
alone. As shown in Figure 15, the on-tissue analysis indicated an increase in the levels of larger
mass native glycan ions (m/z > 2500) detected in the double digest of PNGaseF and sialidase
(Figure 15a–c). These structures are consistent with the sialidase products of glycans that
contained tri- and tetra branched chains with multiple N-acetylglucosamine-galactose (LacNAc)
dimers (408). A representative overlay image of three of these structures detected only in the
combined sialidase/PNGaseF digest is shown in Figure 16d. Sialidase digestion of 2AB modified
glycans also demonstrated shifts in the detection of smaller glycan species following normal
phase HPLC separation (Figure 12).
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The methods developed for mouse brain tissues were applied to a frozen slice of human
kidney containing both medulla and cortex regions. As shown in Figure 17, representative Nglycans released by on-tissue PNGaseF digestion can be detected that are specific to either cortex
or medulla regions. Compared to the mouse brains analyzed, the total number of glycan species
was slightly reduced in the human kidney sections. Beyond these kidney tissues and mouse brain
tissues, we have found it is necessary to optimize the length of incubation and amount of
PNGaseF digestion conditions for each tissue type being tested. Overall, these baseline conditions
described for mouse brains have worked as useful starting points for any new tissue being
analyzed.
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Figure 15. Mass Spectra of N-Glycans Released with PNGaseF and Sialidase. Three serial
sections from a mouse brain were prepared and either (a) untreated, (b) digestion with PNGaseF,
or (c) a combination of PNGaseF and Sialidase S. Recombinant PNGaseF (20 mU) alone or in
combination with 100 mU Sialidase S (Prozyme) were applied using a Bruker ImagePrep prior to
2 hr incubation at 37° C.
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Figure 16. Novel Glycans Observed After Sialidase Release. MALDI-MSI results of the
average spectra shown in Figure 15, where a representative overlay image of the unique glycans
detected with the sialidase and PNGaseF combination is shown for m/z values of 2673.5 (blue),
2694.2 (orange) and 3364.7 (green). A raster distance of 125 microns was used per MALDI laser
acquisition across the tissues.
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Figure 17. N-Glycan MALDI-IMS of a Normal Human Kidney Tissue Section. Three serial
sections from a human kidney were prepared and either untreated (data not shown), digested with
PNGaseF, or analyzed by H&E staining. Cortex and medulla regions were confirmed by a
pathologist. Recombinant PNGaseF (20 mU) was applied using a Bruker ImagePrep followed by
a 2 hr incubation at 37° C. Following MALDI-MSI, m/z values that are specific to PNGaseF
treated tissue are observed. Shown are the results for an m/z value of 2767.7 (a) localized in the
cortex, while the m/z values of 2139.4 (b) and 1973.2 (c) are localized primarily in the medulla
when compared to the H&E stain (d). An overlay of the three m/z values is provided (e). A raster
distance of 125 microns was used per MALDI laser acquisition across the tissues.
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3.2.5 Discussion
We describe a new mass spectrometry-based glycan imaging approach in combination
with on-tissue PNGaseF digestion to spatially profile released N-linked glycans in their local
microenvironment. The method has been designed to facilitate the tissue analysis of the cell
surface glycans in frozen tissues while maintaining histopathology compatible preparation
workflows. While MALDI-IMS has primarily been utilized to spatially profile proteins, lipids,
drug and small molecule metabolites in tissues, it has not been previously applied to N-linked
glycan analysis. Coronal slices of mouse brain tissues were ideal for method development
because of the robust glycan signal and the existence of an N-glycan catalogue, provided by the
Consortium for Functional Glycomics, that documents known N-glycans present in mouse brain
tissue (407). Therefore the off-tissue extraction of glycans from PNGaseF digested brain slices
for permethylation and mass spectrometry profiling or normal phase HPLC analyses could be
readily compared to on-tissue glycan species, in particular for assigning glycan structure and
composition. The Consortium of Functional Glycomics reference spectra library of permethylated
N-glycan species from mouse brains as detected by MALDI lists over 40 identified structures.
We estimate that 30 or more N- glycan species can be detected on-tissue in mouse brains by our
current MALDI-IMS workflows, including the 28 structures listed in the panels of Figure 13.
This number varies depending on the location of the tissue cut within the brain and the number of
sub-regions present. MALDI-IMS detection of brain substructure regions of protein, small
molecule metabolites and lipid distributions in brain substructure regions is well documented, so
detection of specific N-linked glycan isoform distribution is not surprising, and represents to our
knowledge the first demonstration of this (396,409–411). The specific distribution of N-glycans
in the medulla and cortex regions of the human kidney tissue (Figure 17) also demonstrates suborgan structure specificity of glycan species expression.
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MALDI mass spectrometry is a common detection method for analysis of complex
carbohydrates, including routine analysis of N-linked glycans released from glycoproteins by
PNGaseF. From a practical perspective, our approach used a recombinant PNGaseF enzyme
engineered for increased stability and activity. In addition, the amount of commercially available
preparations of PNGaseF that would be required to perform the described experiments would not
be economically feasible for most laboratories. The recombinant enzyme is also not formulated
with detergents and additives that are common components of commercial enzyme, many of
which can interfere with MALDI ionization. However, glycan analysis by MALDI is notoriously
complicated by problems with glycan dissociation and sodium adduct additions. It is common to
observe the loss of sialic acid when native glycans are analyzed by MALDI MS, hence the need
for modifications like permethylation or 2-aminobenzoate that stabilize and help ionize sialic acid
containing glycans (247). Most common chemical modification methods require organic solvents
and the need to separate reaction products, thus these are not feasible for on-tissue derivatization
and retention of spatial distributions. The MALDI-IMS profiling of the A2 glycan standard ontissue was similarly affected, with the number of Na ions and loss of sialic acid being a factor for
an effective prediction of structure. In addition to those glycans listed in Figure 13 that we have
cross-referenced for structure identification, there are multiple PNGaseF-released ions detected
that have not been correlated to reported structures. Many of these are larger species m/z > 3500,
and like those glycan ions assigned structures, all will ultimately require confirmatory structural
characterization involving tandem MS identifications off tissue (412,413). Use of MALDI alone
may be difficult to structurally identify very high mass poly-lactosamino-glycan species ontissue, but some of these higher mass glycans are potentially profilable by MALDI-IMS (408).
Differential exoglycosidase digestion strategies more amenable to native glycan identification ontissue and preservation of spatial distribution, analogous to that described for sialidase (Figure
15), are ongoing. Preliminary experiments in negative ion mode using other matrices have
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yielded promising results, and we expect this could be a partial solution for more effective
detection of native sialylated glycan species.
Overall, we present a functional MALDI-IMS workflow for on-tissue analysis and
distribution of N-glycan species, and there remains room for continued improvement of the assay
and analysis workflow. We only report the use of one type of MALDI matrix, data was only
collected in positive ion mode, and only fresh frozen tissues were used. Except for those glycans
directly compared with reference standards, the structural assignments are correlative to existing
databases and subject to known limitations of MALDI analysis. Further verification of these
assigned structures by tandem mass spectrometry approaches is ongoing. Evaluation of different
chemical matrices for either positive or negative ion mode analysis are ongoing, as well as
refinement of methods to profile N-glycans in formalin- fixed paraffin-embedded (FFPE) tissues.
As MALDI-IMS has been used to effectively profile proteins in FFPE tissues, we expect that
these methods should be adaptable for glycan analysis in FFPE tissues (144,414). We believe this
capability of profiling N-glycans spatially on tissue will have significant application to tissues
representing many types of human diseases, especially the changes in glycosylation associated
with oncogenesis. It is well documented that malignant transformation and cancer progression
result in fundamental changes in the glycosylation patterns of cell surface and secreted
glycoproteins, and the majority of current FDA-approved tumor markers are glycoproteins or
glycan antigens (209,412,415,416). Therefore, development of a molecular assay like the
MALDI-IMS approach we describe could directly profile these pathologically relevant
carbohydrates in their local microenvironment and accelerate approaches to aid in the diagnosis,
prognosis, staging, and treatment of many types of cancers. Coupled with many new improved
high resolution mass spectrometry options for intact glycopeptides and small molecule
carbohydrate binding probes, there is potential to link the tissue distribution of glycans from
MALDI-IMS to the glycoproteins carrying them (320,321,417,418).
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3.3.1 Abstract
A recently developed matrix-assisted laser desorption/ionization imaging mass
spectrometry (MALDI-IMS) method to spatially profile the location and distribution of multiple
N-linked glycan species in frozen tissues has been extended and improved for the direct analysis
of glycans in clinically derived formalin-fixed paraffin-embedded (FFPE) tissues. Formalin-fixed
tissues from normal mouse kidney, human pancreatic and prostate cancers, and a human
hepatocellular carcinoma tissue microarray were processed by antigen retrieval followed by ontissue digestion with peptide N-glycosidase F. The released N-glycans were detected by MALDIIMS analysis, and the structural composition of a subset of glycans could be verified directly by
on-tissue collision-induced fragmentation. Other structural assignments were confirmed by offtissue permethylation analysis combined with multiple database comparisons. Imaging of mouse
kidney tissue sections demonstrates specific tissue distributions of major cellular N-linked
glycoforms in the cortex and medulla. Differential tissue distribution of N-linked glycoforms was
also observed in the other tissue types. The efficacy of using MALDI-IMS glycan profiling to
distinguish tumor from non-tumor tissues in a tumor microarray format is also demonstrated. This
MALDI-IMS workflow has the potential to be applied to any FFPE tissue block or tissue
microarray to enable higher throughput analysis of the global changes in N-glycosylation
associated with cancers.

3.3.2 Introduction
Tissues obtained from surgeries or diagnostic procedures are most commonly preserved
in formalin-fixed paraffin-embedded (FFPE) tissue blocks. These tissues are fixed in formalin
and processed as paraffin-embedded tissue blocks. The embedding process preserves the cellular
morphology and allows tissues to be stored at room temperature, causing FFPE fixation to be
used by many tissue banks and biorepositories (419,420). For cancer biomarker discovery, FFPE
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tissues are particularly attractive because they are archived for years and are much more widely
available than cryopreserved tissue. When combined with clinical outcomes, FFPE tissues are a
rich source of samples for biomarker discovery and validation in retrospective studies. While the
fixation method has many benefits, the formalin treatment results in the formation of methylene
bridges between the amino acids of the proteins, complicating further analysis by mass
spectrometry. There has been continued progress in improving extraction methods of trypsin
digested peptides from FFPE tissues in recent years, in parallel with improved high resolution
sequencing analysis of peptides by mass spectrometry (387,421). Incorporation of multiple FFPE
tumor tissue cores in a tissue microarray (TMA) format also has proven to be effective for
immunohistochemistry analysis of potential biomarker candidates, and TMAs are increasingly
being used for validation of alterations in protein expression associated with emerging genetic
mutation phenotypes and transcriptional profiling studies (422–424). The main advantages of
experiments performed with TMAs are the ability to include multiple cores from the same subject
tumors, improved sample throughput, statistical relevance and multiplexed analysis of diverse
molecular targets (422,425). Thus, it is possible to place up to 100 samples with duplicates and
controls on a single slide. When correlated with associated clinical outcomes, this provides a
powerful method for biomarker discovery and validation while minimizing reagent use and
assuring that each core in the TMA is treated under identical conditions.
It is well documented that malignant transformation and cancer progression result in
fundamental changes in the glycosylation patterns of cell surface and secreted glycoproteins
(209,415,416). Glycosylation of proteins are post-translational modifications most commonly
involving either N-linked addition to asparagine residues or O-linked additions to serine or
threonine residues. Current approaches to evaluate glycosylation changes generally involve bulk
extraction of glycans and glycoproteins from tumor tissues for analysis by mass spectrometry or
antibody array platforms, however, this disrupts tissue architecture and distribution of the
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analytes. Broad affinity carbohydrate binding lectins and a small number of glycan antigen
antibodies can be used to target glycan structural classes in tissues, but not individual glycan
species. Additionally, these detection methods for global alterations in glycosylation requires
staining on many adjacent tissue sections, making large scale assessments on many samples
difficult, expensive and time consuming. There are only a few reported studies examining
glycosylation related changes of proteins or glycolipids in FFPE cancer tissues, and these focus
primarily on determining the levels of the protein carriers or glycosyltransferases through
immunostaining (426–428).
One potential approach to assess glycan changes in tissues is matrix-assisted laser
desorption/ionization imaging mass spectrometry (MALDI-IMS). This technique has been used
to directly profile multiple protein, lipid and drug metabolite in tissue, generating molecular maps
of the relative abundance and spatial distribution of individual analytes linked to tissue
histopathology (138,143,395–399). MALDI-IMS analysis of peptides following trypsin digestion
of FFPE TMAs have also been reported (144,429,430). Recently, our group reported a MALDIIMS method workflow to directly profile N-linked glycan species in fresh/frozen tissues (431).
Adapting this method for the analysis of N-glycans in FFPE tissues would serve to extend the
application of the technique to larger retrospective sample sets and TMAs.
In this report, we describe the application of MALDI-IMS glycan imaging to various
formalin-fixed tissues. Formalin-fixed mouse kidney tissues were used to optimize antigen
retrieval, PNGaseF digestion and glycan detection conditions for MALDI-IMS. This was
followed by N-glycan analysis of clinical FFPE tissue blocks from prostate and pancreatic
cancers, as well as a commercial tissue microarray of hepatocellular carcinoma (HCC). Glycan
identity was confirmed by on-tissue collision-induced dissociation (CID) and off-tissue
permethylation analysis. An optimized MALDI-IMS workflow is presented that allows routine
simultaneous analysis of 30 or more glycans per FFPE tissue, including TMA formats. The
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approach is amenable to any FFPE tissue, and represents an additional molecular correlate assay
for use with the TMA format. Furthermore, depending on the construction of the TMA and
targeted tumor type, the approach has the potential to identify novel glycan biomarker panels for
cancer detection and prognosis. To our knowledge, this represents the first instance of using
MALDI-IMS to profile N-glycans in FFPE tissue blocks or TMAs.

3.3.3 Materials and Methods
3.3.3.1 Materials
The glycan standard NA2 was obtained from ProZyme (Hayward, CA). Trifluoroacetic
acid, sodium hydroxide, dimethyl sulfoxide, iodomethane and α-cyano-4-hydroxycinnamic acid
(CHCA) were obtained from Sigma-Aldrich (St. Louis, MO). HPLC grade methanol, ethanol,
acetonitrile, xylene and water were obtained from Fisher Scientific (Pittsburgh, PA). ITO slides
were purchased from Bruker Daltonics (Billerica, MA) and Tissue Tack microscope slides were
purchased from Polysciences, Inc (Warrington, PA). Citraconic anhydride for antigen retrieval
was from Thermo Scientific (Bellefonte, PA). Recombinant Peptide N-Glycosidase F (PNGaseF)
from Flavobacterium meningosepticum was expressed and purified as previously described (431).

3.3.3.2 FFPE Tissues and TMAs
All human tissues used were de-identified and determined to be not human research
classifications by the respective Institutional Review Boards at MUSC and Van Andel. Mouse
kidneys were excised from euthanized C57BL/6 mice and immediately placed in 10% formalin
prior to processing for routine histology and paraffin embedding. Mice were housed in an
Institutional Animal Care and Use Committee-approved small animal facility at MUSC, and
tissues obtained were harvested as part of approved projects unrelated to glycan tissue imaging. A
liver TMA was purchased from BioChain consisting of 16 cases of liver cancer in duplicates, and
one adjacent non-tumor tissue for each case. Tissues were from 14 male and two female patients
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with an average age of 47.5 with a range of 33 to 68 years old, with additional information
provided in Supplementary Table 1. A de-identified prostate tumor FFPE block, stored for 10
years representing a Gleason grade 6 (3+3)/stage T2c adenocarcinoma from a 62 year old
Caucasian male, was obtained from the Hollings Cancer Center Biorepository at the Medical
University of South Carolina. A pathologist confirmed the presence of approximately 10%
prostate cancer gland content in the sample. A de-identified large-cell undifferentiated pancreatic
carcinoma FFPE tissue section with low CA19-9 staining was obtained from the Van Andel
Institute Biospecimen Repository. For each section analyzed, histological analysis and staining
with hematoxylin and eosin (H&E) were performed.

3.3.3.3 Washes for Deparaffinization and Rehydration
Tissue and TMA blocks were sectioned at 5μm and mounted on positively charged glass
slides measuring 25 x 75mm, compatible with the Bruker slide adaptor plate. The slides were
heated at 60°C for 1hr. After cooling, tissue sections were deparaffinized by washing twice in
xylene (3 minutes each). Tissue sections were then rehydrated by submerging the slide twice in
100% ethanol (1 minute each), once in 95% ethanol (one minute), once in 70% ethanol (one
minute), and twice in water (3 minutes each). Following the wash, the slide was transferred to a
coplin jar containing the citraconic anhydride buffer for antigen retrieval and the jar was placed in
a vegetable steamer for 25 minutes. Citraconic anhydride (Thermo) buffer was prepared by
adding 25μL citraconic anhydride in 50mL water, and adjusted to pH 3 with HCl. After allowing
the buffer to cool, the buffer was exchanged with water five times by pouring out ½ of the buffer
and replacing with water, prior to replacing completely with water on the last time. The slide was
then desiccated prior to enzymatic digestion. Tris buffer pH 9-10 was also effective, but
citraconic anhydride buffer was used for all experiments in this study.
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3.3.3.4 N-Glycan MALDI-IMS
An ImagePrep spray station (Bruker Daltonics) was used to coat the slide with a 0.2mL
aqueous solution of PNGaseF (20µg total/slide) as previously described (431). Adjacent control
tissue slices lacking PNGaseF were generated by covering them with a glass slide during the
spraying process. Following application of PNGaseF, slides were incubated at 37°C for 2hr in a
humidified chamber, then dried in a desiccator prior to matrix application. The matrix, α-Cyano4-hydroxycinnamic acid matrix (0.021g CHCA in 3mL 50% acetonitrile/50% water and 12µL
25%TFA) was applied using the ImagePrep sprayer. Released glycan ions were detected using a
SolariX dual source 7T FTICR mass spectrometer (Bruker Daltonics) (m/z = 690-5000 m/z) with
a SmartBeam II laser operating at 1000 Hz, a laser spot size of 25μm. Images of differentially
expressed glycans were generated to view the expression pattern of each analyte of interest using
FlexImaging 4.0 software (Bruker Daltonics). Following MS analysis, data was loaded into
FlexImaging Software focusing on the range m/z = 1000-4000 and reduced to 0.95 ICR
Reduction Noise Threshold. Observed glycans were searched against the glycan database
provided by the Consortium for Functional Glycomics (www.functionalglycomics.org). Glycan
structures were generated by Glycoworkbench and represent putative structures determined by
combinations of accurate m/z, CID fragmentation patterns and glycan database structures (432).

3.3.3.5 Permethylation of Tissue Extracted N-glycans:
PNGaseF sprayed mouse kidney tissue slides were incubated for 2hr at 37°C; 50μL water
was applied on top of the tissue and incubated for 20 minutes to extract the released native Nglycans. The water was removed from the tissue, and then concentrated under vacuum by
centrifugation. Permethylation was performed as described (431), and glycans analyzed by
MALDI. Masses detected in the permethylation experiments were searched against the
permethylated glycan database provided by the Consortium for Functional Glycomics (407).
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3.3.3.6 Collision-Induced Dissociation of N-linked Glycans
Glycan standards were spotted on a stainless steel MALDI plate using CHCA matrix and
desiccated to yield a homogenous layer. Tissues were prepared as previously described for
MALDI imaging of FFPE tissues. 10 spectra of 1000 laser shots with a laser frequency of 1000
Hz were averaged for each spectra provided. The collision energy varied between 60-70V.

3.3.3.7 TMA Statistics
Mass spectra from TMA tissue Regions of Interest (ROIs) representing each tissue core
were exported directly from FlexImaging and analyzed using an in-house workflow. The peak
lists were first deconvoluted followed by calculating the mean peak intensity of points in each
ROI, resulting in a monoisotopic peak list corresponding to signal intensity in each region.
Comparison of tumor versus non-tumor was accomplished with a Wilcoxon rank sum test.
Individual peaks were also evaluated to discriminate between tumor and non-tumor using receiver
operator characteristic curves.

3.3.4 Results
3.3.4.1 Analysis of Formalin-Fixed Mouse Kidneys and Human Cancer Tissues.
Mouse kidney tissues were fixed in formalin and used as an initial model system to
develop MALDI-IMS glycan imaging workflows for FFPE tissues. These tissues were chosen
due to the availability of reference glycan structures and spectra, and previous MALDI-IMS
glycan imaging data from our laboratory for fresh/frozen tissue analysis (407,431). A summary
workflow schematic is provided (Figure 18). Tissues were cut at 5 microns, deparaffinized and
rehydrated in sequential xylene/ethanol/water rinses, followed by antigen retrieval in citraconic
anhydride pH 3. The rehydrated tissues were sprayed with PNGaseF, incubated for glycan
release, sprayed with CHCA matrix, and then analyzed by MALDI-IMS. While all data shown
herein uses CHCA, 2,5-dihydroxybenzoic acid (DHB) matrix could also be used successfully for
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Figure 18. MALDI-IMS Workflow for Imaging N-Glycans on FFPE Tissues

122

N-glycan imaging of FFPE tissues. As shown in Figure 19, there were multiple ions detectable
only in the tissue incubated with PNGaseF that were not present in the control tissue with no
PNGaseF application. Different glycans were distributed across the cortex or medulla regions.
For example, a Hex4dHex2HexNAc5 ion (m/z = 1996.74) is present in the cortex and medulla
(Figure 19c), while a Hex5dHex2HexNAc5 glycan (m/z = 2158.76) is more specific to the cortex
(Figure 19d). An overlay of the MALDI-IMS images for these two ions from the PNGaseF
treated sections (Figure 19e) and the control tissue (Figure 19f) demonstrates that these two ions
are released by PNGaseF. In control kidney tissues that were only sprayed with aqueous
PNGaseF solution lacking enzyme, or tissue slices that were not processed by antigen retrieval
plus and minus PNGaseF digestion, only matrix ions or paraffin/formalin polymer were detected
(data not shown). A summary glycan image panel of 28 glycan ions detected in these kidneys,
sodium adducts and observed/expected m/z values is provided in Figure 20. Additionally, Nglycans were extracted from the tissue following on-tissue PNGaseF digestion, permethylated and
analyzed by MALDI. A representative spectra from this analysis is provided in Figure 21. These
permethylated values were also compared with MALDI reference spectra for mouse kidney
glycans from the Consortium for Functional Glycomics. The imaged glycan ions were correlated
to the reference spectra glycans, illustrated in Figure 22, and could be matched to all 28 glycan
species highlighted in the reference spectra.
We next assessed whether the method was compatible with two representative archived
pathology FFPE tissue blocks, one for pancreatic cancer and one for prostate cancer. A section of
human pancreatic cancer tissue of complex histology was processed, incubated with PNGaseF
and glycans detected by MALDI-IMS (Figure 23). Different N-glycans were detected that could
distinguish between non-tumor, tumor, tumor necrotic and fibroconnective tissue regions. A
representative glycan image overlay of four m/z values that correspond to the sodium adducts of
potential N-glycan species is shown in Figure 23a, each representing a specific region of the
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Figure 19. MALDI-IMS of N-Glycans on a Mouse Kidney Tissue Section. Two mouse
kidneys were sliced at 5 µm prior to proceeding with the MALDI-IMS workflow. One tissue was
covered with a glass slide during PNGaseF application to serve as an undigested control tissue.
An average annotated spectra from the tissue that received PNGaseF application is provided (a).
Tissue regions were assessed by H&E stain (b). The labeled peaks correspond to native Nglycans that have been reported for the mouse kidney on the Consortium for Functional
Glycomics mouse kidney database. Two of these ions were selected and their tissue localization
was assessed. Hex4dHex2HexNAc5 at m/z = 1996.7 (c) is located in the cortex and medulla while
Hex5dHex2HexNAc5 m/z = 2158.7 (d) is more abundant in the cortex of the mouse kidney. An
overlay image of these two masses is also shown (e), as well as the corresponding image from
untreated PNGaseF control tissues (f).
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Figure 20. N-Glycan Panel of FFPE Kidney Sections. Ions detected in the kidney with enzyme
application were compared to the control tissue. Ions that were only observed in the tissue
following PNGaseF application were compared to the glycans found in the mouse kidney
database on the Consortium for Functional Glycomics. The panel provides the glycan species, the
projected mass for the sodium adduct, and our observed mass for the sodium adduct.
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Figure 21. Permethylation of Extracted N-Glycans from a Mouse Kidney. Mouse kidney Nglycans were extracted from the imaging slide after PNGaseF application and digestion. Glycans
were dried down and underwent permethylation as previously described. The permethylated m/z
values were then compared to the permethylation data from the Consortium for Functional
Glycomics mouse kidney database (www.functionalglycomics.org).

Figure 22. Correlation of Released N-Glycans with CFG Database.
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Figure 23. MALDI-IMS of a Human Pancreas FFPE Block. A FFPE block of pancreatic
tissue from a human patient was cut at 5 µm prior to and selected for MALDI-IMS.
Histopathology found four unique regions in the H&E of this tissue block. The tissue block
contained tumor tissue, non-tumor tissue, fibroconnective tissue representing desmoplasia
surrounding the tumor tissue, and necrotic tissue (b). MALDI-IMS was able to distinguish these
four regions based off of specific ions after MALDI-IMS. M/z = 1891.80 (red) is found in the nontumor (NT) region of the pancreas and corresponds to Hex3dHex1HexNAc6, while m/z = 1743.64
(blue) represents Hex8HexNAc2 and is predominant in the tumor region (T) of the tissue.
Desmoplasia (DP) is represented by m/z = 1809.69 (green) corresponding to
Hex5dHex1HexNAc4. In the region where necrosis was identified (TN), m/z = 1663.64 (orange)
was elevated corresponding to Hex5HexNAc4. Image spectra were acquired at 200 µm raster. (c).
Representative individual glycan images for the pancreatic FFPE tissue slice.
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tissue (Figure 23b). A glycan of m/z = 1891.80 (red)/Hex3dHex1HexNAc6 was detected
primarily in the non-tumor region of the pancreas, while a glycan of m/z = 1743.64
(blue)/Hex8HexNAc2 was predominant in the tumor region of the tissue. A region of
desmoplasia surrounding the tumor region, an area of increased extracellular matrix proteins and
myofibroblast-like cells resulting in a dense fibrous connective tissue, is represented by a glycan
of m/z = 1809.69 (green)/Hex5dHex1HexNAc4 (433). A region of tumor necrosis is represented
by a different glycan of m/z = 1663.64 (orange)/Hex5HexNAc4. Additional examples of tissue
distributions of other individual glycan species are shown in Figure 23c.
A human prostate tissue block containing both tumor and non-tumor gland regions was
also analyzed by MALDI-IMS. A heterogeneous N-glycan distribution reflective of the tissue
histology was observed, and as an example of stroma and gland distributions, two glycan ions and
two sub-regions within the tissue are highlighted in Figure 24. Distribution of glycans of m/z =
1663.56 (Hex5HexNAc4) and m/z = 1850.65 (Hex4dHex1HexNAc5) are shown in Figure 24b-c.
A higher resolution tissue imaging analysis was done for selected regions as marked in the panel,
with the H&E images (Figure 24d-f) highlighting stroma and gland substructures. In both
instances, m/z = 1850.65 is present in both the stroma and glands, while m/z = 1663.56 is
predominantly located in the stroma. An overlay of these two ions depicts the stroma as an orange
color, demonstrating the presence of both red and green, while the glands are predominantly
green. The distribution of other representative individual glycan ions is provided in Figure 25,
including the distribution of high-mannose glycan species (Man5-Man9) associated with the
heterogeneous tumor region in this tissue.

3.3.4.2 On-Tissue Glycan Fragmentation and Structural Composition
The glycan structures identified by imaging of the FFPE tissue blocks were assigned
based on the comparison to permethylated species, glycan reference databases and previous
studies (144). An on-tissue approach to further verify N-glycan structures was done using
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Figure 24. MALDI-IMS of a Human Prostate FFPE Tissue Block. An archived FFPE block
of prostate tissue from a human patient was cut at 5 µm and prepared for MALDI-IMS glycan
analysis, (a). H&E image. A global glycan imaging experiment performed with a raster of 225
µm demonstrated a heterogeneous expression of two glycan ions (b). at m/z = 1663.56 and (c).
m/z = 1850.65. Stromal versus gland distribution were further assessed in a high resolution
experiment at 50 µm raster (d–f). Column (d) indicates a 2× amplification of the H&E, and
distribution of the same two glycans are shown at this magnification for m/z = 1663.56 (red) and
m/z = 1850.65 (green), and an overlay image. Column (e) (enlargement of upper region shown in
d). and (f) (enlargement of lower region shown in d), show two highlighted regions of stroma and
glands enhanced at 10× resolution, with the same colors and glycans shown for column (d).
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Figure 25. N-Glycan Panel in Prostate Tissue. A representative image of 12 glycoforms in a
prostate tissue block, where high mannose glycoforms exhibited elevated abundance in the tumor
tissue.
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collision-induced dissociation (CID) directly on the human pancreatic tissue. Released native
glycans from pancreatic cancer FFPE tissues were used as a source for on-tissue CID analysis,
and a representative MALDI spectra of these glycans is shown in Figure 26a. For comparison, a
Hex5HexNAc4 (m/z = 1663.6) purified standard (also termed NA2) was spotted on a stainless
steel MALDI target plate and fragmented by CID, generating a robust fragmentation pattern of
glycans for this ion as previously reported by Harvey et al (247). The same glycan ion was
abundant in pancreatic tissue after PNGaseF release of N-glycans (Figure 27) and was selected
for CID. As shown in Figure 5b, the CID fragmentation pattern of m/z 1663.6 in pancreatic tissue
was the same as the N-glycan standard, confirming detection of NA2 directly in pancreatic tissue
(Figure 27). Mass shifts due to loss of individual sugar ions were detected, such as Hex (resulting
in m/z = 1502.5), HexNAc (resulting in m/z 1460.5), and Hex + HexNAc (resulting in m/z =
1298.5) (Figure 26). An ion at m/z = 712.2, which has been previously characterized as the
sodium adduct of Hex3HexNAc1, was also detected (247). The structures of 13 other glycan ions
were confirmed using this CID approach, and additional fragmentation data and spectra are
provided in Figure 26.

3.3.4.3 Glycan MALDI-IMS of a Hepatocellular Carcinoma Tissue Microarray
The ability to perform N-glycan analysis on FFPE tissues potentially enables the analysis
of multiple FFPE tissue cores in a TMA format. Initial experiments were performed using a
commercially available hepatocellular carcinoma (HCC) TMA (BioChain) consisting of samples
from 16 individual patients, with two tumor tissue cores and one non-tumor tissue core per patient
(Figure 28). Additional patient data are provided in Sup Sheet 4. Glycan MALDI-IMS was done
as described for the other FFPE tissues, and imaging data for two representative glycan ions at
m/z = 2393.92 (Hex7HexNAc6) and m/z = 1743.62 (Hex8HexNAc2) are shown in Figure 28.
Analysis of the cumulative MALDI spectra and detected ions for each tissue core were processed
and compared using an in-house bioinformatic workflow followed by statistical
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Figure 26. CID of N-Glycans from Human Pancreas Tissue. Representative CID spectra from
8 glycans selected for on tissue fragmentation are provided in an annotated format.
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Figure 27. Comparison of the Fragmentation Pattern of a Glycan Standard with the same
Ion on Tissue. (a). A representative MALDI spectra for native N-linked glycans from pancreatic
cancer FFPE tissue. (b). NA2 glycan standard (m/z = 1663.6) was fragmented using CID,
revealing a variety of cleavages across glycosidic bonds as demonstrated in the spectrum (a).
When the same ion was fragmented on the pancreatic tissue, the fragmentation pattern was the
same, verifying that we were detecting Hex5HexNAc4 in the human pancreas.
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Figure 28. N-Glycan Imaging of a Liver TMA. A liver TMA purchased by BioChain consisting
of 2 tumor tissue cores and one normal tissue core from 16 patients was imaged (200 µm raster).
The H&E (a) provides the TMA location (red letters and numbers) and classifies whether the row
is tumor (green bar) or non-tumor (red bar). M/z = 2393.95 (c) and m/z 1743.64 (d) were able to
distinguish between hepatocellular carcinoma and uninvolved liver tissue. An overlay of these ion
demonstrates that m/z = 2393.95 is elevated in tumor tissue and m/z = 1743.64 is elevated in
normal tissue (b).
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analysis. Of the 176 identified ions from the HCC TMA, 132 were increased in tumor cores, and
83 ions had a p-value <0.05. Interestingly 78 (94%) of the significantly different ions were
elevated in tumor cores. After cross-referencing this list of 176 ions with glycans presented in this
paper and our previous study, 26 N-glycans of high-confidence structure determinations were
selected, listed in Table 2 (431). Of these 26 known glycans, ion intensities of 13 species were
significantly different in tumor and normal tissue (p<0.05), and 21 were increased in tumor
relative to normal. FlexImaging was then used to demonstrate the distribution and relative ion
intensities of each glycan across the TMA (Figure 29). Additionally, ROC curves were used to
evaluate how well each of the glycan ion intensities discriminates tumor versus non-tumor. Of
the 176 identified ions, 61 had area under the ROC curve (AuROC) >0.80, indicating they are
strong classifiers. For two glycans at m/z = 2393.95 (Hex7HexNAc6) and m/z = 1743.64
(Hex8HexNAc2), both had an AuROC > 0.80 and a p-value < 0.05, with m/z 2393.95 being
elevated in tumor tissue and m/z 1743.64 being elevated in non-tumor tissue, as demonstrated by
the log2-fold change value (tumor/non-tumor) (Figure 28). In the overlay (Figure 28b), tumor
tissue is predominantly green and non-tumor tissue is predominantly red, confirming results from
our statistical analysis. This data, although from limited numbers of samples, demonstrates the
potential ability of a panel of glycans to be used to accurately discriminate cell types or outcomes
on a TMA by MALDI-IMS.

3.3.5 Discussion
Multiple N-linked glycans can be directly profiled from FFPE tissue blocks and TMAs
while maintaining intact architecture. The basic methodology, which mirrors that of MALDI-IMS
analysis of peptides in FFPE tissues and TMAs, requires deparaffinization and antigen retrieval
prior to PNGaseF application (144,429,430). The ability to adapt the N-glycan imaging method
originally designed for fresh/frozen tissues to encompass FFPE tissue and TMA blocks increases
the scope and speed of glycan-based studies that can be performed in tissues (431). In initial
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Table 2. Comparison of Tumor and Non-Tumor Glycans Detected in Hepatocellular
Carcinoma Tissue Microarrays.
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Figure 29
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studies of formalin-fixed mouse kidney slices, the MALDI-IMS workflow successfully identified
all 28 of the glycans in the mouse kidney database provided by the Consortium for Functional
Glycomics. Many of the structures of these glycans were verified by permethylation (Figure 21)
and CID experiments (Figure 26). As observed with the mouse brain, these glycans were not
homogenously present across the entire mouse kidney slice, but were either predominantly
located in the cortex, or distributed across the cortex and medulla (Figure 20) (431). This unique
distribution of N-glycans associated with tissue sub-structure or disease status was also observed
in human pancreas and prostate tissue slices. In the pancreas, an overlay of four different glycans
was able to map the normal pancreas tissue, tumor pancreas tissue, a region of desmoplasia, and a
necrotic region (Figure 23a). Similarly, an overlay of two glycans could distinguish between
prostate stroma and glands (Figure 24).
In general, the peak intensities of PNGaseF-released glycans in the FFPE tissues seems to
be more intense than that obtained with fresh/frozen tissue sections. This may be a result of the
more extensive heating and washing steps required in the deparaffinization and rehydration steps.
It is this increased detection sensitivity that facilitated CID fragmentation of N-glycans directly
from the tissue (Figure 26, Figure 27b). Under the conditions used, CID generated mainly
fragments across the glycosidic bonds, which were useful in characterizing that the structure was
an intact hexose or HexNAc. This did not provide any information regarding anomeric linkages
between sugar residues. The amount of fragmentation observed was directly related to the relative
intensity of each parent N-glycan ion, and inversely related to the mass of the parent ion
observed. This is typified by the extensive fragmentation of two glycans of m/z = 1663.50 and
m/z = 1809.64 Figure 26, Figure 27b).
One drawback to using FFPE tissues is residual polymer from the paraffin block adjacent
to the tissue. Detection of this polymer is more predominant in the lower mass range of the
imaging runs, and can overlap with potential glycan masses, complicating detection and further
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statistical analysis. This polymer can be observed in the average spectra of the mouse kidney
tissue after PNGase application (Figure 19a) from m/z = 1250-1300, 1450-1500, and 1650-1700.
An additional key to distinguishing polymer peaks is the analysis of spectra from the nonPNGaseF treated control tissues. Particularly for the TMA format, the ion selection program that
we report can detect and account for polymer peaks relative to glycan ions. These polymer peaks
seem to vary in terms of intensity compared to N-glycan ions depending on what tissue is being
used. It is possible that this variation is a function of different formalin formulations, variations is
tissue processing (i.e. amount of time in formalin), storage time or variations in the tissue itself
(419,420). These considerations will be further monitored and evaluated as more glycans from
FFPE tissues are analyzed.
In relation to potential cancer diagnostic applications, the most significant aspect to
developing a method to image N-glycans on FFPE tissue blocks could be the ability to use TMAs
for high-throughput glycan-based experiments. Not only does the method increase the number of
tumor samples that can be analyzed in one experiment, but it could also be used to compare the
glycans detected in a TMA core versus the larger source FFPE tissue. N-glycan MALDI-IMS of
the HCC TMA (Figure 28) is provided as an example, but we have already obtained initial glycan
profiling data from TMAs representing prostate, kidney, lung, breast, colon and pancreatic
cancers. In the HCC TMA, a statistically significant increase in tetra-antennary N-glycan (m/z =
2393.95) and decrease in Man-8 glycan (m/z = 1743.64) was detected in HCC cores compared to
adjacent non-tumor tissue (Figure 28 and Table 2). The tetraantennary N-glycan has been
previously demonstrated to be elevated in HCC compared to matched adjacent non-tumor tissue
by Mehta et al. (434). Continued investigations will be performed on whether these two ions can
distinguish between matched HCC and non-tumor tissues in other HCC TMAs. Our data analysis
identified a total of 176 ions in the tissue, with the majority of significantly different ions being
increased in HCC relative to non-tumor tissue, including 21 known or previously identified
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glycans. It is unclear how this trend of increased glycan levels relates specifically to tumor related
biochemical changes, though the role of glycosylation in tumor development is well documented.
Future work will also focus on determining the identity of the remaining ions to distinguish other
glycan species from the aforementioned polymer peak contaminants.
Currently, MALDI-IMS provides a new approach to effectively visualize and evaluate Nglycan localization in tissue sections. It does not solve the known limitations of MALDI analysis
of underivatized glycans like loss of sialic acids, nor does it provide anomeric linkage
information for N-glycan structure. Established tandem mass spectrometry methods of glycan
extraction, modification and fragmentation are more capable of providing this structural
information. Combining the glycan tissue maps generated by MALDI-IMS to target regions of
interest for further tandem mass spectrometry analysis of glycans could be a new synergistic
approach to more effectively identify tumor-associated glycans and glycoproteins in situ. Use of
other glycosidases like sialidase, as we have previously reported, or fucosidases, could further
extend the utility of the combined methods (431). Overall, the ability to effectively profile Nglycans on FFPE tissue blocks and TMAs provides new opportunities to evaluate glycan profiles
associated with disease status.
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3.4 Disease-Related Applications of and Limitations of MALDI-IMS
3.4.1 Introduction
Hepatocellular carcinoma (HCC), a subtype of liver cancer that accounts for
approximately two-thirds of all liver cancers, is among the most common and aggressive
malignancies worldwide (435). As incidence rates continue to rise, early detection disease
biomarkers are highly sought after and offer the potential to drastically improve patient
outcome(436–439). Both proteomic and glycomic approaches have led to significant advances in
HCC biomarker research. Proteomic analysis has identified several tumor pathways that are
altered in HCC (440–443). Additionally, glycoproteins such as peroxiredoxin 3, osteopontin, and
alpha fetoprotein (AFP) have been identified as potential HCC biomarkers (444–448). However,
these proteins display limited sensitivity in the background of liver cirrhosis or benign diseases.
More recently, it was observed that α1,6 core fucosylated AFP offers improved specificity for
HCC than AFP alone (350,449,450). Thus, core fucosylated AFP, assessed through the AFP-L3
test, is the only test approved by the United States Food and Drug Administration for the
detection of hepatocellular carcinoma. Elevated levels of core fucosylation are not specific for
AFP, but are also observed on transferrin and alpha-1-antitrypsin among other proteins (451–
455). Total serum glycomic studies have also identified increases in core α1,6-linked and α1,3linked outer-arm fucosylation, N-glycan branching, and sialylation in HCC samples
(219,434,456,457).
As nearly all current cancer biomarkers are glycoproteins or carbohydrate antigens, and
as highlighted for HCC, a global analysis of N-glycans from HCC tissue sections using MALDIimaging mass spectrometry (IMS) could extend and complement the continued development of
N-glycan biomarkers associated with HCC (416,458). We have recently developed a MALDIIMS approach for profiling N-glycans directly in frozen and formalin-fixed paraffin-embedded
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(FFPE) tissues (431,459). The method relies on the spraying of a molecular coating of PNGaseF
and on-tissue cleavage of N-glycans prior to matrix application. Relative to other classes of
biomolecules targeted by MALDI-IMS, the method offers ready identification of the individual
glycan species and creation of structural reference databases (459). In this report, the utility of the
method is demonstrated for profiling multiple N-glycans using different FFPE tissue slices of
HCC. Current data analysis approaches are also summarized, as well as use of a novel
derivatization method to stabilize sialic acids in a linkage-dependent/differentiating manner, and
therefore better characterize larger, sialic acid containing N-glycans (237). As the methodology is
still evolving, areas to improve glycan detection by MALDI-IMS and structural characterization
are discussed.

3.4.2 Materials and Methods
3.4.2.1 Materials
Trifluoroacetic acid, α-cyano-4-hydroxycinnamic acid (CHCA), sodium hydroxide
(NaOH), 1-hydroxybenzotriazole hydrate (HOBt), and trypsin were obtained from Sigma-Aldrich
(St. Louis, MO). Ammonium bicarbonate, HPLC grade methanol, ethanol, acetonitrile, xylene
and water were obtained from Fisher Scientific (Pittsburgh, PA). 1-(3-Dimethylaminopropyl)-3ethylcarbodiimide hydrochloride (EDC) was obtained from Oakwood Chemical (West Columbia,
SC). ITO slides were purchased from Bruker Daltonics (Billerica, MA) and Tissue Tack
microscope slides were purchased from Polysciences, Inc (Warrington, PA). Citraconic anhydride
for antigen retrieval was from Thermo Scientific (Bellefonte, PA). Recombinant Peptide NGlycosidase F (PNGaseF) from Flavobacterium meningosepticum was expressed and purified as
previously described (431), and is available commercially as PNGase F Prime™ from Bulldog
Bio (Portsmouth, NH).
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3.4.2.2 FFPE Tissues
All but one tissue sections used in this study were de-identified and obtained
commercially from BioChain. These include a slide with two FFPE tissue sections from a 60 year
old female with a poorly differentiated hepatocellular carcinoma; patient matched tumor and
normal FFPE tissue sections from a 53 year old male with hepatocellular carcinoma, and a patient
matched renal cell carcinoma tumor and lymph node tissue with renal cell carcinoma metastasis
from a 28 year old female. A subset of a commercially available renal tissue microarray (TMA)
from BioChain was also analyzed, where two cores from each patient (oriented vertically) were
present. One de-identified pancreas tissue was obtained by MUSC and was determined to be not
human research classifications by the respective Institutional Review Boards at MUSC.

3.4.2.3 Washes for Deparaffinization and Rehydration
Slide preparation proceeded as described in our previous paper (459). Briefly, FFPE
tissue sections not acquired precut from BioChain, were sectioned at 5μm and mounted on slides
compatible with the Bruker slide adaptor. All slides were heated at 60°C for 1hr to ensure tissue
adhesion to the slide. After cooling, the slide was deparaffinized by washing with xylene and
rehydrated in a series of ethanol and water washes. Citraconic anhydride (Thermo) was used as
the antigen retrieval buffer and the retrieval process took place over 25 minutes in a vegetable
steamer. After allowing the buffer to cool, the buffer was gradually exchanged to 100% water.
The slide was then desiccated to dryness prior to enzymatic digestion.

3.4.2.4 MALDI Imaging Workflow
An ImagePrep spray station (Bruker Daltonics) was used to coat the slide with a 0.2mL
aqueous solution of PNGaseF (20µg total/slide) as previously described (431). As a negative
control, adjacent control tissue slices were shielded from PNGaseF application by covering the
tissue section with a glass slide. Digestion occurred in a humidified chamber at 37°C for 2hr.
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Slides were desiccated prior to α-cyano-4-hydroxycinnamic acid matrix application (0.021g
CHCA in 3mL 50% acetonitrile/50% water and 12µL 25% TFA) using the ImagePrep sprayer.
Released glycan ions were detected using a SolariX dual source 7T FTICR mass spectrometer
(Bruker Daltonics) (m/z 690-5000) with a SmartBeam II laser operating at 1000 Hz, a laser spot
size of 25μm. Following MS analysis, data was loaded into FlexImaging Software focusing on
the range m/z = 1000-4000 and reduced to 0.95 ICR Reduction Noise Threshold. FlexImaging 4.0
(Bruker Daltonics) was used to generate images of differentially expressed glycans. Observed
glycans were searched against the glycan database generated using GlycoWorkbench (432).
Presented glycan structures were generated in GlycoWorkbench and represent putative structures
determined by combinations of accurate m/z and off-slide derivatization experiments.

3.4.2.5 Ethyl Esterification
N-glycans were extracted from slides as described previously and dried by vacuum
centrifugation (431,459). The ethyl esterification protocol, including the modification and
enrichment, was adapted from Reiding et al. (237). Briefly, 2µL water and 40µL 0.25M
HOBt/EDC were added to dried glycans followed by incubation at 37°C for 1hr. 40µL
acetonitrile was added and the mixture was placed at -20°C for 20 minutes. Glycans were
enriched using cotton-HILIC tips according to Selman et al. Shortly, cotton wool composed of
100% cotton (Assured, Rio Ranch, NM) was inserted in 20µL tips and equilibrated with 10µL
water three times followed by 10µL 85% ACN three times. Samples were loaded and unbound
material removed by washing three times with 10µL 85% acetonitrile with and without 1% TFA,
respectively. Tip-bound glycans were eluted in 10µL water. Enriched and modified glycans were
spotted on an Anchorchip MALDI plate (Bruker Daltonics) with 2,5-dihydroxybenzoic acid
(DHB) at a concentration of 5mg/mL in 50% ACN/50% water/1mM NaOH. Ethanol was then
used for recrystallization.
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3.4.3 Results
3.4.3.1 Influence of Histopathology on MALDI-IMS of N-glycans
Initial MALDI-IMS of a commercially available FFPE HCC tissue of complex
histopathology demonstrated the specific release of N-glycans following PNGaseF digestion and
the ability of released glycans to distinguish tissue subtypes and pathologies. Two serial sections
were prepared identically with the exception that one tissue received PNGaseF while the other
was shielded from enzyme application to serve as a negative control. Average spectra of each
tissue region were obtained from FlexImaging and revealed a robust signal increase following
PNGaseF digestion (Figure 30a) compared to the control tissue (Figure 30b). Putative glycan
structures were annotated using GlycoWorkbench based on mass accuracy and previous studies,
but no information is available regarding specific anomeric linkages (431,459). All glycan
structures reported herein are the [M + Na]+ adducts unless otherwise noted. Peaks corresponding
to three glycans, Hex5HexNAc4NeuAc1 (m/z = 2100.759, blue), Hex5HexNAc4 (m/z =
1663.582, red) and Hex9HexNAc2 (m/z = 1905.612, green) are displayed in an overlay image
(Figure 30c). These glycans map to the tissue histopathology marked on the H&E stain (Figure
30d). Analysis of the H&E stain revealed three predominant tissue morphologies; necrosis
(outlined in red), HCC tissue (outlined in green) and fibroconnective tissue (outlined in blue).
Images of individual N-glycans demonstrate the propensity of glycans to be elevated in one tissue
type (Figure 34). Interestingly, high-mannose glycans were elevated in the tumor tissue, while
fucosylated or sialylated/fucosylated complex biantennary glycans were elevated in the
fibroconnective tissue.
While the initial experiment demonstrated the ability of N-glycan localization to define
pathology in HCC tissue blocks, the ability to distinguish tumor vs. normal tissue is of more
clinical significance. Analysis of a patient matched tumor and normal FFPE tissue sample
145

Figure 30. PNGaseF Releases N-linked Glycans from HCC Tissue in a Spatially Defined
Manner. A HCC tissue slide (Biochain) containing two serial slices of HCC tissue was prepared
from MALDI-IMS as described above. One section was shielded from enzyme application to
serve as a negative control. Robust signal correlating to released N-linked glycans was observed
in the average spectra of the tissue receiving PNGaseF application (a). Similar signatures were
not observed in the control tissue (b). Three select ions were selected in FlexImaging and
displayed as an overlay image. Hex5HexNAc4NeuAc (m/z = 2100.7, blue), Hex5HexNAc4 (m/z
= 1663.6, red) and Hex9HexNAc2 (m/z = 1905.6, green) each display unique localization within
the tissue slice (c). Upon histological analysis of an H&E stain (d), these regions were identified
to be fibroconnective tissue, necrotic tissue, and HCC tissue respectively.
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Figure 31. Diverse Organs with Similar Properties Display Conserved Glycan Patterns.
Fibrous tissue from three diverse tissue types were imaged and displayed similar N-glycosylation
properties. Images from lymph tissue with a ccRCC metastasis (a), pancreatic cancer tissue with
complex histopathology (b), and liver tissue with complex histopathology (c) are provided. In
each tissue, the ions corresponding to Hex5HexNAc4, Hex5dHex1HexNAc4, and
Hex5dHex1HexNAc4NeuAc1 display similar localization patterns with each being elevated in
the fibrous tissue regions. Hex5HexNAc4 and Hex5dHex1HexNAc4 are represented by the
sodium adduct of the native glycan, while Hex5dHex1HexNAc4NeuAc1 is represented as a
doubly sodiated adduct of the native glycan. Fibroconnective tissue regions are outlined in black
on the H&Es while fibrotic ccRCC tumor tissue is outlined in red.

147

revealed overall glycan heterogeneity between the two tissues. While Hex8HexNAc2 (m/z =
1743.565, red) is present in both the normal and tumor sections, Hex7HexNAc6 (m/z = 2393.854,
green) is largely absent in the normal tissue (Figure 32a,b). This observation is evident in the
image overlay, where the normal tissue image is red in color due to the presence of
Hex8HexNAc2 and the absence of Hex7HexNAc6, while the tumor tissue is yellow due to the
presence of both Hex7HexNAc6 and Hex8HexNAc2 (Figure 32c). This finding is consistent with
our previous studies made in the analysis of an HCC TMA (459). Interestingly, while
Hex8HexNAc2 is present in both the matched tumor and normal tissues and is elevated in the
normal HCC tissue, it is elevated in the tumor tissue compared to necrotic and fibroconnective
tissue regions (Figure 30, Figure 34). This trend emphasizes the importance of histological
analysis when utilizing MALDI-IMS as a technique.

3.4.3.2 Similarities of Glycan Distribution Across Tissue Types.
The distribution of N-glycans in different fibroconnective tissues from other sources
besides HCC tissues was further assessed. Lymph tissue with a clear cell renal cell carcinoma
(ccRCC) metastasis (Figure 31a), pancreatic cancer and adjacent normal tissue (Figure 31b), and
the hepatocellular carcinoma tissue presented earlier (Figure 31c), all with regions of fibrous
and/or fibroconnective tissue, were analyzed by MALDI-IMS for N-glycans. The regions of
fibroconnective tissue (outlined in black) and fibrous tumor tissue (outlined in red) are defined on
the H&E image for each tissue (Figure 31). In each tissue, three biantennary N-glycans were
commonly detected at higher levels in the fibrous/ fibroconnective tissue compared to adjacent
regions: Hex5HexNAc4 (m/z = 1663.582), Hex5dHex1HexNAc4 (m/z = 1809.661), and
Hex5dHex1HexNAc4NeuAc1 (m/z = 2122.720; [M - H + 2Na]+). In all tissues, the
Hex5dHex1HexNAc4NeuAc1 glycan had the highest specificity for fibrous tissue regions. The
Hex5HexNAc4 was detected at greater signal intensity in more regions of the tissues, and we
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Figure 32. MALDI-IMS Reveals N-glycans that can Distinguish Tumor from Normal in
Matched HCC Tissue Samples. Matched HCC tumor and normal tissue (biochain) were
analyzed by MALDI-IMS after PNGaseF release of N-glycans. M/z = 1743.56 (Hex8HexNAc2)
was present in both tissues (a), while m/z = 2393.85 (Hex7HexNAc6) was primarily in the tumor
tissue only (b). An overview of these two glycan species where m/z = 1743.56 is displayed in red
and m/z = 2393.85 is displayed in green confirms this finding. In the overlay, the normal tissue is
primarily red but the tumor tissue is yellow in color as a result of both glycan species being
present (c). H&E staining of both tissues is provided (d).
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have also noticed that this glycan is likely a marker of tissue regions where blood is present,
illustrated in Figure 31b.

3.4.3.3 Validation of N-Glycan Structures by Off-Tissue Glycomic Analysis
MALDI ionization of glycans often results in the loss of labile sialic acids from glycans.
We performed a recently introduced glycan modification approach, termed ethyl esterification, to
assess whether the loss of sialic acids is occurring in MALDI-IMS experiments. This procedure
results in lactonization of α2,3-linked sialic acids and ethyl esterification of α2,6-linked sialic
acids, resulting in a 46.04 Da mass shift (237). Following ethyl esterification of glycans, glycans
are enriched using cotton-HILIC tips. Glycans from a HCC tissue were retrieved from the tissue,
subjected to the ethyl esterification protocol, and spotted on an anchorchip MALDI plate. An
annotated spectrum is provided (Figure 33). A list of 33 representative N-glycans present in the
MALDI-IMS and/or ethyl esterification experiments, as well as the glycans theoretical m/z value
is provided in Table 3. The results demonstrate a close overlap of observed m/z values for both
approaches with theoretical m/z values obtained from GlycoWorkbench. Additionally, a majority
of N-glycans were present in both the MALDI-IMS and off-tissue ethyl esterification
experiments. However, when comparing the ethyl esterification average spectrum (Figure 33)
with the MALDI-IMS average spectrum (Figure 30a), it is evident that complex and sialylated Nglycans are more predominant after ethyl esterification than in MALDI-IMS: an example being
Hex5HexNAc4NeuAc1 which has the highest signal intensity in the ethyl esterification spectrum
(m/z = 1936.692 & m/z = 1982.733), but is only detected as minor peaks in the imaging average
spectrum (m/z = 1954.589 & m/z = 1976.707). This result may be attributed to a reduction in
signal intensity of sialylated N-glycans in MALDI-IMS due to the loss of sialic acid upon insource decay, reflected in the comparatively higher level of detection of Hex5HexNAc4 (m/z =
1663.582) in the MALDI-IMS average spectrum.
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Figure 33. EE of
HCC
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Figure 34. N-glycans Can Distinguish Complex Histopathology in HCC Tissue. N-glycan
distribution mapped to specific histological regions in an HCC tissue. High mannose N-glycans
were more abundant in the HCC tissue regions, while complex and hybrid N-glycans were more
abundant in the necrotic and fibrous tissue regions.
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Table 3. Comparative Analysis of N-glycans from MALDI-IMS and Ethyl Esterification.
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3.4.3.4 Glycosylation can Distinguish Cancer Subtypes
The ability of N-glycans to distinguish tissue subtypes and pathologies does not only
pertain to HCC. A higher-throughput, TMA-based imaging experiment was performed to
characterize and compare a large number of renal cancer samples in a single experiment. In the
data provided, the classification of each set of tissue cores is outlined by a specified color.
Examples of normal cortex (blue), normal medulla (purple), clear cell carcinoma (green),
transitional cell carcinoma (red), chromophobe renal cell carcinoma (yellow), granular cell
carcinoma (light blue), and carcinosarcoma tissue cores (white) are represented in the TMA.
Hex5dHex2HexNAc5 (m/z = 2158.918) was elevated in all six normal cortex tissue cores (Figure
35a), while Hex5dHex1HexNAc4 (m/z = 1809.705) was consistently elevated in the normal
medulla

cores

(Figure

35b).

An

overlay

of

Hex5dHex2HexNAc5

(blue)

and

Hex5dHex1HexNAc4 (purple), is capable of distinguishing normal kidney anatomy (Figure 35f).
The expression of other N-glycans varied across tumor tissue cores with various specificity. In
comparison to all other tissue subtypes, Hex5dHex2HexNAc4 (m/z = 1955.748) was elevated the
most in clear cell carcinoma tissues (Figure 35d), while Hex7HexNAc2 (m/z = 1581.569) was
most abundant in the granular cell carcinoma example (Figure 35c). In an overlay of
Hex5dHex2HexNAc5 (blue), Hex5dHex1HexNAc4 (purple), and Hex5dHex2HexNAc4 (green),
the clear cell carcinoma tissue cores are distinguished from the normal cortex and medulla cores
(Figure 35g). Finally, there is an enormous degree of heterogeneity across the tumor cores, an
example being Hex5HexNAc4 (m/z = 1663.570) which is much more abundant in two of the
clear cell carcinoma cores in comparison to the rest of the clear cell carcinoma cores (Figure 35e).
The glycans selected for display are representative of a larger population of N-glycans that were
observed in the experiment. Interestingly, N-glycans in the transitional cell carcinoma were
consistently lower in abundance than the other tissue cores on the TMA.
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Figure 35. Aberrant Glycosylation in RCC TMA can Distinguish Cancer Subtypes. A RCC
TMA was processed by MALDI imaging and revealed individual glycans or multiple glycans that
offer diagnostic potential for disease or cancer subtypes. Hex5HexNAc5dHex2 is elevated in the
normal cortex compared to all other tissue types (a), while Hex5HexNAc4dHex1 is more
abundant in the normal medulla (b). Man7 was elevated in granual cell carcinoma (c) while
Hex5HexNAc4dHex2 (d) and Hex5HexNAc4 (e) were elevated in the clear cell carcinoma cores.
Furthermore, various overlays could differentiate the tissue subtypes (f-g).
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3.4.4 Discussion
Profiling of N-glycans in fresh/frozen tissues, FFPE tissue blocks and TMAs is a new
application of MALDI-IMS methodology that has the potential to identify systemic disease
markers and elucidate disease etiology. This methodology is particularly relevant for cancer
tissues, as most known cancer biomarkers are glycoproteins or carbohydrate antigens, including
AFP for HCC (219,434,451–457). The MALDI-IMS glycan profiling data presented herein,
although from only a limited number of HCC tissues, illustrates this potential. Compared to other
biomolecules targeted by MALDI-IMS like lipids, metabolites and proteins/peptides, N-glycans
offer a particular advantage in that there are relatively fewer total glycan ion signals that are
detected in a given tissue. Assigning the underlying composition for each glycan is rather
straight-forward on the basis of accurate masses, albeit anomeric linkages are not differentiated.
In addition to mass accuracy, glycan compositions can be validated by a variety of approaches,
such as CID and derivatization. Structural standards and several glycan reference databases are
available (407,459).
Knowing the identity of the glycan offers many other opportunities for application to cell
biology and genomic studies, particularly as these structures are synthesized by specific
glycosyltransferases, and modified by specific glycosidases. This facilitates comparative analysis
of genomic data for these enzymes from the same tissues. Knowing the glycan composition also
allows inference of different cell biology aspects related to biosynthesis, vesicular trafficking or
degradation processes involving N-glycans. We have found across multiple tumor types, and
illustrated herein, that identifying a specific tumor glycan profile in tissues is fairly
straightforward (459). Herein, this principle has been further expanded as consistent glycan
signatures for fibroconnective tissue have been observed across cancer types (Figure 31). We are
further testing whether detecting changes in glycan profiles can be used as surrogate indicators of
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changes in glycoprotein expression associated with cancer development and progression, as well
as responses to treatment. Current efforts are also directed at using the N-glycan profiles as a
tissue map to identify disease-specific regions of interest for subsequent glycopeptide analysis
strategies.
There still remain many challenges associated with improving the approach, some of
which were also highlighted herein. Detection of high mass N-glycans by MALDI mass
spectrometry, particularly those glycans containing sialic acids, has always been a challenge as
previously described (230,248,249). We are addressing these challenges in three ways, at the
instrumentation level, with on-tissue analysis approaches, and with off-tissue analysis
approaches. The source configuration of the SolariX 7T FTICR instrument used for these
experiments is already inherently amenable to better detection of sialic acid glycans. Compared to
most MALDI-TOF instruments (non-FTICR), less vacuum and a cooling gas following laser
desorption/ionization is present. This combination has been reported to aid in the retention of
sialic acids on glycoconjugates. The ability to selectively capture specific glycan ions directly
from tissue for CID is also an advantage of the SolariX instrument (459). Comparison of Nglycan profiles of the same tissue slides in different MALDI-TOF instruments is ongoing, with
emphasis on how detection of sialic acid containing glycans differ across instrument
configurations. In this context, different MALDI matrix formulations are also being tested and
compared. These are all cumulatively being assessed in the optimization for detection of higher
mass glycan species.
Based on mass accuracy of standards and derivatization experiments, we show that while
sialylated N-glycans are detected in MALDI-IMS (Figure 30a), they appear to be of lower
abundance than may be naturally occurring (Figure 33) (431,459). To correct for this limitation,
different on-tissue and off-tissue derivatization approaches of the N-glycans are being
investigated. Attempts to globally modify N-glycan reducing ends (i.e. 3-aminoquinoline) or
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specifically modifying labile sialic acid residues (i.e. p-toluidine or ethyl esterification) represent
potential solutions (235,237). We believe that some modification of the above off-tissue
derivation approaches used for N-glycans could be adapted to an on-tissue MALDI-IMS profiling
workflow. Additionally, performing MALDI-IMS in negative ion mode offers another reasonable
option for partially retaining sialic acids of N-glycans (247).
Given the ability to use FFPE tissues as the primary source for N-glycan imaging and
their general availability, there is a potential to leverage this approach to discover glycan
biomarkers of HCC and other cancer types. To facilitate biomarker discovery, the described
techniques must be used with large numbers of tissue samples on sample slides or in tissue
microarray format, highlighting the need for an accurate method to directly compare between
samples/experiments. In the example provided within, N-glycan signatures were capable of
distinguishing both tumor from non-tumor tissue cores, but also between tumor subtypes (Figure
35). To determine the significance of these glycans, a similar study involving an increased
number of tissue cores is required. Ongoing research is directed at determining best practices for
data normalization and incorporating internal standards into experimental workflows. These
issues are common to all MALDI-IMS experiments (460,461). One apparent solution is to utilize
a biologically unique glycan as an internal standard that can serve dual purpose to calibrate in the
appropriate mass range as well as serve to normalize signal between samples/experiments. By
incorporating such an internal standard into the matrix spray, it would allow to correct for
differences in matrix deposition, tissue ionization, as well as changes in signal intensity across
experiments. Likewise an approach using informative peaks may be the most appropriate method.
Only after large enough data sets are generated will we be able to determine the best approach to
analyze these larger sample sets. Use of TMAs for glycan MALDI-IMS can certainly facilitate
the increase in sample numbers (459).
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In conclusion, the profiling of N-glycans offers many new avenues of research that can
be initiated by, and complemented with, MALDI-IMS strategies. Challenges and limitations of
the approach are evident, but we believe most can be addressed moving forward as more samples
are analyzed, new derivation and matrix strategies tested, and long-term, continued improvement
in instrumentation platforms.
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Chapter 4: Application of Novel
Glycomic Approaches to Identify
Pancreatic Cancer Disease Markers
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4.1 Introduction
Pancreatic cancer represents one of the most deadly cancers, both in terms cancer related
deaths per year and 5-year survival rates. The dismal 5-year survival rate following detection,
which is around 6%, can be attributed to poor understanding of disease etiology, rapid disease
progression, late diagnosis, limited effective treatment options, and resistance to therapeutic
intervention (2). Patient outcome is significantly improved when the cancer is detected at an early
stage and before it has spread to regional lymph nodes or metastasized to distant sites. This is
largely because these patients are eligible for surgical resection, which represents the only
curative treatment for pancreatic cancer (3,5,8). Unfortunately, it is estimated that only 9% of
patients are diagnosed with localized pancreatic cancer (5). Therefore, efforts directed at the early
diagnosis of pancreatic cancer and further understanding of biological pathways implicated in
disease progression are extremely important.
An in-depth analysis of aberrant glycosylation, a hallmark of all cancers, offers the
potential to advance the understanding of pancreatic cancer and identify new disease markers.
Furthermore, glycoproteins and glycan antigens are ideal targets for initial discovery phase
disease marker studies, as they [1] are prevalent in biological fluids, [2] play a direct role in
cancer progression and metastasis, and [3] represent a majority of the protein-based FDA
approved biomarkers. Both individual glycan antigens and alterations in the glycosylation
biosynthetic machinery have been implicated in pancreatic cancer. The carbohydrate antigen 19-9
(SLeA, CA19-9) is the most well defined disease marker for pancreatic cancer and the target of
the only FDA approved blood test for the management of pancreatic cancer (332,333).
Functionally, CA19-9 has been implicated in disease metastasis through the interaction of the
antigen with endothelium E-selectin (337). However, CA19-9 is not used as a clinical disease
marker for pancreatic cancer, as elevated levels are detected in benign diseases and other sites of
cancer (341–343). Additionally, between 5-15% of the population do not express
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fucosyltransferase 3 and are therefore incapable of expressing CA19-9, even with advanced
pancreatic cancer (333,343). While elevated CA19-9 is the most pronounced glycosylationrelated change in pancreatic cancer, global alterations in glycosylation have been detected. At a
fundamental level, the malignant processes resulting in the formation of pancreatic cancer involve
several common mutations in oncogenes and tumor suppressors. These mutations ultimately
affect the glycan biosynthesis pathway in pancreatic cancer. Constitutive KRAS activation
increases the expression of GLUT1, HK1, HK2, PFK1 and LDHA, all of which impact
glycosylation by directing glycolytic intermediates to the HBP (40,361). Similarly, the dense
stroma and ECM accumulation surrounding pancreatic cancer results in a hypoxic
microenvironment and initiates anaerobic glucose metabolism through glycolysis (354,355). The
shift to glycolysis is accompanied by an upregulation of GLUT1, HK2, PFK1, PFK2, PKM2,
GFPT1 and GFPT2 (354,462). Importantly, in vitro knockdown of GFPT1, a key modulator of
entry into the HBP, exhibited the same reduction in tumor growth as the extinction of mutated
KRAS, directly implicating glycosylation in tumor growth (40). In addition to enzymatic
regulation of the hexosamine biosynthetic pathway, glycosyltransferases have been reported to be
alternatively expressed in pancreatic cancer (336,463–465). Alterations in the hexosamine
biosynthetic pathway and glycosyltransferase expression are apparent in global glycoform
analysis, where increases in fucosylation, sialylation and glycan branching have been observed
(343,373). However, the pancreatic cancer glycome has been analyzed on a relatively small
subset of patients, often ignoring individual glycoforms in favor of structural motifs.
Recent analytical advances have improved the ability to monitor changes in the glycome
in relation to cancer status. Traditional techniques characterized fluorescently labeled glycans
based off of their retention time in chromatographic separations or by sequential enzymatic
digestion (466). As chromatographic separation is required for each individual sample, this
method is not ideal for high-throughput disease marker experiments. Other studies have utilized
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mass spectrometers to characterize disease-related changes in glycan expression levels, although
lengthy desalting and derivatization steps are frequently employed (467). When applied to the
analysis of biological tissues, these methods result in a complete loss of glycan localization. As
up to 90% of the tumor volume is occupied by surrounding stromal cells, this analysis may
differentiate the non-diseased tissue from the stroma, as opposed to the tumor (24). Conversely,
immunostaining with lectins or monoclonal antibodies directed at specific glycosylation
structures or antigens can probe glycan localization within tissue sections, but does not target or
identify individual glycoforms. To this end, our laboratory has introduced a novel approach to
study specific N-linked glycan localization using MALDI-IMS on fresh frozen and FFPE tissue
sections (431,459). This technique has been further explored and validated by other laboratories
(468,469). In addition to simply localizing and identifying N-glycans in tissue sections, we have
recently demonstrated the potential of the method for the identification of individual glycans that
discriminate tumor from non-tumor tissue specimen in a high-throughput TMA-based approach.
The present aim is an example of how MALDI-IMS of N-linked glycans can be adapted
to the identification of disease markers for pancreatic cancer. In the aim herein, we report
MALDI-IMS of N-glycans in TMAs and whole tissue blocks, followed by subsequent glycan
characterization by mass accuracy and derivatization. As the spatial localization of N-glycans is
retained during MALDI-IMS, analysis of tissue blocks can be further interrogated to look at
glycosylation patterns in histological regions other than the tumor and non-tumor regions. Finally,
N-glycan distribution was correlated with CA19-9 staining on serial slides, to determine any
correlations between CA19-9 and released N-glycans.

163

4.2 Materials and Methods
4.2.1 Materials
Trifluoroacetic acid, α-cyano-4-hydroxycinnamic acid (CHCA), sodium hydroxide
(NaOH), and 1-hydroxybenzotriazole hydrate (HOBt) were obtained from Sigma-Aldrich (St.
Louis, MO). HPLC grade methanol, ethanol, acetonitrile, xylene and water were obtained from
Fisher

Scientific

(Pittsburgh,

PA).

1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide

hydrochloride (EDC) was obtained from Oakwood Chemical (West Columbia, SC). Tissue Tack
microscope slides were purchased from Polysciences, Inc (Warrington, PA). Citraconic anhydride
for antigen retrieval was from Thermo Scientific (Bellefonte, PA). Recombinant Peptide NGlycosidase F (PNGaseF) from Flavobacterium meningosepticum was expressed and purified as
previously described, and is available commercially as PNGase F Prime™ from Bulldog Bio
(Portsmouth, NH) (431). Cotton tips for HILIC enrichment of N-glycans were produced using
100% cotton swabs from Assured (Rio Ranch, NM).

4.2.2 FFPE Tissues, TMAs, and Plasma
All human tissues and TMAs used were de-identified and determined to be not human
research classifications by the respective Institutional Review Boards at MUSC. For each section
analyzed, histological analysis and staining with hematoxylin and eosin (H&E) was performed
and regions of diverse pathology were annotated by a pathologist. Plasma from patients with
pancreatitis and PDAC were de-identified and determined to be not human research
classifications by the respective Institutional Review Boards at MUSC.

4.2.3 Sample Preparation for MALDI Imaging
Tissues and TMA blocks were sectioned at 5μm and mounted on slides (25 x 75mm)
compatible with the Bruker slide adaptor. After mounting, sections were dewaxed and antigen
retrieval proceeded as described in Section 3.3.3.3.
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PNGaseF (20μg/slide) was applied to slide-mounted tissue blocks and TMAs using the
ImagePrep spray station (Bruker Daltonics) as previously described (459). N-glycan release
occurred during a 2hr incubation at 37°C in a humidified chamber, followed by desiccation and
matrix application. For the TMAs, α-Cyano-4-hydroxycinnamic acid matrix (CHCA), consisting
of 0.021g CHCA in 3mL 50% acetonitrile/50% water and 12µL 25%TFA, was applied using the
ImagePrep sprayer. The TM-Sprayer (HTX Imaging) was used to coat slides containing whole
tissue blocks with CHCA. CHCA was prepared at a concentration of 5mg/mL in 50% ACN/50%
H2O at .1% TFA. CHCA was applied at 70°C at .0017mg/mm2.

4.2.4 Glycan Derivatization
N-glycans were extracted from slides as described previously and dried by vacuum
centrifugation (431). The ethyl esterification protocol, including the modification and enrichment,
was adapted from Reiding et al. (237). The protocol proceeded as described in Section 3.4.2.5.

4.2.5 CA19-9 and SLeX Staining
Serial sections of five of the TMAs were stained with CA19-9 and SLeX. Individual
cores were manually scored for the presence or absence of stain and annotated for the presence of
tumor or non-tumor tissue. Sensitivity, specificity, positive predictive value and negative
predictive value were calculated for both stains individually across the five TMAs.

4.2.6 Data Processing
Imaging data was loaded into FlexImaging 4.1 (Bruker Daltonics) for visual analysis of
tissue blocks and TMAs. TMAs were searched against an N-glycan library to identify N-glycans
present across all six TMAs. For computational peak picking of the TMAs, Regions of Interest
(ROIs) representing each tissue core were exported from data analysis using the hierarchical
clustering option and further processed using an in-house workflow.
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To assess the mass accuracy of N-glycans, N-glycans present in all six TMAs were
manually tabulated along with the accurate mass of the glycans. In addition to the accurate mass,
m/z values were reported from the imaging peak picking tool as well as individual spectra from a
tissue imaging experiment. To generate the m/z values from individual spectra, one spectra
localized to the tumor tissue and one spectra localized to the non-tumor tissue were loaded into
FTMS processing (Bruker Daltonics) and recalibrated. PPM errors were calculated for both the
picked peaks and the individual spectra.

4.2.7 Glycomic Analysis of Plasma Pools
Plasma from patients with pancreatitis and PDAC were pooled together for glycomic
analysis. 10μL of plasma from each pool was diluted in 90μL H2O prior to digestion with 1μg
PNGaseF overnight at 37°C. N-glycans were extracted from the sample following the addition of
400μL MeOH, 100μL CHCl3, and 300μL H2O and centrifugation at 14,000 x g for 2 minutes. The
aqueous phase was collected, dried by vacuum centrifugation, and ethyl esterified as described in
Section 3.4.2.5.

4.3 Results
4.3.1 N-Glycan Variation in Complex Histopathology Regions
FFPE tissue blocks containing both pancreatic cancer and matched non-cancer tissues, as
well as other complex histopathology regions, were selected for N-glycome analysis by MALDIIMS. N-glycans in these tissue sections displayed patterns of regionalized distribution that
correlated with histopathology analysis by H&E staining. In the example provided, the regions of
the tissue section are outlined in different colors, with each color corresponding to a different
histological region, as annotated by a pathologist (Figure 36a). These regions are pancreas tumor/
pre-cancerous lesions (green), intestine mucosa (yellow), fibroadipose connective tissue (blue),
smooth muscle (orange), and non-tumor pancreas tissue (red). N-glycans were identified that
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Figure 36. Heterogeneous Distribution of N-Glycans in Pancreatic Cancer Tissue Sections.
A PDAC tissue section of complex histology was profiled by MALDI-IMS. In the H&E, tumor/
pre-cancerous lesions (green), intestine mucosa (yellow), fibroadipose connective tissue (blue),
smooth muscle (orange), and non-tumor pancreas tissue (red) are all outlined. In the MALDI-IMS
images, individual glycans correlate with defined histology regions. Hex6dHex1HexNAc5 (b,
tumor), Hex5dHex3HexNAc5 (c, intestine mucosa), Hex5HexNAc4NeuAc1 (d, fibroadipose
connective tissue), Hex4dHex1HexNAc4 (e, smooth muscle), and Hex6HexNAc2 (f, non-tumor
pancreas) are among these N-glycans.
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Figure 37. Panel of N-Glycan Distribution in PDAC Tissue Section. Upwards of 90 ions
corresponding to N-glycoforms were observed in an individual tissue section. In a representative
panel of these glycoforms, many of these glycans exhibit a distribution pattern related to regions
of complex histology.
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were either highly elevated or nearly exclusively detected in each region. Hex6dHex1HexNAc5
(m/z = 2174.771) is elevated in the tumor region of the pancreas, which contrasts with
Hex6HexNAc2 (m/z = 1419.476), which is elevated non-tumor pancreas (Figure 36b,f ).
Similarly, Hex5HexNAc4NeuAc1 (m/z = 1976.677) and Hex4dHex1HexNAc4 (m/z = 1647.586)
are elevated in the fibroadipose connective tissue and smooth muscle regions, respectively
(Figure 36d-e). Unlike the other N-glycans above which are elevated in defined tissue regions but
expressed at lower levels throughout the tissue section, Hex5dHex2HexNAc5 (m/z = 2304.834)
is almost exclusively observed in the intestine mucosa (Figure 36c). Overall, close to 90 Nglycans were identified in the tissue section that correspond to our glycan library, most having a
distribution that correlates with a certain histology-derived region of the pancreas. The most
abundant N-glycans are annotated in the overall average spectra from the imaging experiment
(Figure 36g). A selected panel of N-glycans demonstrates the differential distribution of Nglycans across the tissue section (Figure 37).

4.3.2 Individual N-Glycan Discriminators for Pancreatic Cancer
As N-glycan distribution varies between tumor and non-tumor regions of the pancreas in
whole tissue blocks, we wanted to determine if individual glycans were consistently altered
between tumor and non-tumor tissue sections across different patients. To this end, a higherthroughput study based on the analysis of six TMAs was performed to allow a larger number of
samples to be surveyed in a reduced amount of time. Each TMA consisted of patient matched
tumor and non-tumor tissue cores. Figure 38 provides a detailed workflow schematic of the data
processing steps utilized to generate individual or panels of N-glycans that can distinguish tumor
from non-tumor tissue cores. Initially, the data were loaded into an in-house peak picking
algorithm, which identified 54 monoisotopic peaks present across all six TMAs. A total of 23
peaks that corresponded to N-glycans were identified from the 54 peaks (Table 4). The
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Figure 38. Workflow Schematic for the Identification of Individual and Panels of N-Glycan
Disease Markers. Six TMAs were imaged by MALDI-IMS to add an element of throughput to
the disease marker discovery process. Many glycoforms were detected in all 6 of the TMAs and
were selected for further analysis of individual discriminators and as panels of biomarkers. For
panel identification, 2/3rds of the data was used to optimize the variables for an LDA model,
while the remaining 1/3rd of the data was used to test the performance of the model.
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Table 4. Individual Glycan Discriminators for Pancreatic Cancer.
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expression level of the glycans was assessed by their p-value and Log2FC (Table 4). All Nglycans were detected as the [M + Na]+ adduct, except for sialylated glycans which were
observed as singly or doubly sodiated ions. Of the peaks corresponding to glycans, 17 were
elevated in the tumor tissues at a statistically significant level (p ≤ .05), while none were elevated
in the non-tumor cores at a statistically significant level. Initially peaks were characterized as Nglycans by comparing the observed m/z values to a library of N-glycan structures, but peaks were
further validated by glycan release and derivatization using ethyl esterification of sialic acids. For
this approach, glycans were extracted from a tissue section, underwent derivatization and
enrichment, and were spotted on a MALDI plate prior to analysis. Of the 23 peaks corresponding
to N-glycans in the structural library, all 23 were observed in the glycan derivatization
experiment (Sup Sheet 5). However, additional N-glycans were detected in the analysis following
derivatization. The five N-glycans with the highest Log2FC values were all complex, fucosylated
N-glycans, and all had a Log2FC ≥ 1.11. While the level of these glycans were significantly
different between tumor and non-tumor (p ≤ .05), individual discriminators displayed poor
sensitivity and specificity for distinguishing the conditions. For example, Hex7dHex1HexNAc7
(m/z = 2742.983) (data not shown) was only elevated in a small subset of tumor tissues, while
Hex6dHex1HexNAc5 (m/z = 2174.771) was elevated in a majority of tumor cores but also some
non-tumor cores (Figure 39e). In representative images from five pancreas tissue blocks,
Hex6dHex1HexNAc5 was primarily localized to the tumor tissue, but was frequently detected in
regions not characterized as tumor tissue by a pathologist (Figure 39a). This general trend is
reflected in the statistical data, in which Hex6dHex1HexNAc5 is elevated in the tumor over the
non-tumor tissue cores, with a log2FC = 1.11 (Figure 39a). In contrast, m/z = 1419.476
(Hex6HexNAc2) is more ubiquitously expressed throughout the tissue blocks (Figure 39b) and
TMA (Figure 39f), which is reflective of the low log2FC of the Hex6HexNAc2 glycan, where
log2FC = -.08. Of the three high-mannose N-glycans detected across all six TMAs, all had a low
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Figure 39. Combinations of Individual Discriminators Reveal More Robust Differences in
Tumor and Non-Tumor Samples. Representative images of 5 tissue sections of complex
histology and 2 tissue microarrays, looking at the localization of Hex6dHex1HexNAc5 (a,e),
Hex6HexNAc2 (b,f), and the overlay of the two glycans (c,g). In the TMA, tumor cores are
outlined in green, while non-tumor cores are outlined in red. Furthermore, in overlay images,
Hex6dHex1HexNAc5 is presented in green, while Hex6HexNAc2 is presented in red. The
overlay of the two glycans is able to distinguish tumor from non-tumor cores in both the whole
tissue blocks and the tissue microarray.
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or negative Log2FC value and were not significantly different between the tumor and non-tumor
cores.

4.3.3 N-Glycan Biomarker Panels
The combination of N-glycans improved the ability of the platform to distinguish tumor
from non-tumor tissues, both visually in the MALDI-IMS data and empirically in the statistical
data. In comparison to the individual discriminators, the visual image overlay of
Hex6dHex1HexNAc5 (green) and Hex6HexNAc2 (red) in both the tissue blocks (Figure 39c) and
TMA (Figure 39g), yields more pronounced differences between the tumor from non-tumor tissue
regions, as outlined by the pathologist (Figure 39d). To generate a N-glycan biomarker panel, a
supervised machine learning algorithm was applied across the glycans identified in all six TMAs,
focusing on the ability of the multiple N-glycans to distinguish tumor from non-tumor tissue
cores (Table 4). With this approach, 2/3rd of the data was subjected to a sequential feature
selection process to minimize the misclassification error of the LDA model, and the remaining
1/3rd was used as a validation set. In the LDA model, Hex7dHex1HexNAc7 (m/z = 2742.9280)
and Hex6dHex2HexNAc5 (m/z = 2320.7524) displayed the lowest error rate of .1458 (Figure
40a). Additionally, the image overlay of Hex7dHex1HexNAc7 (green) and Hex6dHex2HexNAc5
(red) in three TMAs validates the statistics (Figure 40b-d). The predictive characteristics of the
model were compared against CA19-9 and SLeX staining of the same TMAs. The LDA model
consisting of two glycans was able to outperform both CA19-9 and SLeX staining in negative
predictive value, and CA19-9 in positive predictive value (Table 5).

4.3.4 Comparison of Plasma and Tissue N-Glycome
Pooled plasma samples from patients with pancreatic cancer and pancreatitis were
analyzed for differences in the N-glycome following ethyl esterification. Very few differences in
the plasma N-glycome were observed in the two conditions (Figure 41a,b). This may be attributed
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Figure 40. LDA Model of N-Glycan Discriminates Tumor from Non-Tumor Tissue Cores.
Supervised machine learning algorithms, specifically the Linear Discriminate Analysis (LDA),
were used to identify important features to distinguish tumor from non-tumor tissue sections. Two
glycans (Hex7dHex1HexNAc7, m/z = 2742.9820; Hex6dHex2HexNAc5, m/z = 2320.7524) were
observed to be important, and the performance of the LDA model based off of these two features
was tested for performance of the biomarker panel (a). Representative images from three of the
TMAs are presented with an overlay of Hex7dHex1HexNAc7 (green) and Hex6dHex2HexNAc5
(red) (b-d).
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Table 5. Comparison of LDA Model to Carbohydrate Antigen Staining. The
sensitivity, specificity, positive predictive value (PPV) and negative predictive value
(NPV) were calculated based off of the markers ability to distinguish tumor from nontumor tissue sections.
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Pancreatitis Plasma
Glycome

Pancreatic Cancer
Plasma Glycome

Pancreatic Cancer
Tissue Glycome

Figure 41. Pancreatic Cancer and Pancreatitis Plasma Glycome. The derivatized N-glycome
from pooled plasma from patients with pancreatic cancer (b) and pancreatitis (a) exhibited little
difference from one another. In contrast the pancreatic tissue glycome was more robust,
suggesting the plasma glycome is not reflective of the tissue glycome.
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to the presence glycoforms from abundant serum glycoproteins, such as immunoglobulins. On the
other hand, the N-glycome from glycans extracted from a pancreatic cancer tissue block exhibited
robust differences in the glycan species identified compared to the pancreatic cancer plasma pool
(Figure 41c).

4.4 Discussion
The aim of this study was to investigate the ability MALDI-IMS analysis of N-glycans to
be utilized as a disease marker identification platform for pancreatic cancer. To achieve this goal,
TMAs were used for initial disease marker identification, but results were validated in both
TMAs and whole tissue blocks. A secondary goal was to compare the classification metrics of
individual discriminators to panels of N-glycans. Due to the enormous biological heterogeneity
between individuals with cancer, single markers rarely have the sensitivity and specificity needed
for screening asymptomatic patients. Biomarker panels, even when some of the markers are not
adequate predictors of disease on their own, can improve disease classification (470). While
aberrant glycosylation is known to be a hallmark of cancer, including pancreatic cancer, few
studies have assessed alterations of N-linked glycosylation in pancreatic tissue sections. Instead,
most studies monitor CA19-9 serum expression, which is primarily present on O-glycans and
glycolipids (334,335). However, CA19-9 expression has well defined limitations for its use as a
diagnostic disease marker. In our initial analysis of N-glycan distribution of pancreatic cancer
tissue blocks, the expression levels of various N-glycans seem to correlate to complex
histological regions present in the tissue blocks (Figure 36). The need for diagnostic markers for
pancreatic cancer, limitations in currently available disease markers, and the observation of Nglycans that correlate to tumor and non-tumor tissue regions make pancreatic cancer an ideal
disease model for this manuscript.
Given the lack of software available to process data from the SolariX FTICR mass
spectrometer, mainly due to the enormous size of the high-resolution data, our laboratory
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developed an in-house approach for peak picking and generation of biomarker panels (Figure 38).
For the peak picking function, a bucket table consisting of m/z values and the corresponding
relative intensity was generated by using the hierarchical clustering function present in the
FlexImaging software. In the peak picking process, a total of 54 peaks were detected in all six
TMAs, 23 of which correspond to masses present in our N-glycans structural library (Table 4,
Sup Sheet2). Of the identified N-glycans, 20 are elevated in the tumor over the non-tumor tissue
cores, 17 of which have a p-value ≤ .05. The high-mannose glycans observed have a negative
(Hex6HexNAc2, Hex8HexNAc2) or low (Hex7HexNAc2) log2FC value, with p-values > .05. It
is clear that there is room for optimization in the peak picking process, as manual data processing
identified peaks corresponding to 50 N-glycans that are present in all six TMAs (Sup Sheet 5).
Furthermore, the peak picking selection, which uses binned windows for peak selection, exhibits
higher m/z errors than individual processed spectra loaded into the FTMS processing software.
After data processing, nearly all errors are below 10 PPM, which is significantly better than the
PPM errors observed using the binned windows (Sup Sheet 5). Of the 23 peaks that correspond to
N-glycans, all but one are detected in both the individual spectra and in the off-tissue
derivatization and enrichment of N-glycans. As demonstrated by the table, many glycans are not
observed in the peak picking algorithm but can be detected by FTMS processing and following
glycan derivatization and enrichment (Sup Sheet 5).
Following the peak picking process, combinations of N-glycans were evaluated for their
potential to distinguish tumor from non-tumor tissue sections, both visually and computationally.
An overlay of two identified N-glycans, Hex6dHex1HexNAc5 and Hex6HexNAc2, is able to
visually differentiate tumor from non-tumor tissues in whole tissue blocks and TMAs (Figure 39).
For panel identification, the 23 peaks corresponding to N-glycans were subjected to supervised
machine learning algorithms and sequential feature selection to identify N-glycan panels that are
capable of distinguishing tumor from non-tumor tissue cores. The LDA model highlights the
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importance of Hex7dHex1HexNAc7 and Hex6dHex2HexNAc5 in distinguishing tumor from
non-tumor sections (Figure 40). This model outperforms CA19-9 staining metrics on serial TMA
sections

(Table

5). Both comparisons mentioned above, Hex6dHex1HexNAc5 vs.

Hex6HexNAc2 and Hex7dHex1HexNAc7 vs. Hex6dHex2HexNAc5, contrast N-glycans with a
large Log2FC and a p-value ≤ .05 with N-glycans with a negative Log2FC and p-value ≥ .05
(Table 4). Additionally, as little correlation was found between N-glycans and the CA19-9
antigen, it is possible to incorporate CA19-9 expression metrics into the biomarker panel to
potentially improve the predictive value (470).
By validating the glycan distribution on whole tissue blocks, we were able to evaluate
glycosylation trends in relation to complex histopathology. Among the findings, two important
observations warrant further discussion. As previously mentioned, pancreatic cancer is only
curable if detected at an early stage prior to becoming locally invasive or metastatic. As such,
markers capable of detecting of pre-cancerous lesions are particularly useful. The overlay of
Hex6dHex1HexNAc5 and Hex6HexNAc2 (Figure 39c, top tissue), is able to differentiate both
low and high grade IPMN lesions from the non-tumor pancreas tissue. Interestingly,
Hex6dHex1HexNAc5 (Figure 39a, top tissue) has a higher relative intensity in the tumor regions
than the pre-cancerous lesions, suggesting a signature gradient that coincides with cancer stage.
However, not all of these lesions ultimately become cancerous, so additional tests are required to
determine if these glycans can distinguish lesions that will become cancerous from lesions that
will remain dormant. Secondly, one of the most significant limitations of cancer biomarkers is
their poor ability to differentiate tumor from benign diseases. In the examples of whole tissue
blocks provided, the overlay of Hex6dHex1HexNAc5 and Hex6HexNAc2 is also able to
differentiate tumor from chronic pancreatitis (Figure 39c). As CA19-9 is limited from a clinical
perspective by its poor specificity in distinguishing malignant from benign conditions, this
finding is particularly promising.
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It is unlikely that MALDI-IMS will be used clinically for the early detection of pancreatic
cancer, as tissue biopsy samples are extremely invasive and are unlikely to be collected before the
disease is too advanced. Early detection disease markers for pancreatic cancer should utilize
biological fluids. However, initial targeted approaches on tissue sections can reduce the
complexity associated with plasma analysis (471). While no plasma from non-diseased patients
was tested, glycomic profiling was unable to distinguish pooled plasma from pancreatitis and
pancreatic cancer patients (Figure 41a,b). High-mannose N-glycans and members of the glycan
biomarker panel were noticeably absent from plasma samples. However, these glycans were
observed in the ethyl esterified N-glycans following extraction from tissue blocks, verifying that
the derivatization allows for the detection of these glycoforms (Figure 41c). Thus, trends
observed by tissue imaging are not reflective of the plasma glycome. However, it is unclear
whether the absence of important glycoforms is attributed to their absence on plasma proteins or
suppression caused by the large dynamic range of proteins in the plasma. Depletion of abundant
glycoproteins from the plasma may enable the detection of low abundance glycoforms (472,473).
While analysis of the plasma glycome does not correlate with our imaging results, the imaging
data mirrored that reported in serum from PDAC patients, which exhibited overall elevated levels
of glycosylation but no differences in high-mannose and hybrid N-glycans (385).
In conclusion, a novel disease marker discovery platform was developed that utilizes
MALDI-IMS of N-linked glycans in a high-throughput TMA study. Expression levels of
individual and panels of N-glycans were shown to be capable of differentiating tumor from nontumor tissue, as well as other complex pathologies. Furthermore, the developed platform
described herein can be applied to any disease for initial screening purposes. Additionally, the
consistency of glycosylation trends between our tissue imaging results and published literature on
serum, suggest that these glycan biomarker panels may be successful in non-invasive serum
screening for pancreatic cancer.
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Chapter 5: Application of Novel
Glycoproteomic Approaches Directed at
Pancreatic Cancer
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5.1 Introduction
The ability to distinguish pancreatic cancer from non-diseased specimen by aberrations in
glycosylation has been established, both herein and elsewhere. To date, the glycan antigen CA199, represents the only FDA approved blood test for the management of pancreatic cancer
(332,333). Profiling the glycome has identified other glycoforms, including N- and O-linked
glycoforms, that are differentially expressed in pancreatic cancer serum and tissue specimen
(331,373,385,474,475). In tissue sections, we have recently reported experimental results from a
high-throughput MALDI-IMS approach that demonstrate the potential of N-glycans to distinguish
tumor from non-tumor tissue specimen with high sensitivity and specificity. These alterations in
the total glycome are reflective of a pattern of altered glycosylation across many proteins (156).
These glycan discriminators offer insights into the tumorigenic process, but it is doubtful that
they can serve as early stage biomarkers in biological fluids due to a lack specificity for
pancreatic cancer. Unlike individual glycoforms, glycoproteins that originate from a specific
tissue have had clinical success as early stage cancer biomarkers. For example, alpha-fetoprotein
(AFP) and prostate-specific antigen (PSA) originate from, and can detect the presence of, liver
and prostate cancer, respectively (160,161,349). While profiling the glycoprotein expression level
is informative, linking aberrant glycosylation to the corresponding protein can improve the
clinical utility of biomarkers. The most promising example of leveraging both protein expression
and glycoform occupancy in a single biomarker is AFP-L3, which outperforms AFP due to the
elevation of fucosylated AFP in malignant liver diseases compared to non-malignant liver
diseases (160,350,351). The identification of similar glycoproteins for pancreatic cancer to aid in
the early identification of the disease would greatly improve pancreatic cancer treatment options
and survival.
Early proteomic profiling of pancreatic cancer specimen revealed a general upregulation
of glycoproteins in pancreatic cancer; especially those involved in regulating cellular
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organization, adhesion, transport and immune system response (364,377). These observations
were confirmed by global hydrazide enrichment of glycoproteins from pancreatic cancer tissue
specimen, which identified 252 proteins that had aberrant expression of N-glycopeptides (283).
However, both pancreatic cancer and pancreatitis exhibit similar trends in glycoprotein
expression levels, with a limited number of glycoproteins that are uniquely expressed in the
cancer specimen (283,380). Thus, it is important to link glycoforms to the glycoproteins in order
to distinguish malignant disease from normal and benign specimen. To investigate specific
glycoproteins as disease markers, most approaches utilize trends in aberrant glycosylation to
determine the appropriate enrichment strategy. Efforts have been directed at linking CA19-9 to
protein carriers. Mucins have long been reported to be the primary carrier of the CA19-9 antigen,
but CEACAM proteins, agrin, galectin-3-binding protein, ezrin, tPA, cathepsin D, necdin, and
neutrophil cytosol factor 2 are now known to carry the antigen (273,373,476). While CA19-9 is
thought to be present on N- and O-glycans, it is unknown what specific glycoforms are modified
with the glycan antigen (273,334,335). Other glycoproteomic approaches have assessed
differential glycosylation in pancreatic cancer by selectively enriching glycan epitopes using
lectin enrichment. The lectin enrichment of glycoproteins bearing specific glycan motifs, such as
α2,6 sialic acids (SNA) or fucose residues (AAL), followed by downstream proteomic analysis of
the enriched glycoproteome, identified glycoproteins that could differentiate pancreatic cancer
from non-cancer specimen (318,343,384). Given the poor overlap in glycoprotein enrichment
across various enrichment strategies, it is likely that other disease markers remain undiscovered.
Recent advances to the field of glycoproteomics can lead to a deeper understanding of the
role that glycosylation plays in pancreatic cancer and the identification of disease markers. From
a targeted glycoproteomics standpoint, there is a significant need to continue to identify proteins
that are modified by the CA19-9 antigen. As CA19-9 is expressed in malignant and benign
diseases, identification the carbohydrate antigen on proteins unique to cancer would improve the
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sensitivity and specificity of disease detection. Furthermore, CA19-9 is not the only aberration in
pancreatic cancer glycosylation. The global assessment of all glycoproteins and their attached
glycoforms would also aid in disease marker identification. However, due to the inherent
complications of glycoproteomics, these studies are rare. Intact glycoprotein analysis of complex
samples requires appropriate glycopeptide enrichment steps to overcome limitations of dynamic
range, reduced ionization efficiency and heterogeneity associated with glycosylation
(221,264,265). Many of these studies use lectin enrichment, which limits analysis to specific
glycoforms.
In this manuscript, we aim to utilize novel mass spectrometry based approaches to
combine glycomic and proteomic information as a mechanism to identify disease marker
candidates that can be further assessed as clinical markers for pancreatic cancer. In one approach,
the incorporation of azide-labeled sialic acid analogs into pancreatic cancer cell lines provides a
highly efficient enrichment strategy for sialic acid containing glycopeptides. When applied to cell
lines with well characterized CA19-9 expression levels, significant variations in protein
expression levels highlight a population of proteins that can be further assessed as CA19-9
carriers. In this study, Panc1 and Miapaca2 cell lines express low levels of CA19-9, while
BXPC3 and Capan2 cell lines express high levels of CA19-9. As few studies have profiled the
significance of N-glycans in terms of their ability to carry the CA19-9 motif, a general profile of
the N-glycome is also reported in relation to the CA19-9 expression. In addition to inferences
about CA19-9 expression, the glycoproteome reported within catalogs sialylated glycoproteins in
pancreatic cancer. The second aim is directed at advancing methodologies available for intact
glycopeptide analysis. Starting with the analysis of glycoprotein standards, we outline a workflow
that can be used for the comprehensive analysis of an enriched glycoprotein or adapted for broad
glycoproteomic research. As opposed to commonly employed lectin enrichment strategies, the
glycopeptide enrichment approach herein is relies on physiochemical properties of the glycan,
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enabling an unbiased enrichment, regardless of the glycoforms. Protocols using hydrophilic
interaction chromatography (HILIC) and strong anion exchange (SAX) are outlined in the
sections below.

5.2 Materials and Methods
5.2.1 Materials
Cell culture media were purchased from Mediatech, Inc. (Manassas, VA). Trypsin-EDTA
used for cell culture and FBS for media supplementation were purchased from Gibco (Grand
Island, NY). A mixture of Penicillin-Streptomycin-Amphotericin B was purchased from MP
Biomedicals (Solon, OH). The click sugar analogs and the alkyne-agarose enrichment kit came
from Life Technologies (Grand Island, NY). HPLC grade methanol, HPLC grade ethanol, HPLC
grade acetonitrile, HPLC grade chloroform, HPLC grade water, histological grade xylenes, PBS,
.5mL Zeba spin columns, and ammonium bicarbonate were obtained by Fisher Scientific
(Pittsburgh, PA). SDS, EDTA, TrisBase, DTT, 1-hydroxybenzotriazole hydrate (HOBt), sodium
hydroxide (NaOH), trypsin, calcium chloride (CaCl2), fetuin, transferrin and asialofetuin were
obtained from Sigma-Aldrich (St. Louis, MO). 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride (EDC) was purchased from Oakwood Chemical (West Columbia, SC). NP-40 was
purchased by Boehringer Manheim Gmbh (Germany). SAX solid phase extraction cartridges and
C18 ZipTips came from Waters (Milford, MA) and Millipore (Ireland), respectively. Hydrazide
coupling buffer was purchased by Bio-Rad (Hercules, CA) and SiMag-Hydrazide beads came
from Chemicell GmbH (Berlin, Germany).

5.2.2 Cell Culture
Pancreatic cancer cell lines BXPC3, Capan2, Miapaca2, and Panc1 were provided
generously by Dr. Charles Smith and were cultured as suggested by the American Type Culture
Collection (ATTC). Both Panc1 and Miapaca2 cells were cultured with Dulbecco's Modified
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Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum and a 1X solution of
Penicillin-Streptomycin-Amphotericin B. BXPC3 and Capan2 cell lines were cultured in RPMI
Medium supplemented with 10% fetal bovine serum and a 1X solution of PenicillinStreptomycin-Amphotericin B. All cell lines were maintained at 37°C in a 5% CO2/air
environment.

5.2.3 Glycomic Analysis of Cell Lines
5.2.3.1 N-Glycan Release by PNGaseF
For N-glycan analysis of the cell lysate, cells were cultured to 80% confluency and
washed with PBS, prior to being scraped and pelleted. Cell pellets were lysed with 200μL of lysis
buffer (1% SDS, 5mM EDTA and 25mM Tris Base) for 1hr at 4°C. The cell lysate was sonicated
for 10 seconds using a probe sonicator at 30% power. Protein from 100μL of cell lysate was
precipitated by the addition of 400μL methanol, 100μL chloroform, and 300μL water, followed
by centrifugation at 14,000 x g for 2 minutes. After discarding the top aqueous layer, the proteins
were pelleted by the addition of 400μL methanol and centrifugation at 14,000 x g for 3 minutes.
The proteins were resuspended in a 1% SDS solution and reduced in 10mM DTT at 95°C for 5
minutes. After cooling to room temperature, 2.5μL NP40 and 2.6μg PNGaseF were added to the
proteins from each cell line and digestion took place at 37°C overnight. Released glycans were
collected by repeating the chloroform-methanol precipitation as described above and collecting
the upper aqueous layer. The glycans were concentrated by vacuum centrifugation prior to
beginning the ethyl esterification protocol.

5.2.3.2 Glycan Derivatization
The ethyl esterification protocol for released glycans was adapted from Reiding et al. and
performed as described in Section 3.4.2.5 (237).
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5.2.3.3 Data Processing
Glycan ethyl esterification of cell lines was performed in two experimental replicates for
each cell line. Spectra were loaded into Compass DataAnalysis (4.0, Bruker Daltonics) and
spectra were exported as .xy files for peak picking using Progenesis MALDI (Nonlinear
Dynamics, Durham, NC). After the first round of peak picking, peaks that corresponded to known
glycans were selected for further data processing. Other peaks corresponding to glycans that were
not initially picked by Progenesis were manually added. For data visualization purposes, a heat
map was generated that compares the ion intensity of a mass in a specific cell line to the average
ion intensity across all cell lines. In the heat map, clades of interest were selected and individual
glycan structures were identified based off of mass accuracy using GlycoWorkbench.

5.2.4 Click Chemistry Enrichment of Glycoproteins
5.2.4.1 Sugar Incorporation
Cell lines were cultured under conditions as described in section 5.2.2. For click
chemistry analysis of cell lines using azide-labeled sugar analogs, cell lines were cultured to 50%
confluency prior to treatment with the sugar analog. After 48 hours, the cells were washed with
PBS, collected by scraping in 1mL PBS, and pelleted by centrifugation at 1,500 x g for 2 minutes.
For each experimental replicate, separate plates from each cell line were treated with the 20nM
ManNAz sugar analog, 20nM GalNAz sugar analog, or a corresponding volume of DMSO.

5.2.4.2 Click Chemistry Enrichment
The click chemistry-mediated glycoprotein enrichment as described by the invitrogen
protocol was scaled down to adjust for a smaller number of starting cells and performed for the
capture of azide-modified proteins with alkyne-agarose beads (294). Briefly, lysis buffer was
added to cells, which then sat on ice for 10 minutes prior to 6 x 3 second sonications at 30%
power with a probe sonicator. The lysed cells were centrifuged briefly to remove cell debris and
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the cell lysate was then added to prepared alkyne-agarose resin. Glycoprotein binding occurred
following the addition of the supplied catalyst solution by end-over-end rotation overnight. After
overnight incubation, all non-azide modified proteins were removed by discarding the supernatant
after centrifugation and washing the resin with H2O. Glycoproteins were reduced in the provided
SDS wash buffer supplemented with 10mM DTT at 70°C for 15 minutes. The wash buffer was
removed following centrifugation and alkylation occurred by the addition iodoacetamide
followed by incubation in the dark for 30 minutes. Bound glycoproteins were transferred to the
provided spin columns and washed with SDS wash buffer, 8M Urea/100mM Tris, and 20% ACN
as described in the protocol. Glycoproteins were digested with trypsin during an overnight
incubation at 37°C. Released peptides were collected, reconcentrated and desalted using C18
ZipTips prior to LC-MS/MS. In total, two experimental replicates were performed and at least
two technical replicates for each experimental replicate group were processed by LC-MS/MS.
Following a thorough removal of nonspecific interactions, bound N-glycopeptides were released
overnight during an incubation with 2.6μg PNGaseF at 37°C. Released off-bead peptides were
collected and desalted using a C18 ZipTip prior to LC-MS/MS.

5.2.4.3 LC-MS/MS and Bioinformatics
A single dimension RPLC separation was employed prior to tandem MS. Dried peptides
were resuspended in 10μL Buffer A (97.8% HPLC grade H2O, 2% acetonitrile, 0.2% formic
acid), injected using a Dionex U3000 nano-LC system (Thermo Scientific), and passed through a
C18 trap column (C18 pepMap 100, 5μm, 300 μm x 5mm ID, Thermo). From the trap column,
peptides proceeded to an in-house C18-reverse phase analytical column (.0075mm ID, 15cm)
consisting of Waters YMC-ODS C18-AQ 5mm resin. Peptides were eluted using a linear gradient
of increasing concentration of Buffer B (97.8% acetonitrile, 2% HPLC grade H2O, 0.2% formic
acid). For the analysis of trypsin digested glycoproteins following click chemistry enrichment, the
flow rate was set to 200nL/min and ramped from 2% Buffer B to 50% Buffer B using a 180
189

minute linear gradient. Peptides released by PNGaseF incubation were eluted using a 240 minute
linear gradient of 2-50% Buffer B at a flow rate of 200nL/min.
For the analysis of tryptic peptides and previously glycosylated peptides released from
the alkyne-agarose resin with PNGaseF, the top 10 most abundant peptides were fragmented by
CID in a data dependent fashion. The precursor ion scan was collected in the Orbitrap and CID
was performed in the ion trap. The normalized collision energy was set to 35%, with a dynamic
exclusion set for a repeat count of 2, repeat duration of 30 seconds and an exclusion duration of
100 seconds. Data were searched using Mascot (version 2.4.1, Matrix Science, London, UK) via
Proteome Discover (version 1.4.0.288, Thermo Scientific). The data were searched against a
UniProt Swiss Prot Homo sapien protein database (2014_07 release) with canonical and isoform
entries. Proteins found in the common Repository of Adventitious Proteins (40,872 entries) were
added to the protein database. The parameters were set to allow up to 2 missed cleavages, with a
10 ppm precursor mass tolerance and a .8 Da fragment mass tolerance. Carbamidomethyl (Cys)
was defined to be a static modification, while protein N-term acetylation, oxidation (Met), and
deamidation (Asn, Gln) were set as dynamic modifications. Data were also searched against an
automated decoy database in Mascot. Normalized spectral counts were generated in ProteoIQ
(version 2.3.08, Premier Biosoft, Palo Alto CA) and the protein readout was generated after
specifying ≥ 2 peptides for a given protein and the protein false discover rate (FDR) <5%.
Normalized spectral counts for each experimental replicate were produced by averaging the
appropriate technical replicates from the sample (Sup Sheet 9). For data processing, if no spectral
counts were observed, or if the average of the sugar analog treated condition was less than 5 times
that of the DMSO treated condition, the spectral count value was artificially set to 1.
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5.2.5 Intact Glycopeptide Analysis
5.2.5.1 Glycoprotein Digestion
Glycoprotein standards for the evaluation of glycopeptide enrichment strategies were
dissolved in H2O, reduced in 10mM DTT at 60°C for 30 minutes and alkylated in 25mM
iodoacetamide in the dark for 30 minutes. The glycoprotein standards were then diluted with
100mM AMBIC, brought to a final concentration of 2mM CaCl2, and digested with trypsin
overnight at 37°C at a ratio of 1:100 trypsin:sample.

5.2.5.2 Glycopeptide Enrichment
For intact glycopeptide analysis, glycopeptides were enriched using strong anion
exchange (SAX) SPE cartridges and cotton-HILIC tips. For enrichment with SAX SPE
cartridges, the cartridge was washed and preconditioned with 1mL ACN, 1mL .1M
triethylammonium acetate, 3mL H2O, and 1mL 95% ACN 1% TFA. Digested peptides were
resuspended in 400μL 50% ACN, .1% TFA and applied to the SPE cartridge along with 3mL
95% ACN, 1% TFA. After the sample was allowed to flow through the cartridge, the cartridge
was washed with 3mL 95% ACN 1% TFA and glycopeptides were eluted with 500μL 50% ACN
.1% TFA. Alternatively, cotton-HILIC tips were also used for the enrichment of glycopeptides.
Peptides were first resuspended in 80% acetonitrile. The cotton-HILIC tips were washed 5x with
10μL H2O and 3x with 10μL 85% ACN, followed by sample loading 40x, tip washing with 3x
10μL 85% ACN .1% TFA, and glycopeptide elution in 10μL H2O.
For selective enrichment of sialylated glycopeptides by hydrazide enrichment,
glycoproteins were incubated with 2mM periodic acid on ice for 10 minutes. Oxidation was
quenched by the addition of glycerol. Proteins were desalted with a Zeba desalting column buffer
exchanged with coupling buffer, prior to overnight incubation with hydrazide magnetic beads at

191

room temperature. Sample washing, digestion and glycopeptide release was performed as
described (286).

5.2.5.3 Glycan Release and Derivatization
Enriched glycopeptides were digested with PNGaseF overnight at 37°C. Glycans were
derivatized and enriched as described section 5.2.3.2.

5.2.5.4 LC-MS/MS and Bioinformatics
The same configuration of the LC-MS/MS, including the trap and analytical columns,
were used as described in section 5.2.4.3. Peptides were eluted using a 120 minute linear gradient
of 3-50% buffer B.
Analysis of intact glycopeptides proceeded through a product dependent ionization
strategy, termed HCD-pd-ETD, on the Orbitrap Elite. The acquisition parameters were as follows.
Precursor ions were detected in the Orbitrap with the resolution set to 60,000 with an m/z range
from 400 - 2000. The top 10 most abundant ions were selected and fragmented by HCD and
detected in the Orbitrap at a resolution of 15,000. For HCD fragmentation, the values for the
minimum signal required, isolation width, normalized collision energy, and activation time were
set to 500.0, 2.00, 35.0, and .100, respectively. The detection of glycan specific oxonium ions
among the top 30 most abundant fragment ions triggered ETD fragmentation with supplemental
activation enabled on the precursor ion. The parameters for the minimum signal required,
isolation width, and normalized collision energy remained consistent between the HCD and ETD
fragmentation parameters.
Byonic software version 2.2.9 (Protein Metrics, San Claros, CA) was used for intact
glycopeptide identification following LC-MS/MS analysis. Briefly, data files were directly loaded
into Byonic and searched against the appropriate protein database files. The parameters for the
search were set as follows. Cleavage sites for trypsin digest were set to RK, with the C-terminal
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cleavage side, semi-specific N-ragged digestion specificity and missed cleavages were set to -1.
The precursor mass tolerance, fragment mass tolerance (HCD) and fragment mass tolerance
(ETD) were set to 6ppm, 10ppm, and .6 daltons, respectively. Carbamidomethylation (Cys) was
set as a fixed modification, oxidation (Met) and methylation (Cys) were set as common
modifications, and pyroglutamate (pyroGlu) formation of N-terminal glutamate and glutamic acid
were set as rare modifications. In total, the analysis was established to allow a maximum of two
common modifications and 1 rare modification. N-glycosylation modifications were listed as a
common modification in the search. For intact glycopeptide analysis, an N-glycan library was
selected from Byonic or manually entered if glycomic identification had been previously
performed. Data were viewed using the generated excel spreadsheet or the Byonic Viewer
software. To confirm the presence of a glycopeptide, the ETD spectra and preceding HCD spectra
were manually assessed in the LC-MS/MS analysis using the Xcaliber software 2.2 SP1.48
(Thermo Scientific, Pittsburgh, PA) to ensure the presence of oxonium ions in the HCD spectra.

5.3 Results
5.3.1 Glycomic Profile of Pancreatic Cancer Cell Lines
Profiling of the N-glycome was performed following ethyl esterification derivatization
and HILIC enrichment. The analysis of four cell lines with characterized CA19-9 expression
levels revealed general trends in glycan expression that correlated to CA19-9 status. In all cell
lines, the peak corresponding to Man8 was the largest peak detected in the spectra and serves as a
point of comparison (Figure 42). Importantly, the low CA19-9 cell lines exhibited a higher
relative intensity of the Man8 peak and more intense high molecular weight ions (m/z > 2750),
which correspond to branched, multiply sialylated N-glycans (Figure 42a,b). Alternatively, the
high CA19-9 expressing cell lines exhibit more complexity in the MALDI spectra between m/z =
2000 and m/z = 2500 (Figure 42c,d). A molecular heat map was generated to visualize glycan
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Figure 42. N-Glycan Profiling of Four Pancreatic Cancer Cell Lines. The N-glycans from
four pancreatic cancer cell lines with characterized CA19-9 expression levels were released and
derivatized by ethyl esterification. Noticiable differences in the annotated spectra were observed
between the high CA19-9 expressing cell lines (c-d) and the low CA19-9 expressing cell lines
(a-b).
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Figure 43. Molecular Heat Map of N-Glycans from the Cell Lines. Individual glycoforms
were detected in progenesis and were compiled in a heatmap comparing the average intensity of
an individual glycoform from one cell line, the the average across all four cell lines (a). Clades
were identified of glycoforms that were elevated in both of the low CA19-9 expressing cell lines
(b) or the high CA19-9 expressing cell lines (c). Glycoforms of interested were drawn using
GlycoWorkbench software.
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abundance in regards to CA19-9 expression levels (Figure 43). Clades that displayed consistent
alterations that corresponded with CA19-9 levels were further assessed to look at the broad Nglycan structural features. In the low CA19-9 expressing cell lines, a general trend of elevated
high-mannose N-glycans was observed, as well as sialylated tri- and tetraantennary N-glycans
(Figure 43b). In the high CA19-9 cell lines, the most predominant trend was the presence of
multiply fucosylated N-glycans (Figure 43c).

5.3.2 Sialylated Glycoprotein Profile of Pancreatic Cancer Cell Lines
Glycoprotein enrichment by click chemistry followed by proteomic analysis revealed
numerous glycoproteins present in the pancreatic cancer cell lines, many of which exhibited
trends that coincided with CA19-9 expression levels. In all, 535 unique proteins were identified in
at least one ManNAz treated cell line. Of these 535 proteins, 429 (80.2%) were identified as
glycoproteins by searching the Uniprot human proteome for the glycoprotein PTM keyword
(KW-9991). Data were further processed by their group-averaged normalized spectral counts to
compare the protein fold change between the high and low CA19-9 expressing cell lines. Using
this approach, 102 proteins were elevated in the high CA19-9 cell lines, while 97 proteins were
elevated in the low CA19-9 cell lines. The Uniprot accession IDs for both classes of proteins
were assessed by WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt/) using both GO and
KEGG enrichment analysis to identify the top 10 most significantly enriched pathways. Among
interesting findings, both GO and KEGG enrichment analysis identified pathways involved in Oglycan biosynthesis and processing to be enriched in the high CA19-9 cell lines (Table 6).
Upon manual inspection, known CA19-9 carriers were identified among the proteins that
were elevated in the high CA19-9 expressing cell lines. These proteins include members of the
mucin and CEACAM family of proteins, as well as galectin-3-binding protein. The data were
further processed to identify glycoproteins that were exclusively detected in both high CA19-9
expressing cell lines. In all, 37 proteins met this criteria in at least one experimental replicate, of
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Table 6. WebGestalt Pathway Analysis. The proteins elevated in the high CA19-9 cell lines and
the low CA19-9 cell lines were processed by WebGestalt to do KEGG and GO Pathway Analysis
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Table 7. Exclusive Identification of Glycoproteins in High CA19-9 Expressing Cell Lines.
Proteins that were uniquely identified in the high CA19-9 cell lines (at least one replicate) were
compiled.
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which 11 proteins satisfied these conditions in both experimental replicates (Table 7), including
CEACAM1, CEACAM5, and CEACAM6. To assess the contribution of N-linked glycosylation
to the glycoprotein enrichment, bound N-glycopeptides were released with PNGaseF and
analyzed by LC-MS/MS (Sup Sheet 8). A majority of the proteins were not identified after
PNGaseF release, emphasizing the importance of O-linked glycosylation. Interestingly, galectin3-binding protein, was among the proteins identified after PNGaseF.

5.3.3 Optimization of Intact Glycopeptide Analysis
Fetuin, asialofetuin and transferrin glycoprotein standards were utilized to validate the
experimental and instrumental parameters for intact glycopeptide identification by LC-MS/MS.
Initially, to confirm the enrichment of glycopeptides over non-glycosylated peptides from the
glycoprotein standard, a combination of LC-MS/MS and MALDI-MS was used. For this process,
peptides were either desalted using a C18 ZipTips or glycopeptides were enriched by SAX SPE
cartridges. Enriched glycopeptides were incubated with PNGaseF to generate previously
glycosylated peptides. Peptides (Figure 44a), enriched glycopeptides (Figure 44c), and previously
glycosylated peptides (Figure 44b) were all spotted on a MALDI plate with CHCA matrix. LCMS/MS of the total peptide solution was also performed and searched against a protein database
containing fetuin and transferrin. MALDI analysis of the peptide sequences revealed numerous
peptides for both fetuin and transferrin that corresponded to the peptide m/z values identified by
LC-MS/MS. In contrast, the ions detected following SAX enrichment displayed generally larger
m/z values that did not correspond to the LC-MS/MS analysis, but likely correspond to in-source
decay of the glycan moieties on the glycopeptides. This hypothesis was verified by MALDI
analysis of deglycosylated peptides, which identified all five peptides known to be Nglycosylated on fetuin and transferrin. A similar trend was observed when using cotton-HILIC
tips for glycopeptide enrichment as opposed to SAX SPE cartridges (data not shown).
Additionally, the N-glycans were released by PNGaseF following glycopeptide enrichment to
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Figure 44. MALDI Analysis of Enriched Glycopeptides. To test for the efficacy of
glycopeptide enrichment, peptides were enriched using C18 (a) or SAX (c) SPE cartridges.
Peptides characterized from fetuin (green text) and transferrin (blue text) are annotated in the
spectra. SAX enriched glycopeptides were digested with PNGaseF to release N-linked glycans,
which resulted in the identification of deglycosylated peptides from all of the known Nglycopeptide sites (b). Furthermore, sites of deamidation resulting from PNGaseF release are
presented in red text.
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Figure 45. Glycomic Analysis of Enriched Glycopepdies from Fetuin and Transferrin.
Glycans were released from enriched peptides by PNGaseF and then characterized by MALDI
analysis of the ethyl esterified glycoforms. Presented is an annotated spectra of the derivatized
glycoforms.
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profile the corresponding glycoforms. A spectra of ethyl esterified glycans for fetuin and
transferrin is provided (Figure 45). Analysis of identified glycoforms revealed primarily complex,
sialylated N-glycans with some fucosylation present.
SAX enriched glycopeptides from the glycoprotein standards were then analyzed on the
Orbitrap Elite using the HCD-pd-ETD ionization settings for the identification of intact
glycopeptides and the corresponding glycoforms. ETD spectra were searched in Byonic to
identify N-glycosylated peptides. In the Byonic search, peptides were searched against a
manually defined N-glycan library consisting of identified glycans (Figure 46). In the search
readout, all five sites of N-glycosylation were detected with N-glycan modifications present
(Figure 47). A further interrogation of the glycopeptides after removal of all glycopeptides with a
score < 50, identified six glycoforms present on both Fetuin and Transferrin. The number of times
a specific glycoform was present on a specific peptide was recorded, and demonstrates Nglycoform heterogeneity (Figure 46).
In an alternative approach, glycoprotein standards were enriched using magnetic
hydrazide resin. Under low oxidizing conditions, only sialic acids are oxidized and form covalent
bonds with the hydrazide resin. After tryptic digest, intact glycopeptides can be released by acid
hydrolysis, which cleaves the glycosidic bond between the sialic acid and terminal galactose
residues. Intact glycopeptide analysis on the Orbitrap Elite identified similar glycopeptides as
after SAX glycopeptide enrichment, with the exception that no sialylated glycans were identified
(Figure 48).

5.4 Discussion
The carbohydrate antigen CA19-9 is the most well characterized disease marker for
pancreatic cancer, but knowledge of the glycoform and glycoprotein carriers of the antigen is still
incomplete. To our knowledge, no examples of specific N-glycoforms that carry the motif are
known. Additionally the contribution that N-glycosylation makes to antigen expression is poorly
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Figure 46. N-Glycan Identification from Glycoprotein Standards. Glycans identified from the
Byonic search for both fetuin and transferrin are listed, as well as the number of times each
glycoform was observed on a specific peptide. The table represents a list of glycoforms that were
identified in the glycomic analysis and were used in the Byonic search.
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Figure 47. Peptide Sequences Identified by ETD Ionization. ETD spectra from the HCD-pdETD analysis of the glycoproteins were searched with Byonic. Peptides, including intact
glycopeptides, from both fetuin and transferrin were identified.
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Figure 48. Comparison of N-Glycan Identification from SAX and Selective Hydrazide
Enrichment. Glycoforms identified on each peptide during intact glycopeptide analysis on SAX
and selective hydrazide enrichment reveal similarities in the common core structure of the
glycoform. The predominant difference is that the glycoforms identified following selective HZ
enrichment is that no sialylated glycoforms are observed, which is expected as glycoforms were
released by acid hydrosis to cleave the sialic acids.
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characterized. To address these limitations, we performed N-glycomic and glycoproteomic
profiling of pancreatic cancer cell lines with well characterized CA19-9 expression levels. In the
glycomic analysis, a selective derivatization strategy was used to distinguish α2,3- and α2,6linked sialic acids by induced changes in the molecular weight. Across the cell lines, general
trends in the relative abundance of N-glycans were observed between high and low CA19-9
expressing cell lines (Figure 42). Interestingly, the overall level of sialylated N-glycans was not
increased in high CA19-9 expressing cell lines, as originally hypothesized. In fact, the most
noticeable difference was that multiply fucosylated N-glycans were increased in high CA19-9
expressing cell lines, while high-mannose glycans were elevated in low CA19-9 expressing cell
lines (Figure 43). This finding suggests that the fucosyltransferase responsible for CA19-9
expression on O-glycans also plays a role in N-glycosylation. In our data, only two of the Nglycoforms elevated in the high CA19-9 cluster contained a sialic acid, none of which were α2,3linked. Additionally, in the glycoproteomic analysis, there were few protein identifications
following PNGaseF incubation, suggesting CA19-9 is primarily present on O-glycans.
Interestingly, galectin-3-binding protein and CEACAM proteins were both identified following
PNGaseF release. As galectin-3-binding protein is known to express CA19-9 on N-glycoforms,
further assessments of CEACAM N-glycans should be performed (273). Given the glycomic and
glycoproteomic results, it is evident that CA19-9 is predominantly carried on O-linked glycans.
One of the primary limitations of CA19-9 as a clinical disease marker is that a large population of
individuals do not express fucosyltransferase 3 and are therefore incapable of expressing CA19-9
(333,343). Profiling the N-glycome of patients with pancreatic cancer that do not express CA19-9
should reveal a similar decrease in polyfucosylated N-glycans.
Glycoproteomic analysis of the cell lines further implicated processes related to Oglycosylation as a primary distinguisher between high and low CA19-9 expressing cell lines
(Table 6). Additionally, numerous proteins that are known CA19-9 carriers were identified to be
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elevated in the high CA19-9 expressing cell lines. Among these proteins, some were uniquely
expressed in the high CA19-9 expressing cell lines (Table 7). Given the propensity for the
technique to identify known CA19-9 carriers in the high CA19-9 cell lines, identified proteins
should be tested for CA19-9 expression (273,373,476). Importantly, determining CA19-9 protein
carriers has improved the performance of the antigen as a disease marker (477). Yeu et al. used a
sandwich-ELISA assay to profile CA19-9 expression on selected proteins from serum samples,
and found elevations in the glycan antigen on MUC5ac, even in cases where the protein level did
not change (373). A receiver operating characteristic (ROC) curve showed that using CA19-9 on
MUC5ac instead of MUC5ac protein expression improved the AUC from .72 to .90 (373). The
same group found that combining information related to total CA19-9 expression with the level of
CA19-9 on MUC5ac and MUC16 was able to improve the performance of the disease marker
(478).
While inferences can be made about proteins with regard to CA19-9 expression, this data
largely details and catalogs variances in glycoprotein sialylation and not CA19-9 specifically.
Thus, it is likely that many of the proteins identified do not express CA19-9. Various integrins
were observed to be elevated in the high CA19-9 cells and have been reported in literature as
exhibiting higher levels of sialylation in pancreatic cancer. Given the dynamic role of sialic acid
in tumor progression, the comprehensive library of sialylated glycoproteins identified in the click
chemistry approach can be assessed in serum samples (362,363).
While click chemistry represents a promising technique for initial disease marker
discovery, the primary limitation of the approach is that it does not enable analysis of the glycan
motifs on specific proteins. As observed with AFP-L3, this information can be critical to
improving the clinical utility of the disease marker. To adjust for these limitations, intact
glycoproteomic workflows were optimized on glycoprotein standards. SAX enrichment of a
mixture of fetuin, asialofetuin and transferrin was able to specifically enrich glycopeptides from
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the non-glycosylated peptides, as assessed by both MALDI and LC-MS/MS (Figure 44).
However, asialylated glycoforms were largely missing during glycomic and glycoproteomic
analysis, suggesting SAX is an efficient enrichment strategy for sialylated glycopeptides. There
was a high degree of overlap between glycans that were detected in the glycomic analysis
compared to glycans identified in the glycoproteomics workflow (Figure 45). When applied to
complex protein mixtures (i.e. serum, tissue, cell lysates), SAX and HILIC glycopeptide
enrichment were insufficient to enrich glycopeptides from the total glycopeptide mixture present.
Traditionally, glycoproteomic analysis has been limited due to issues of broad dynamic range of
proteins and a limited number of glycopeptides among total peptides (221,262–264). To
compensate for these limitations, glycoconjugate enrichment is required to selectively enrich
glycopeptides prior to analysis by LC-MS/MS. Glycopeptide enrichment strategies that rely on
physiochemical properties generally exhibit poor specificity for glycopeptide enrichment, so
other approaches should be considered (310). To increase the specificity of glycopeptide
enrichment, a new technique involving hydrazide chemistry under low oxidizing conditions was
used to enrich sialylated glycoproteins (276,286). With this technique, intact glycopeptides can be
released and surveyed, at the expense of the terminal sialic acid. In our data, the underlying
glycoforms detected in the selective hydrazide enrichment and SAX glycopeptide enrichment
were largely similar (Figure 48), with the main difference being the lack of sialic acid due to acid
hydrolysis release. Glycoprotein enrichment using covalent bond formation to solid phase support
is more efficient and could mitigate issues of protein dynamic range in the analysis of complex
samples. However, this approach is only useful in characterizing sialylated glycopeptides, and not
for general analysis. The intact glycoproteomic approach outlined can be further implemented to
the study of pancreatic cancer. Individual glycoproteins observed in the click chemistry approach
can be enriched by immunoprecipitation and profiled by LC-MS/MS to characterize the presence
and occupancy of individual glycoforms. Alternatively, aberrantly expressed glycoforms and the
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corresponding glycoprotein identified by MALDI-IMS could be enriched by lectin enrichment in
order to identify the protein carriers.
In conclusion, this aim expanded the field of pancreatic cancer glycoproteomics by
defining a class-specific role of glycans as CA19-9 expressors, identifying putative CA19-9
carrier proteins, documenting sialylated glycoproteins in pancreatic cancer, and developing
methodologies for intact glycopeptide analysis of identified proteins. While intact glycopeptide
analysis was performed on glycoprotein standards, future work can apply the outlined methods to
isolated or total glycoproteins from biological samples. As CEACAM proteins were identified in
the elevated high CA19-9 cell lines, and sialylation was detected at sites of N-glycosylation,
enrichment and intact glycoprotein analysis of CEACAM proteins is a logical next step.
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Chapter 6: Conclusions, Limitations and
Future Studies
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6.1 MALDI-IMS Optimization for N-Glycan Analysis
6.1.1 Conclusions
We hypothesized that PNGaseF application on tissue sections would release N-linked
glycans and enable glycan localization, identification and relative abundance to be evaluated in a
single experiment. To test this hypothesis, tissue sections from mouse kidneys and brains were
used for initial optimization before further analysis of biologically relevant diseased tissues. To
ensure released ions were N-glycans, a thorough characterization using up-to-date glycomic
methodologies was performed. The application of these approaches revealed:
1.

MALDI-IMS sample preparation techniques employed for MALDI-IMS of

tryptic peptides, including washes to delipidate tissue sections and the application of a
uniform layer of enzyme, can be adapted for the imaging of N-glycans directly from
tissue sections.
2.

The common core structure of N-linked glycans, the limited number of

monosaccharides available and defined biosynthetic pathways make the characterization
of the glycan composition relatively simple. Additionally, comparing ions to a serial
tissue section that is shielded from enzyme application results in a robust difference in
ion population, with N-glycans present only in the digested tissue.
3.

N-glycan localization is often reflective of tissue histology. A majority of glycans

are not observed to be homogenously distributed across entire tissue sections but
correlate with specific cellular populations. N-glycans are elevated in multiple regions of
a tissue, suggesting that there is a concrete difference in glycosylation that is linked to
histology, as opposed to alterations being an artifact of the technique.
4.

Cancer sections of complex histology reveal patterns of N-glycans that correlate

to histopathology analysis. In addition to differentiating tumor from non-tumor tissue
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sections, glycan signatures correlate with inflammation, fibrosis, and regions of tissue
histology.
5.

The composition of released N-glycans detected by MALDI-IMS can be

confirmed by glycan standards, released glycans from glycoproteins, N-glycan structural
libraries, HPLC analysis of 2AB-labeled N-glycans, permethylation, ethyl esterification
derivatization, and CID. A comparison of glycans identified by off-tissue derivatization
experiments to those from MALDI-IMS identified similar glycan compositions.
6.

MALDI-IMS can effectively profile N-glycan distribution in FFPE tissue

sections. The workflow for glycan analysis in these sections results in an increase in ion
intensity over fresh-frozen tissue sections. Superior ion intensity may be a result of more
stringent washes during the antigen retrieval workflow, which possibly reduce ion
suppression attributed to lipid species. Similarly, slide mounted fresh-frozen tissue
sections can be fixed in formalin and subjected to antigen retrieval to produce superior
imaging results.
7.

N-glycans released from fresh-frozen and FFPE tissue sections are consistent

with glycomic analysis using traditional approaches. The analysis of FFPE mouse kidney
sections identified all 28 N-glycans reported to be present in the Consortium for
Functional Glycomics N-glycan database of the mouse kidney. Hex7HexNAc6, which we
reported to be elevated in HCC tumor, has been previously reported to be elevated using
IHC staining techniques.
8.

Experimental throughput is greatly improved by performing experiments in

TMAs. High-throughput N-glycan analysis by MALDI-IMS can identify N-glycans that
are capable of distinguishing tumor from non-tumor tissue cores. In an analysis of an
HCC TMA, Hex7HexNAc6 (elevated in tumor) and Hex8HexNAc2 (decreased in tumor)
both exhibited an AuROC ≥ 0.8 and a p-value < .05.
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9.

There is a common trend of elevated expression of the glycome across multiple

cancers cancer. In HCC, 21 out of 26 identified glycans were elevated in the tumor tissue,
13 of which were elevated at a significant level (p-value < .05). In pancreatic cancer, 20
out of 23 identified N-glycans were elevated in the tumor tissue, 18 of which were
elevated at a significant level (p-value < .05). In both examples, high-mannose N-glycans
were the primary glycoforms that were not elevated in the tumor tissue cores.
10.

Statistical findings in TMAs are representative of N-glycan profiling of whole

tissue blocks.
11.

When applied to TMAs containing molecular subtypes of cancers from a single

organ, glycoform variation by MALDI-IMS can distinguish the molecular subtypes.
Individual N-glycans are expressed with varying abundance across different tumor
subtypes.
12.

Patterns of N-glycan distribution are observed in similar histologies across

different organs. For example, complex biantennary glycans with various degrees of
fucosylation and sialylation, are elevated in fibroconnective tissue in pancreas, renal and
liver tissue.
13.

Aberrations of structurally similar N-glycans can be linked to genomic analysis

and glycosyltransferase expression.
14.

MALDI-IMS has successfully been applied to a broad range of tissue sections: In

the dissertation, examples were provided for mouse kidney, mouse brain, prostate,
pancreas, renal, and liver tissues. In addition to these tissues, the method has also been
applied to placenta, lung, colon, breast tissue and others.

6.1.2 Limitations and Future Research
Aim 1 limitations are grouped into four main categories; [1] the intrinsic need to optimize
novel methodologies, [2] identifying detected glycoforms, [3] well characterized limitations of
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MALDI-MS in glycan analysis, and [4] limitations in MALDI-IMS.
While the pre-imaging workflow has successfully released N-glycans that are amenable
to imaging, sample preparation conditions will need to be further optimized. These conditions
include the washing of the slide, the antigen retrieval process and buffer, the amount of PNGaseF
required, and the time needed for enzyme digestion. It is likely that these conditions will vary
between tissue types.
Due to the branched nature of N-glycans, the glycomic approach outlined yields the
composition of the N-glycan but fails to identify glycan linkages. Distinguishing linkages
between different glycoforms with the same composition is essential to understanding how the
glycan functions biologically, as subtle differences can have dramatic implications for
interactions with glycan-binding proteins. In order to obtain this information by mass
spectrometry, N-glycans must be fragmented to generate both cross-ring cleavages and cleavages
across the glycosidic bonds (247). However, MALDI ionization primarily produces cleavages
across glycosidic bonds (218). Additionally, fragmentation of ions during MALDI-IMS of tissue
sections is generally less effective than analysis of enriched material. A variety of approaches can
be adapted in order to generate information indicative of anomeric linkages. In one approach, Nglycan imaging and N-glycan extraction, could be performed on serial tissue sections. This
general approach was outlined for both permethylation and ethyl esterification in order to validate
the underlying glycan composition. Derivatization, chromatographic separation and tandem
MS/MS experiments on extracted glycans could generate cross-ring cleavages that could be used
to make inferences about the glycan structure (479). Alternatively, sequential on-tissue
exoglycosidase digestion could be used to assess linkages of ions corresponding to specific
glycoforms. In initial experiments, application of sialidase on tissue in conjunction with PNGaseF
cleaved terminal sialic acids and altered the glycan profile observed. Derivatization strategies that
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selectively distinguish linkages of specific monosaccharides, such as ethyl esterification of sialic
acids, could also be adapted to on tissue experiments.
MALDI-MS is one of the most established methods for N-glycan analysis, but is plagued
by well-documented limitations. In positive ion mode, neutral N-glycans are primarily observed
as the [m + Na]+ adduct, but acidic glycans do not ionize efficiently suffer from dissociation of
sialic acids (250). The dissociation of sialic acid residues results in overlapping peaks that
artificially distort the abundance of the non-sialylated glycan. The ion source for the SolariX
FTICR is under intermediate pressure, which reduces the loss of sialic acid to some extent (241).
To compensate for these factors, glycomic analysis by MALDI-MS often relies on derivatized Nglycans, which functions to stabilize the labile monosaccharides and improve detection
sensitivity. However, these methods often require glycan enrichment, which functions to remove
excess salts and derivatization reagents, but is thus incompatible with MALDI-IMS (230).
Alternative derivatization strategies that could stabilize labile sialic acid modifications while the
glycan is still attached to the protein are promising alternatives. Both ethyl esterification and ptoluidine derivatization of sialic acids could be performed on tissue sections, and labeling
reagents could be removed by washing prior to enzymatic digestion (235,237). As we have
specifically observed in-source decay of sialic acids, selective labeling of these monosaccharides
would greatly improve imaging analysis. MALDI-IMS in negative ion mode could also be used
to profile sialylated N-glycoforms (480). An added benefit of glycan profiling in negative ion
mode is that more cross-ring cleavages could occur by CID, yielding more information on
anomeric linkages.
Given the sheer size of high resolution FTMS data, statistical approaches such as ClinPro
Tools (Bruker Daltonics) do not work for biomarker identification. For this reason, an in-house
script for peak picking and data mining was generated. Data processing using the in-house script
has resulted in ions that do not correspond to N-glycans, but seem to be able to distinguish
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between tumor and non-tumor tissues. This finding may be attributed to the effects of tissue
thickness or cellular morphology differences that affect ionization but are not indicative of ion
concentration. Another limitation of the peak picking process is that it uses binned windows,
which are not ideal for selecting the center of the picked peak and cause artificially high PPM
errors (481). Furthermore, the comparison of results from multiple imaging slides requires
extreme consistency in the mass accuracy of the identified ions. Mass variation should be
minimal across different time points, including across entire imaging experiments and separate
imaging experiments. Eliminating mass defects will allow the peak picking approach to select
identical peaks across experiments, providing more consistent data. In addition to the built in lock
mass function, other studies have optimized calibration and peak picking approaches for the
FTMS to allow for identification of analytes with sub-PPM mass accuracy (481).
MALDI-IMS is associated with relative concentrations, but ideal biomarker discovery
techniques should utilize a more quantitative workflow. For MALDI-IMS, quantitative data
requires an efficient matrix/enzyme application to generate a uniform and homogenous spray, and
relies on the assumption that tissue morphology does not affect ionization efficiency. Efforts
directed at identifying appropriate internal standards for normalization within and across slides
are being investigated (460). To deal with the limitation of MALDI-IMS for comparing imaging
analysis on different slides and working towards a quantitative analysis, a labeled or non-human
N-glycan could be applied homogenously on the tissue section during the matrix application step.
In a study by Pirman et al., MALDI-IMS following the incorporation of an deuterated internal
standard resulted in quantitative results that were comparable to LC-MS/MS analysis (461).
Alternatively a stable isotope labeled N-glycan could be applied homogenously on a tissue
section to be used as an internal calibrant and normalization factor. Tao et al. developed an
approach to obtain relative quantitation of N-glycans by incorporating

18

O-water onto the

reducing end of glycans and profiling by direct infusion (482). In an alternative approach, Walker
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et al. demonstrated the utility of using xylosylated plant glycoproteins to control for enzymatic
digestion efficiency (483). Released glycans from the glycoproteins could be used to monitor
digestion efficiency, serve as an internal calibrant, and be used for normalization across imaging
experiments.
MALDI-IMS of fresh-frozen, FFPE, and formalin fixed tissue sections should be
compared to assess any variations that depend on tissue specimen acquisition and storage. While,
we observe higher signal in FFPE tissue sections compared to fresh-frozen tissue sections,
individual trends of glycan abundance and localization should be compared. Few studies have
investigated the impact the FFPE fixation has on PTMs, or more specifically glycosylation.
Proteomic analysis of FFPE tissue sections is impacted by factors relating to sample storage and
antigen retrieval (484). The affect that these analytical factors have on glycosylation should be
determined. If processes related to tissue acquisition and initial storage conditions significantly
alter glycomic profiling, special care should be taken to insure studies use tissue collected using
well-defined tissue preservation protocols.

6.2 Glycomic Profiling of Pancreatic Cancer Tissue Specimen
6.2.1 Conclusions
Preliminary findings from pancreatic cancer tissue blocks revealed N-glycan patterns that
correspond to tissue histology. Based off of these findings, we hypothesized that N-glycan
profiling by MALDI-IMS could differentiate tumor from non-tumor tissue sections in a large
high-throughput study. For this study, six TMAs consisting of patient-matched tumor and nontumor tissue from 76 patients were surveyed. Data were then processed manually and by machine
learning approaches to identify panels of N-glycans that are capable of distinguishing tumor from
non-tumor tissue. The expression of selected N-glycans was validated on whole pancreatic cancer
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blocks and linked to complex histopathology. By performing research relevant to this aim, we
found:
1.

Upwards of 90 ions corresponding to N-linked glycans can be identified in a

single pancreas tissue block.
2.

Individual N-glycan distribution can be linked to regions of pancreas histology.

Not only can the profile of an individual glycan distinguish tumor from non-tumor tissue,
but also GI tissue, fibroadipose connective tissue, smooth muscle, and more.
3.

An in-house peak picking algorithm and data processing tool identified 54

monoisotopic peaks, 23 of which correspond to N-glycans, that are present across all of
the TMAs. Among the identified N-glycans, nearly all are elevated in tumor compared to
non-tumor tissue.
4.

While individual N-glycans are able to differentiate tumor from non-tumor tissue

cores, the use of a single N-glycan discriminator results in many false identifications. In
contrast, the combination of multiple N-glycans in a biomarker improves the sensitivity
and specificity of the assay
5.

When assessing glycosylation patterns between tumor and non-tumor tissue

cores, complex fucosylated N-glycans are the most elevated glycoforms in tumor tissue
sections, while high-mannose N-glycans are present in similar amounts between tumor
and non-tumor tissue cores. This trend is reflective of published literature performed on
pancreas serum specimen.
6.

A

glycan

biomarker

panel

consisting

of

Hex7dHex1HexNAc7

and

Hex6dHex2HexNAc5 can able to outperform CA19-9 staining in terms of sensitivity and
specificity for distinguishing tumor from non-tumor tissue cores.
7.

In an analysis of whole tissue blocks, the relative expression levels of tumor-

elevated N-glycoforms are elevated in premalignant lesions compared to non-tumor
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tissue. This finding suggests that aberrant N-glycosylation occurs during the process of
tumor initiation, potentially implicating N-glycosylation in the tumorigenic process. This
finding is clinically relevant, as early stage disease markers for pancreatic cancer should
identify cancer prior to malignancy.
8.

In an analysis of whole tissue blocks, the relative expression levels of tumor-

elevated N-glycoforms are also elevated in tumor tissue compared to benign, diseased
tissue. This finding is important as CA19-9 does not adequately distinguish tumor and
benign diseases, leading to a poor specificity.

6.2.2 Limitations and Future Research
While this aim identified tumor associated N-glycans, there are several limitations that
should be addressed to improve the study. The primary limitations for this aim can be categorized
into [1] MALDI-IMS limitations, [2] data processing, and [3] disease specific limitations.
For more information on the limitations in MALDI-IMS for glycomic analysis, a
thorough review is present in section 6.1.2. The main limitations that pertain to this aim involve
comparative studies across multiple imaging experiments, the labile nature of sialic acid, and
complications determining the anomeric linkages of monosaccharides. In pancreatic cancer, the
elevation of the CA19-9 motif is well characterized, and consists of a terminal α2,3-linked sialic
acid and an outer arm fucose residue. In our analysis, few N-glycans are both sialylated and
fucosylated, suggesting CA19-9 is absent on N-glycans. However, of the glycans that were
elevated in pancreatic cancer, the top five in terms of log2FC possess a fucose residue.
Determining the location and linkage of this fucose is important, as sialic acids are known to
dissociate during MALDI ionization. Approaches to stabilize sialic acid residues during MALDIIMS were outline in Section 6.1.2. However, the limitation of the unknown anomeric fucose
residue can be resolved by other experimental techniques. Comunale et al. used HPLC analysis
and fluorescence detection of labeled glycans in conjunction with sequential exoglycosidase
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digestion to differentiate core from outer arm fucose residues on a protein of interest (453).
Lectins with specificity for core fucose can also be used to enrich glycoproteins prior to digestion
with PNGaseF and glycomic analysis (485). The absence of glycoforms of interest would suggest
the presence of branched fucose residues. Methods that directly correlate with MALDI-IMS
could also be applied to differentiate core vs. outer arm fucose residues. Digestion with
fucosidases that are specific to core fucose, either before or after PNGaseF but prior to MALDIIMS, should result in a mass shift from the loss of core fucose, if present. If the distribution of the
glycoforms of interest remains the same after digestion with the fucosidase, the tumor glycans
possess outer arm fucose. Alternatively, serial tissue sections could be stained with lectins with
specificity for defined fucose linkage. However, this method would not directly confirm whether
the presence of core or outer arm fucose is on N-glycans.
As noted in the text, data processing was observed to be a limitation for this aim. While
peak picking identified 50 ions that were present across all six TMAs, 23 of which corresponded
to N-glycans, there was a noticeable lack of some of the more prevalent N-glycans, such as
Hex5HexNAc4. A manual inspection of an N-glycan library identified 50 N-glycans that were
present in all six TMAs. Thus, during peak picking, a little less than half of the glycans that are
present were picked. This deficiency further impacts biomarker panel generation, as the machine
learning algorithms process fewer N-glycan signatures. Additionally, as outlined in Section 6.1.2,
identified peaks were selected using mass spectral binning, which limits the high mass resolution
achievable by the FT-MS (481). The process of mass spectral binning across six TMAs likely
contributes to the artificially high PPM errors observed and may create slight differences across
TMAs resulting in the exclusion of N-glycans from being identified by peak picking. Future
directions dealing with MALDI-IMS of peak picking, mass accuracy, and analysis of multiple
slides is outlined in Section 6.1.2. A novel direction related to this aim deals with the missing Nglycans from peak picking. The peak picking process is initiated in FlexImaging by performing
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hierarchical clustering, which produces a bucket table of ions and the relative intensity of the ion
at that location. Glycans that are not reported in the pick peaking data, but are manually observed
in the data, are often missing from the bucket table for at least one TMA. To adjust for these
omissions, the relative abundance of individual ions can be selected in FlexImaging and exported
individually, enabling a complete N-glycan analysis by downstream processing.
Finally, this aim looks at glycan biomarkers for pancreatic cancer in general, as opposed
to identifying unique differences between the subtypes of pancreatic cancer. While adapting the
method to enable analysis of FFPE tissue blocks improves sample numbers for distinguishing
tumor vs. non-tumor, PDAC makes up about 90% of all pancreatic cancer incidences, so sample
constraints may prevent PDAC to be distinguished from other subtypes of pancreatic cancer at a
statistically significant level.
Glycan biomarker panels and their ability to differentiate malignant from benign tissues,
as well as identify premalignant lesions, should be investigated using a larger cohort of tissue
specimen directed at those specific comparisons. The poor ability to distinguish malignant from
benign conditions is a significant limitation of disease markers, not limited to CA19-9 for
pancreatic cancer, at it lowers the predictive value positive of disease markers by falsely
classifying individuals with benign diseases as having malignant diseases. Preliminary evidence
from MALDI-IMS of pancreatic tissue blocks in conjunction with histopathology analysis,
suggests that N-glycan patterns can differentiate tumor tissue from benign non-tumor tissue. This
trend needs to be followed up in a larger data set to confirm this finding across multiple patients,
preferably by conducting MALDI-IMS on TMAs directly constructed to compare malignant and
benign pancreas tissue. In an analysis of one TMA that meet the criteria, Hex6dHex1HexNAc5
was more abundant in the tumor cores compared to chronic pancreatitis (Figure 49).
Pancreatic cancer is often too advanced at the time of diagnosis to allow for surgical
resection. As such, biomarkers for pancreatic cancer should identify the cancer at early stages,
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preferably in the premalignant (PanIN) stage. Preliminary evidence shows that glycan biomarker
panels not only distinguish tumor from non-tumor tissue, but also premalignant lesions from nontumor tissue. Efforts to investigate this trend across a larger tissue cohort should be investigated.
However, this study may not be possible using human tissue specimens, as the disease detection
is made in later stages of pancreatic cancer. To compensate for limitations in clinical specimen,
mouse models of PDAC could be used for this analysis. Inducible KRAS mutations in mouse
models result in the formation of early stage precancerous lesions, but do not result in PDAC. The
combination of other genomic mutations with KRAS mutations are able to form PanIN lesions
which progress to PDAC (486). Variation in the N-glycan profile of PanIN lesions that either
progress or do not progress to PDAC would determine whether glycomic analysis could identify
which lesions would ultimately progress to cancer and warrant surgical resection. These findings
could be validated by histopathology-guided analysis of PanIN lesions in human tissue specimen.
While MALDI-IMS is capable of distinguishing tumor from non-tumor tissue specimen,
it is unlikely that MALDI-IMS will be implemented the clinic. The cost, experience, and time
required for imaging analysis by high-resolution mass spectrometers is prohibitive for this
application. Therefore, identified glycans should be assessed by other techniques that are used in
the clinic. Serial sections of TMAs should be stained with broad specificity lectins directed at the
tumor biomarker panel. Differential lectin staining towards tri- and tetraantennary glycans
(phaseolus vulgaris lectin, L-PHA), fucosylated N-glycans (lens culinaris lectin, LCH, aleuria
aurantia lectin, AAL), and high-mannose glycans (canavalia ensiformis lectin, ConA) may reflect
trends observed for the individual glycan ions. Alternatively, N-glycan release from tissue
sections, derivatization and analysis by HPLC-fluorescence detection or mass spectrometry using
MRM techniques could be applied.
While the direct correlation between the tissue and the disease makes tissues useful for
early biomarker discovery experiments, identified disease markers should be tested in serum. This
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is especially relevant in pancreatic cancer, where screening should occur in asymptomatic
patients in order to identify the disease when resection is still possible. For this purpose,
identified glycan biomarker panels should be tested in serum samples, comparing the serum of
non-diseased patients to that obtained from patients with pancreatic cancer or pancreatitis. This
approach could be adapted to mass spectrometry or lectin arrays. Interestingly, prior studies along
these lines have concluded that serum from PDAC patients exhibited trends of elevated
fucosylation and N-glycan branching, suggesting that the biomarker panel could be applied in the
analysis of serum or biological fluids (385). However, the serum proteome is complicated by a
variety of proteins that are present in high abundance and may conceal aberrations related to the
disease N-glycome. The glycomic analysis of individual proteins that are specific to the disease,
such as AFP for liver cancer, may be more useful than an overall glycomic profiling of the serum.

Figure 49. MALDI-IMS of a TMA Comparing Tumor and Pancreatitis. An overlay of
Hex6dHex1HexNAc5 (green) and Hex6HexNAc2 (red), demonstrated that tumor cores can be
differentiated from pancreatitis cores, by the same glycoforms that can distinguish tumor from
non-diseased pancreas.
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6.3 Glycoproteomic Analysis of Pancreatic Cancer
6.3.1 Conclusions
In an effort to identify proteins that exhibit altered glycosylation in pancreatic cancer, we
performed a selective glycoprotein enrichment technique, as well as optimized a workflow for
future intact glycopeptide analysis. We hypothesized that novel glycoproteomic studies would
identify glycoproteins that differ in terms of protein abundance or protein glycosylation. A sialic
acid analog was incorporated into four cell lines with documented CA19-9 expression levels to
selectively enrich sialylated proteins and to assess the utility of the method in identifying CA19-9
carrier proteins. Furthermore, the role of N-glycoforms as CA19-9 carriers was examined by
glycomic analysis and PNGaseF release of bound N-glycopeptides. A workflow for intact
glycopeptide analysis, including enrichment strategies, mass spectrometry parameters, and data
searching, was optimized. This method can be used to profile glycopeptides on selected proteins.
By performing research relevant to this aim, we demonstrate:
1.

N-linked glycans make little contribution to CA19-9 antigen expression.

Glycomic analysis of high CA19-9 expressing cells reveal trends of elevated
fucosylation, but no elevations in α2,3-linked sialic acids. The observation of elevated
fucosylation suggests a role for the fucosyltransferases responsible for CA19-9 residues
in N-glycosylation.
2.

Click chemistry results in a highly efficient enrichment of sialylated

glycoproteins. 80.2% of proteins identified are classified as glycoproteins in Uniprot. In
total, 535 sialylated proteins were identified using click chemistry.
3.

Overall elevations in total sialyltransferase levels do not seem to be present in

high CA19-9 expressing cell lines. There is very little difference in the total number of
proteins identified in the high CA19-9 expressing cell lines compared to the low CA19-9
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cell lines (102 vs. 97). However, this does not exclude the possibility of elevations in
specific sialyltransferases.
4.

PNGaseF digestion of bound glycopeptides results in a small subset of identified

glycoproteins, validating the glycomic profile results that suggest CA19-9 is primarily on
O-glycans. Glycoproteins identified following PNGaseF release should be further
assessed to determine if they are in fact carriers of the CA19-9 antigen
5.

KEGG and GO pathway enrichment analyses reveal proteins related to O-glycan

synthesis and processing to be among the most enriched pathways in the high CA19-9
cell lines
6.

Click chemistry directed at sialylated glycoproteins identified numerous known

CA19-9 carriers including members of the mucin and CEACAM family of proteins, as
well as galectin-3-binding protein. Thus, the use of click chemistry on samples with
defined CA19-9 status is an appropriate strategy to identify unknown CA19-9 carriers.
However, identified proteins should be validated to ensure that the protein carries the
CA19-9 antigen as opposed to just sialic acids.
7.

For isolated glycoproteins, SAX and HILIC can effectively enrich glycopeptides

over non-glycosylated peptides from the protein standards. In an analysis of fetuin and
transferrin, all sites of N-glycosylation are observed in MALDI and LC-MS/MS analysis.
8.

Intact glycopeptide analysis by HCD-pd-ETD of enriched glycopeptides

demonstrates the concept of microheterogeneity and macroheterogeneity, both within and
across glycoproteins. In the example provided, the number and composition of
glycoforms differs with respect to individual peptides on the same glycoprotein.
9.

A combined workflow integrating glycomic, proteomic, and glycopeptide

analysis can generate a robust characterization of a glycoprotein or mixture of
glycoproteins.
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10.

Selective enrichment of sialylated glycopeptides using hydrazide enrichment at

low oxidizing conditions is consistent with glycopeptide enrichment using SAX or
HILIC, with the exception that N-glycoforms no longer contain the sialic acid residue on
the intact glycopeptide.

6.3.2 Limitations and Future Research
The initial goal of ManNAz-based click chemistry enrichment and downstream LCMS/MS analysis was to identify putative carriers of the CA19-9 antigen and aberrantly expressed
glycoproteins in cell lines. While this approach was validated by the consistency of this approach
with published literature, there remain areas that can be further improved. While BXPC3 and
Capan2 cell lines express high levels of CA19-9 and Panc1 and Miapaca2 express negligible
levels of CA19-9, there are other intrinsic differences in the cell lines. Both BXPC3 and Capan2
cell lines are of epithelial morphology, while Panc1 and Miapaca2 exhibit a mesenchymal
morphology. As multiple differences between the cell lines exist, some of the elevated
glycoproteins may be a result of phenotypic differences not related to CA19-9 expression. These
differences, as opposed to alterations in CA19-9 expression, likely contribute to E-cadherin
elevations in the high CA19-9 cell lines and N-cadherin elevations in the low CA19-9 cell lines.
Furthermore, neuropilin-1 and NCAM protein expression and sialylation have been linked to
pancreatic cancer cell growth and invasion (487,488). Both proteins were expressed in higher
abundance in the low CA19-9 cell lines. To adjust for variation in the characteristics of cell lines,
most importantly differences in cellular morphology, additional controls can be implemented.
Knockdown of EGFR in Panc1 cell lines resulted in a epithelial phenotype for the Panc1 cells and
a concomitant decrease in N-cadherin and an increase in E-cadherin (489). As many proteins
identified as differently upregulated in the low CA19-9 expressing cell lines are linked to cell
migration and angiogenesis, using low CA19-9 expressing cells with an epithelial morphology
may reduce identifications not attributed to CA19-9.
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Sialylated glycoproteins were catalogued using click chemistry, but it is not known how
sialylation of these proteins varies with respect to pancreatic cancer. No immortalized epithelial
cell lines from normal human pancreatic duct cell (HPDE) lines were used in the experiments
above. HPDE cell lines exhibit similarities in gene expression and morphology to normal
pancreas cells (490). HPDE cells should be incorporated into the click chemistry study. While
there is significant variation between high and low CA19-9 expressing cell lines, 337 proteins
exhibited a ≤ 5-fold change in normalized spectral counts. Using an immortalized cell line that
closely resembles normal pancreas ductal cells could identify differences in sialylated
glycoproteins that are consistently elevated in the tumor cells. Sialylated glycoproteins identified
uniquely in the tumor cells should be further investigated at disease markers for pancreatic
cancer. This experiment, as opposed to the one implemented, would identify biomarker for
pancreatic cancer in general, regardless of CA19-9 expression. Sialylated glycoproteins elevated
in both high and low CA19-9 expressing cell lines compared to the HPDE cells could represent
biomarker targets with higher sensitivity and specificity than CA19-9 alone. While no
immortalized non-cancerous cell line was used, 127 sialylated glycoproteins were identified to be
present in all four of the cell lines. Both KRAS and TP53 were found to be significantly enriched
upstream regulators by Ingenuity Pathway Analysis (IPA), based off of the large number of
downstream proteins in the dataset consisting of the 127 glycoproteins found in all four of the cell
lines (Figure 50). Furthermore, the biological process of tumor growth and migration of tumor
cell lines were significantly enriched, and many of the proteins involved in these processes are
downstream of KRAS and TP53 (Figure 51. Interestingly, proteins downstream of KRAS (red
boxes) appear to play a significant role in tumor growth, while those downstream of TP53 (green
boxes) play a significant role in migration. This is consistant with the genetic mutations that occur
during tumorigenisis, where KRAS plays and itiating role in tumor progression but secondary
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Figure 50. Ingenuity Pathways Analysis Reveals Important Upstream Regulators. The 127
proteins observed in across all four cell lines were searched with Ingenuity Pathway Analysis and
identified several enriched upstream regulators, including KRAS and TP53.
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Figure 51. Ingenuity Pathway Analysis Reveals Several Biological Processes Involved in
Pancreatic Cancer. Processes related to tumor growth and migration are heavily enriched in the
glycoproteins identified in all four cell lines. Proteins that play a role in the processes are
downstream of both KRAS (red box) and TP53 (green box) are involved in these processes.
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processes are required to initiate metastatic and aggressive phenotypes. Furthermore, this analysis
identified several biomarker targets for pancreatic cancer that can be confirmed by additional
screening approaches in biological specimen. These targets include clusterin and CD44, which
have been previously documented in pancreatic cancer as playing a role in drug resistance and
aggressiveness.
As a technique, click chemistry enrichment of glycoproteins has several limitations.
Glycoproteins are bound to the alkyne-agarose resin through the incorporated sugar analog.
Glycoprotein identification by mass spectrometry is based on tryptic peptides from glycoproteins
that are not glycosylated, while glycopeptides remain bound to the resin. Thus, the actual site of
glycosylation is not present in the LC-MS/MS data. PNGaseF release of bound N-glycopeptides
enables identification of previously N-glycosylated peptides, but glycoform specific information
is not obtainable. The use of the ManNAz label in the study limited analysis to sialylated
glycopeptides. Based off of glycomic information, it is likely that there are glycoprotein
differences that are not linked to sialic acid. Finally, while elevations in sialylated glycoproteins
were reported, it is unclear whether the differences were at the level of protein expression or
glycoform structure/occupancy. Glycomic analysis revealed significant trends in aberrant in Nglycan fucosylation that should be analyzed. Incorporation of fucose analogs and subsequent
click chemistry can interrogate differences in fucosylation as a result of CA19-9 expression
(289,302). Quantitative mass spectrometry at the proteomic level can identify whether the
changes observed are the glycoform level or glycoprotein level. Stable isotope labeling by amino
acids in cell culture (SILAC) can be implemented in conjunction with click chemistry. Alterations
at the protein level should be reflected in the SILAC experiments, while alterations at the
glycoform level will not appear in the SILAC data. Alternatively, Western blotting of selected
proteins from the click chemistry data can be used to determine changes in protein expression.
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Click chemistry cannot be used for intact glycopeptide analysis or analysis of global
glycosylation. To obtain this information, selected glycoproteins should be subjected to the
Orbitrap workflow and data processing outlined in the dissertation. As referenced, additional
optimization is required to enable analysis of complex protein mixtures by intact glycopeptide
analysis. However, it has been suggested that it is more beneficial to target individual proteins, as
global examination cannot adequately profile the complexity of the proteome to include changes
in glycosylation. Intact glycopeptide analysis using SAX failed to enrich glycopeptides from
asialofetuin, suggesting that only sialylated glycopeptides can be enriched using this technique.
Both SAX and HILIC failed to enrich glycopeptides from complex mixtures adequately enough
to enable glycopeptide profiling. In order to overcome issues of sample complexity, Parker et al.
instituted a combinatorial enrichment strategy involving HILIC enrichment and RPLC
fractionation, prior to online LC-MS/MS analysis (304). Thus, it is unlikely that a single
enrichment approach can be used for complex samples. In addition to enrichment of
glycoproteins using physiochemical enrichment strategies, lectin enrichment of complex
fucosylated N-glycans could identify numerous differences in intact N-glycoprotein analysis.
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